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Flavin-containing monooxygenases (FMOs) are a family of NADPH dependent enzymes 
mainly catalyzing the oxygenation of heteroatom-containing nucleophilic xenobiotics. It 
consists of five isoforms with FMO3 and 5 having highest mRNA levels in adult human liver. 
Thus particular interest was paid to these two isoforms and their structural and functional 
properties were characterized.  
Several mutations of FMO3 have been reported to be associated with the disorder 
trimethylaminuria (TMAu). In phenotyping and genotyping studies of self-reporting TMAu 
patients at the Human BioMolecular Research Institute, a novel FMO3 variant (V187A) was 
discovered that occurred in combination with E158K, E308G, and E305X. FMO3 V187A as 
well as V187A/E158K were recombinantly expressed as maltose-binding fusion proteins 
(MBP-FMO3) and characterized. In combination with the common mutations E158K and 
E308G the novel variant impairs FMO3 oxygenation activity and leads to TMAu. 
In order to investigate structure and function of human FMO5 (hFMO5) sufficient quantities of 
highly purified, well characterized enzyme was needed. Thus, hFMO5 was successfully 
expressed as MBP-fusion protein (MBP-hFMO5), purified and characterized in terms of 
activity, purity, comparability to commercially available FMO5, stability at 4 °C, and 
monodispersity. These studies showed that MBP-hFMO5 was suitable for further studies 
including crystallization attempts. During these, MBP-hFMO5 proved to be stable without 
detergent although detergent was inevitable for extraction from E. coli suggesting that FMO5 
is not an integral membrane protein but rather only associated with the membrane. Further, 
MBP-hFMO5 was crystallized. However, no satisfactory diffraction pattern could be obtained. 
Crystallization of FMO5 seperated from the MBP-tag might improve crystals.  
Also, species-dependent pKa differences of the FMO5 enzyme were investigated. pH 
dependence studies of human and mouse MBP-FMO5 (MBP-mFMO5) were performed 
showing that residues at positions 227 and 228 of MBP-hFMO5 were responsible for the 
higher N-oxygenation activity of the human enzyme at low pH (i.e. pH 6).  
Finally, in order to identify new substrates to further the knowledge of FMO5 active site 
structure and to identify a possible physiological function of FMO5, a high-throughput 
compatible enzyme activity assay was developed and several compounds were screened. Of 
all compounds tested, one (i.e., 4’-(4-bromophenyl)-ω-dimethylaminobutyrophenone 
HCl) was found to be N-oxygenated by MBP-hFMO5. This compound fits into the proposed 
selectivity range of FMO5, having a tertiary amine group on a long carbon side-chain. 
Overall, further compound screens will be needed to identify additional FMO5 substrates and 
gain more knowledge of substrate specificity and of its structure-function relationship. 
                                                                                          Zusammenfassung        
    
  
 
Flavin-haltige Monooxygenasen (FMOs) gehören zu einer Familie von NADPH-abhängigen 
Enzymen, die die Oxygenierung von hauptsächlich Heteroatom-haltigen nucleophilen Xenobiotika 
katalysieren. Die Enzymfamilie besteht aus fünf Isoenzymen, von denen die mRNA Level von 
FMO3 und 5 in der Leber von Erwachsenen am höchsten sind. Daher bestand ein besonderes 
Interesse an diesen zwei Isoformen und an der Charakterisierung ihrer strukturellen und 
funktionellen Eigenschaften. 
Viele in der Literatur beschriebene Mutationen der humanen FMO3 werden mit der 
Stoffwechselerkrankung Trimethylaminurie (TMAu) in Zusammenhang gebracht. In Phäno- und 
Genotypisierungsstudien von TMAu-Patienten, durchgeführt am Human BioMolecular Research 
Institute in San Diego, wurde eine neue FMO3 Variante (V187A) entdeckt, die in Kombination mit 
E158K, E308G und E305X auftrat. Sowohl FMO3 V187A als auch V187A/E158K wurden 
rekombinant als Maltose-bindende Fusionsproteine hergestellt (MBP-FMO3), gereinigt und näher 
charakterisiert. Die durchgeführten Studien zeigten, dass diese neu entdeckte FMO3 Variante in 
Kombination mit den häufig vorkommenden Mutationen E158K und E308G die 
Oxygenierungsaktivität der FMO3 beeinträchtigt und so zu TMAu führt. 
Um Struktur- und Funktionsstudien der humanen FMO5 (hFMO5) durchzuführen, wurden 
ausreichende Mengen an hochgereinigtem, gut charakterisierten Enzym benötigt. Dazu wurde 
hFMO5 als MBP-Fusionsprotein exprimiert, gereinigt und hinsichtlich Reinheit, Ausbeute, 
Aktivität, Vergleichbarkeit mit kommerziell-erhältlicher FMO5, Stabilität und Monodispersität 
charakterisiert. Diese Studien zeigten, dass MBP-hFMO5 für weitere Studien (u.a. 
Kristallisationsstudien) geeignet ist. In diesen stellte sich heraus, dass MBP-hFMO5 auch in 
Abwesenheit von Detergens stabil und aktiv ist, obwohl zu ihrer Extraktion aus E. coli Detergens 
benötigt wird. Daher liegt die Vermutung nahe, dass FMO5 kein integrales Membranprotein ist 
sondern vielmehr nur mit der Membran assoziiert ist. Weiterhin konnte MBP-hFMO5 kristallisiert 
werden. Allerdings wurde kein angemessenes Diffraktionsmuster erhalten. Kristallisation mit dem 
vom MBP-Tag getrennten FMO5 Protein könnte hierbei die Qualität der Kristalle verbessern.  
In einer weiteren Studie wurden Spezies-abhängige pKa-Unterschiede der FMO5 untersucht, 
indem pH-Abhängigkeitsstudien von humaner und muriner MBP-FMO5 (MBP-mFMO5) 
durchgeführt wurden. Diese zeigten, dass die Aminosäuren an Position 227 und 228 der hFMO5 
für die erhöhte N-Oxygenierungsaktivität bei niedrigem pH (d.h. bei pH 6) verantwortlich sind.  
Zuletzt wurde zur Identifizierung von neuen Substraten ein ‘high-throughput’-fähiger 
Enzymaktivitätstest entwickelt, mit dem zahlreiche Verbindungen getestet wurden. Ein neues 
Substrat der FMO5 (4’-(4-Bromphenyl)-ω-dimethylaminobutyrophenon HCl) konnte auf diese 
Weise identifiziert werden, welches gut in das bisher bekannte Selektivitätsmuster des Enzyms 
paßt. Um weitere Erkenntnisse über die Struktur des aktiven Zentrums der FMO5 zu erhalten, 
sind allerdings weitere Untersuchungen nötig. 
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1 Introduction 
1.1 Introduction to Flavin-containing Monooxygenases 
The flavin-containing monooxygenases (FMOs) (EC 1.14.13.8) are a family of 
microsomal, NADPH dependent enzymes that catalyze the oxygenation of 
nucleophilic nitrogen-, sulfur-, phosphorus-, and other heteroatom-containing 
chemicals, drugs, and endogenous substrates [Cashman et al., 2006; Ziegler, 1980]. 
They belong to the group of oxygenases. Oxygenases incorporate oxygen into their 
substrate and thus catalyze the most important oxidation reaction in the metabolism 
of xenobiotics. They are subdivided in monooxygenases and dioxygenases, 
depending whether one or two atoms of molecular oxygen are transferred into the 
substrate, respectively [Testa, 1995]. The most prominent of monooxygenases in 
regards of xenobiotic metabolism are the heme-coupled cytochrome P450 
monooxygenases (P450s). In the early 1960s, it was believed that most, if not all 
NADPH dependent, heteroatom-containing compound oxidations were catalyzed by 
P450s. After the isolation, characterization, and purification of pig liver FMO by 
Ziegler and colleagues [Ziegler, 1980], it was clear that FMO could oxygenate many 
compounds previously thought to be exclusively oxidized by P450. It has been shown 
that the family of enzymes that collectively constitute mammalian FMOs contribute 
significanty to the oxygenation of nucleophilic xenobiotics, generally converting 
lipophilic heteroatom-containing compounds to polar, readily excreted, oxygenated 
metabolites [Cashman, 1995]. Of course, it should be recognized that FMO-mediated 
oxygenation is only one part of the myriad of biotransformation steps that can befall a 
xenobiotic, and the final disposition of a chemical will depend upon further metabolic 
processes, both oxidative and reductive.  
Various names have been given to FMOs over the years. Initially the FMO enzyme 
was known as “Ziegler’s enzyme”, “dimethylaniline monooxygenase”, and “amine 
oxidase”. These terms were soon recognized to be a too restrictive description 
because at least some forms of the enzyme accept substrates as diverse as 
hydrazines, phosphines, boron-containing compounds, sulfides, selenides, iodide, in 
addition to primary, secondary, and tertiary amines. Later, the enzyme was more 
generally appreciated as a multi-substrate FMO [Ziegler, 1993].  
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In 1984 a new FMO was isolated from rabbit lung. This form possessed many 
properties that the well-studied pig liver FMO did not possess and it became 
apparent that FMO enzymes comprised a small family of enzymes [Tynes et al., 
1985; Williams et al., 1984]. In the early 1990s three further FMO enzymes were 
described [Lawton et al., 1993b] and today there is evidence for the existence of five 
forms of mammalian FMO enzymes with conserved amino acid sequences ranging 
between 50 % and 58 %. In addition, 6 FMO pseudogenes, i.e., genes that lost their 
ability to code for a functional protein [Vanin, 1985], have been described [Hernandez 
et al., 2004; Hines et al., 2002].  
1.2 Nomenclature of FMO Enzymes 
In 1994 a nomenclature was developed to provide a systematic guideline for the 
FMOs following the lead for the P450 enzymes [Lawton et al., 1994]. The 
nomenclature is based on amino acid sequence comparison. To be considered a 
member of the mammalian FMO family, a sequence identity of 40 % or higher is 
required. Since other nonmamalian flavoenzymes have a lower sequence identity 
(e.g., the cyclohexane monooxygenase shares only 25 % amino acid sequence 
identity with other mammalian FMOs), they do not belong to this family. Within a 
subfamily, amino acid sequence identity of ≥ 80 % is required. Thus, the five human 
forms of  FMO have 82 – 87 % sequence identity with their known orthologues in 
other mammals but only 50 – 58 % similarity to each other [Cashman, 2005; Phillips 
et al., 1995]. The flavin-containing monooxygenase gene family is designated as 
“FMO”. Individual genes are distinguished by Arabic numbers (i.e., FMO1 through 
FMO5). Genes and cDNA designations are italicized while mRNA and protein 
designations are non-italicized [Lawton et al., 1994]. Because all literature published 
before 1994 used several different methods naming FMO enzymes, Table 1.1 may 
serve as a guide to the nomenclature.  
 
 
 
 
1  Introduction 
   
3 
 
Table 1.1 Summary of mammalian flavin-containing monooxygenases.  
Designation Old name Species Accession number 
FMO1 1A1 Rabbit M32030 
FMO1 Ziegler’s enzyme Pig M32031 
FMO1 FMO-1 Human M64082 
FMO2 1B1 Rabbit M32029 
FMO2 Lung enzyme Rabbit  
FMO3 1D1 Rabbit L10037 
FMO3 HLFMO II Human M83772 
FMO4 1E1 Rabbit L10392 
FMO4 FMO2 Human Z11737 
FMO5 1C1 Rabbit L08449 
Adapted from Hines et al. [Hines et al., 1994] and Cashman et al. [Cashman et al., 
manuscript in preparation]. 
1.3 FMO Gene Organization  
It is thought that gene duplication of a common ancestral gene that took place long 
before the divergence of mammals led to all members of the FMO gene family 
[Phillips et al., 1995]. Therefore, in all mammalian species, orthologues of each of the 
FMO forms should be found. Thus, the individual genes have remained on the same 
chromosomal arm, (i.e., the long arm of human chromosome 1) [Phillips et al., 1995]. 
All FMOs share a similar pattern of intron/exon organization. FMO2, 3, and 5 contain 
eight coding exons (2 through 9), and the size and boundaries of these are highly 
conserved. They also contain at least one non-coding exon (numbered 1). In 
contrast, human FMO1 and 4 contain an additional non-coding exon (numbered 0) 
[Dolphin et al., 1997b; Ziegler, 1991].  
In addition, six human FMO pseudogenes have been described (FMOs 6P, 7P, 8P, 
9P, 10P and 11P) [Hernandez et al., 2004; Hines et al., 2002]. FMOs 1, 2, 3, 4, and 6 
are located on the long arm of human chromosome 1, in a 220 kb cluster of region 
1q23 – 25 [Hernandez et al., 2004]. FMO5 is located outside this cluster in region 
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1q21.1 [Gelb et al., 1997; Hernandez et al., 2004]. Approximately 4 Mb centromeric 
of the original FMO gene cluster is another cluster with five of the FMO pseudogenes 
[Hernandez et al., 2004]. The pseudogene cluster presumably arose through a series 
of independent gene duplication events and not through complete duplication of the 
gene cluster because the nucleotide sequences of members of the human 
pseudogene cluster (FMOs 7P, 8P, 9P, 10P and 11P) are more similar to each other 
than to members of the known gene cluster (FMOs 1, 2, 3, 4 and 6) [Hernandez et 
al., 2004]. 
1.4 Regulation 
1.4.1 Regulation of FMO Gene Expression 
FMO enzymes can be regulated by a number of different factors such as enzyme 
expression and physiological and dietary influences. FMO expression is dependent 
on the tissue, species, and developmental stage [Hines et al., 1994; Ziegler, 1993]. 
These factors have been characterized in a number of animal species, such as 
humans [Cashman et al., 2006; Zhang et al., 2006], mice [Janmohamed et al., 2004], 
rats [Lattard et al., 2001; Lattard et al., 2002a; Lattard et al., 2003a; Lattard et al., 
2002b], pigs [Gasser et al., 1990], and rabbits [Lawton et al., 1990]. Results show 
that FMO expression profiles are quite distinct among different species. Therefore, 
studies concerning FMO in animal models (e.g., toxicology and metabolism studies 
on drugs) are not always easily translatable to humans. Thus, knowledge of FMO 
expression profiles and their regulation in small animals is essential to interpret data 
useful for establishing animal models correctly as well as predicting the data for use 
in studies of drug metabolism in humans. 
1.4.2 Species-, Tissue-, Age-, and Gender-Dependence of FMO 
Expression 
FMO1 
In humans, all FMOs, with the exception of FMO1, are expressed at greater levels in 
adult liver and adult brain compared to fetal liver and fetal brain [Cashman et al., 
2006; Zhang et al., 2006]. Human FMO1 is 83 % sequence identical with mouse 
FMO1 [Cherrington et al., 1998] and 82 % sequence identical with rat FMO1. It 
shares the highest primary structure identity with rabbit (86 %) and pig FMO1 (88 %) 
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[Lawton et al., 1994]. In humans, FMO1 is the most prevalent FMO in adult kidney. 
FMO1 expression in fetal liver, small intestine, and lung is only 10.4, 6.9, and 2.8 % 
of that in adult kidney, respectively [Cashman et al., 2006; Zhang et al., 2006]. While 
in adult liver FMO1 is almost non-existent (i.e., less than 1 % of that in adult kidney), 
other mammals, such as pigs, rabbits, rats, and mice, express FMO1 in a significant 
amount not only in kidney, but also in adult liver. Further, FMO1 was found in the 
lung of guinea pigs, hamsters, mice, and rats [Atta-Asafo-Adjei et al., 1993] as well 
as in mouse brain [Janmohamed et al., 2004]. 
FMO2 
FMO2 is the dominant FMO form in adult human lung as well as in human heart 
[Nishimura et al., 2006]. Also, it is the prominent FMO form expressed at high levels 
in lung of nonhuman primates and other mammals. However, due to a CT 
transition in codon 472, it is not expressed as a full-length active enzyme in most 
humans [Dolphin et al., 1998; Whetstine et al., 2000; Yueh et al., 1997]. Only a small 
portion of the population, mainly from African descent, has one normal allele and 
therefore expresses an active form of this enzyme [Krueger et al., 2004]. FMO2 
expression in kidney, small intestine, and adult liver is only 13.9, 2.3, and 1.8 % of 
that in lung, respectively [Cashman et al., 2006; Zhang et al., 2006]. FMO2 is found 
in the lung of rabbits, guinea pigs, and hamsters and in small amounts in the lung of 
mice [Atta-Asafo-Adjei et al., 1993]. In contrast to other mammals, certain rat species 
only encode a non-functional protein as described for humans [Lattard et al., 2002b]. 
FMO3 
FMO3 is the major drug-metabolizing FMO form in adult human liver. It is expressed 
at a similar magnitude as P450 2C9 that represents around 20 % of total liver P450 
[Klick et al., 2007; Shimada et al., 1994]. In lung, kidney, and fetal liver FMO3 is 
present at 4.5 %, 3.7 %, and 2.1 %, respectively, of the amount in adult liver. Small 
intestine and brain FMO3 constitute less than 1 % of adult liver FMO3 [Cashman et 
al., 2006; Zhang et al., 2006]. FMO3 expression is very low in fetal liver. Birth seems 
necessary, but not sufficient for the onset of FMO3 expression [Klick et al., 2007]. 
During childhood, FMO3 expression increases to approximately 30 % of adult values. 
In contrast to mice, FMO3 expression increases further, in a gender-independent 
mechanism, approaching adult levels by 18 years of age. In some animals (e.g., 
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mice, rats, and dogs), FMO3 expression is gender-dependent and with the exception 
of few species, all other mammals analyzed to date, including other primates, do not 
express FMO3 as the dominant adult hepatic form [Cashman, 1995; Janmohamed et 
al., 2004]. Therefore most small animals represent poor models for human FMO3-
mediated metabolism. Although there is no gender-difference in FMO3 levels in 
rabbits, rabbit liver contains slightly more FMO3 than human liver. Thus, rabbits do 
not represent good models because FMO3-contribution to human liver metabolism 
might be over-predicted [Cashman, 2000; Ripp et al., 1999b]. One of the most 
common animals used in pharmacological and toxicological models to predict 
metabolism, toxicity, and effects in humans are rats that are about two months old 
and in a period of acquisition of sexual maturity. Rats only display gender 
dependence at a young age, but a significant gender difference is not observed in 
FMO3 expression in adult rats [Lattard et al., 2002a] although it was reported that 
adult male rat liver contains slightly more FMO3 than adult female rat liver [Dannan et 
al., 1986; Ripp et al., 1999b]. Nevertheless, in rats, FMO3 levels are significantly 
lower than those in humans and thus metabolism in rats might under-predict the 
human situation. The liver of female mice and female dogs has much higher FMO3 
activity than that of their male counterparts and relative FMO3 levels are comparable 
to those in human liver. Thus, these animals could serve as suitable models for 
human FMO3 activity. Nevertheless, it is important to keep in mind that both species, 
unlike humans, display gender specific FMO3 expression. Also, mice continue to 
express FMO1 in adult liver whereas the FMO1-content of adult human liver is almost 
non-existent [Janmohamed et al., 2004]. 
FMO4 
Compared to other FMO isoforms, FMO4 is detected in low amounts in several 
human tissues. It is most prevalent in adult liver and kidney, whereas fetal liver, small 
intestine, and lung contain about 10.9, 10.8, and 7 %, respectively, compared to 
FMO4 of adult liver [Cashman et al., 2006; Zhang et al., 2006]. In mice, FMO4 mRNA 
is also expressed in liver and kidney while very low amounts of FMO4 mRNA can be 
detected in lung and brain [Janmohamed et al., 2004]. In rats, FMO4 was detected in 
kidney and brain [Lattard et al., 2003a]. 
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FMO5 
In human as well as mouse liver, FMO5 mRNA is the most abundantly expressed 
FMO mRNA [Cashman et al., 2006; Janmohamed et al., 2004]. This is in contrast to 
the long held assumption that FMO3 is the major form in adult human liver. A 
considerable amount of FMO5 is also found in human fetal liver, small intestine, 
kidney, and lung (18.1 %, 12.8 %, 9.8 %, and 4 %, respectively, of the amount 
present in adult human liver) [Cashman et al., 2006; Zhang et al., 2006]. Human 
FMO5 is 84 % sequence identical with mouse FMO5 [Cherrington et al., 1998]. In 
mice, FMO5 mRNA levels are also relatively prominent in male kidney (and to a 
lesser extent in female mouse kidney), lung, and brain [Janmohamed et al., 2004]. 
FMO5 is also found in the liver and kidney of rabbits, rats, guinea pigs, and hamsters 
[Atta-Asafo-Adjei et al., 1993]. Although FMO5 represents ≥ 50 % of the total FMO 
transcripts in adult human liver, the contribution of FMO5 enzyme functional activity 
has not been clearly established primarily due to a paucity of selective substrates. 
1.4.3 Hormonal Regulation 
The mechanisms controlling the expression of FMO have not been fully elucidated. 
However, the effects of hormones on FMO activity have been described in various 
animal models (e.g., rats [Coecke et al., 1998; Dannan et al., 1986; Lemoine et al., 
1991] and mice [Falls et al., 1995; Falls et al., 1997]). Female mice have a greater 
FMO activity than male mice. Testosterone decreasees FMO1 activity and abolishes 
FMO3 activity in female mice and castrated male mice [Coecke et al., 1998; Falls et 
al., 1995]. Progesterone and estradiol do not seem to have an effect on FMO activity 
in mice [Coecke et al., 1998; Falls et al., 1995; Falls et al., 1997]. 
In rats, hepatic FMO is apparently positively regulated by testosterone [Dannan et al., 
1986; Lemoine et al., 1991] and repressed by 17β-estradiol [Coecke et al., 1998; 
Dannan et al., 1986]. Another study [Coecke et al., 1998] suggested no involvement 
of testosterone in rat FMO, contradicting earlier reports. However, age-dependence 
was observed that supported the involvement of testosterone and 17β-estradiol 
regulation of FMO in rats [Lattard et al., 2002a]. In male rat liver, FMO3 levels and 
functional activity increases significantly during puberty whereas FMO1 remaines 
unchanged. However, the FMO3 levels in the liver of female rats stay stable while 
FMO1 undergoes an 85 % decrease as a function of age. The decrease in FMO1 
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might be due to an increase of 17β-estradiol during puberty [Coecke et al., 1998; 
Dannan et al., 1986; Lattard et al., 2002a]. Overall, the age-dependent change 
results in almost no gender difference in rat hepatic FMO3 expression although a 
slightly higher FMO3 level in male rats than in female rats has been reported 
[Dannan et al., 1986; Ripp et al., 1999b]. 
Compared to liver, rat kidney displays a very different FMO expression pattern. In 
female and male rat kidney, FMO1 does not change with age. Levels of FMO3 
mRNA increase significantly in female rat kidney. In male rat kidney FMO3 mRNA 
increases during puberty but decreases to the level of young rats thereafter [Lattard 
et al., 2002a]. 
Other native and synthetic hormones that appear to influence FMO activity include 
cortisol, progesterone, and dexamethasone. Through its diurnal secretion, cortisol 
appears to control hepatic FMO activity in female mice [Dixit et al., 1984]. 
Progesterone and the glucocorticoid dexamethasone increase FMO2 protein levels in 
rabbit lung [Lee et al., 1995]. In the lung of pregnant rabbits FMO2 mRNA and 
protein expression correlate with the plasma peak of progesterone during mid- and 
late-gestation [Hines et al., 1994; Lee et al., 1995]. In rabbit kidney, only 
dexamethasone induces FMO2 protein levels and activity [Lee et al., 1993; Lee et al., 
1995]. Rabbit liver FMO1 may also be regulated during gestation by progesterone or 
glucocorticoids because administration of these steroids resulted in a 4-fold 
enhancement of FMO1 mRNA levels [Lee et al., 1995]. Up to a 20-fold variation of 
FMO activity has been observed in the corpora lutea of the pig during estrous 
[Heinze et al., 1970]. 
Diet may also have an influence on FMO activity. In rats receiving total parenteral 
nutrition (TPN) with addition of choline, FMO activity was increased after 5 days 
[Cashman et al., 2004]. The amount of FMO4 increased 1.6-fold when animals were 
given TPN and choline compared to rats receiving TPN alone [Cashman et al., 2004].  
In fish, osmoregulation was reported to play a role in FMO expression. In trout, FMO 
expression and activity in osmoregulatory organs like gills, kidney, and gut increase 
in a salinity-dependent manner [Larsen et al., 2001]. When euryhaline fish were 
exposed to hypersaline environments, FMO was induced by trimethylamine N-oxide 
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(TMA N-oxide) and urea that acts as an organic osmolyte to counterbalance 
increases of osmotic pressure. Overall, much more work is needed to clarify the role 
of different hormones in the expression of FMO enzymes. 
1.4.4 Transcriptional Regulation  
Several transcriptional factors have been described that might influence FMO 
expression. In view of the developmental regulation of FMO3 and FMO1 in mice and 
humans, this is of importance. For example, nuclear transcription factor Y (NFY), 
upstream transcription factor 1 (USF1), an unidentified GC box binding element, and 
yin yang 1 (YY1) were found to be important for regulating FMO3 transcription, but 
do not appear to have an impact on temporal or tissue-specific regulation of FMO3 
[Klick et al., 2007]. A possible transcription factor that may participate in FMO3 
developmental- and tissue-specific regulation is pre-B-cell leukemia factor 2 (Pbx2), a 
heterodimer with an not yet identified homeodomain protein (Hox) isoform. Pbx2 
appears to be widely expressed in many tissues during and after embryonic 
development [Selleri et al., 2004]. However, Pbx2 DNA specificity and activity is 
dependent upon dimerization with one of the 39 human Hox isoforms that can be 
expressed at different times during development, in different tissues, and act as 
either an activator or repressor. Human FMO3 hepatic expression is restricted to 
postnatal tissue [Koukouritaki et al., 2002] and because it was shown that only eight 
of the 39 Hox isoforms, (i.e., A2, A4, A5, and B2 – B6), are expressed in human adult 
liver [Takahashi et al., 2004], the Pbx2 partner involved in binding the FMO3 
promoter is possibly one or more of these eight Hox isoforms [Klick et al., 2007]. 
Rabbit FMO1 is apparently regulated by the homeodomain-containing hepatic 
nuclear factor HNF1α and the orphan nuclear receptor HNF4α [Luo et al., 2001]. 
HNF1α and HNF4α might be responsible for the FMO1 tissue-selective expression 
pattern because there is a good correlation between the tissue-selective expression 
patterns of HNF1α, HNF4α (i.e., expressed in liver, kidney, intestine, and stomach) 
[Kuo et al., 1990; Sladek et al., 1990] and FMO1 (expressed in fetal liver, adult 
intestine, and kidney) [Luo et al., 2001]. Also, it was suggested that HNF1α and 
HNF4α are likewise important in regulating human FMO1 expression, because the 
regulatory elements identified for rabbit FMO1 share high identity with human FMO1 
and, with the exception of one of the two HNF4α sites, are also able to compete with 
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the rabbit sequences for specific nuclear protein binding [Klick et al., 2007; Luo et al., 
2001]. It was reported that rabbit FMO1 promoter activity might be negatively 
regulated by the YY1 transcription factor [Luo et al., 2001]. However, a later study 
identified an upstream single-nucleotide polymorphism (SNP) (a CA transversion) 
for human FMO1 that lies within the conserved core binding sequence for the YY1 
transcription factor. This SNP was shown to account for significant loss of FMO1 
promoter activity through elimination of YY1 binding. Genotype analysis showed 
individuals of Caucasian, African, and Hispanic descent possessed 11 %, 13 %, and 
30 % frequency, respectively, leading to the proposal that this variant may account 
for the observed interindividual variation of FMO1 expression. The study also 
showed, as has been described earlier [Thomas et al., 1999], that YY1 may act as a 
negative as well as positive regulator for rabbit and human FMO1, respectively 
[Hines et al., 2003].  
1.4.5 Posttranscriptional Regulation 
Posttranscriptional regulation of FMO enzymes requires additional studies. It is not 
known which factors affect FMO mRNA stability or transcript translation. FMO1 was 
shown to be N-glycosylated at amino acid Asn 120 [Korsmeyer et al., 1998]. This 
residue is well conserved suggesting that it may be important for enzyme structure 
and function. However, FMO expression in bacterial cultures showed that 
N-glycosylation is not required for functional enzyme activity. Expression of FMO 
enzymes as N-terminal maltose-binding fusion proteins in E. coli resulted in a more 
stable, active enzyme isolable in high purity [Brunelle et al., 1997]. Coupling poly-His 
to the C-terminus of the protein also resulted in a very stable, readily purified enzyme 
[Lattard et al., 2003b].  
Nitric oxide (NO) appears to modify FMO posttranslationally. It was shown that NO 
suppresses FMO1 activity directly and in a cGMP-independent matter by decreasing 
the half-life of FMO1 mRNA rather than by decreasing its transcription. Under 
treatment with lipopolysaccharides and cytokines that result in conditions of NO-
overproduction, mRNA levels of FMO1 in cultured rat hepatocytes were decreased. 
Treatment with an NO-donor, spermine NONOate, also resulted in decreased FMO 
protein levels and functional activity [Ryu et al., 2004].  
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1.5 Prominent FMO Polymorphisms 
Although FMO1 is the major FMO form in the liver of most adult mammals, in adult 
humans it is more prominent in extra-hepatic drug metabolism. Some allelic variants 
(e.g., R502X, I303T) have been described, but most of them are rare [Furnes et al., 
2003; Hines et al., 2003]. A relatively common variant is FMO1*6, a -9,536CA 
transversion that lies within the binding sequence for the YY1 transcription factor and 
eliminates binding of YY1 resulting in a significant loss of FMO1 promoter activity 
[Hines et al., 2003]. 
The most common FMO2 mutation is a 1414CT mutation that leads to a premature 
stop codon (Q472X). The expressed protein, designated hFMO2*2A, is truncated 
and non-functional. All Caucasians and Asians genotyped to date express this 
inactive protein. Only 26 % of individuals from African descent [Dolphin et al., 1998; 
Whetstine et al., 2000] and 5 % from Hispanic descent [Krueger et al., 2004] possess 
at least 1 allele coding for the catalytically active full length FMO2 protein designated 
hFMO2*1. For the individuals carrying the hFMO2*1 allele this may have an impact 
on drug-metabolism and toxicity, because FMO2 is known to metabolize and 
preferentially bioactivate certain sulfur-containing chemicals such as substituted  
thioureas to reactive metabolites [Krueger et al., 2002]. 
FMO3 represents the major drug-metabolizing FMO form in adult human liver and is 
responsible for the conversion of the strong neuro-olfactant TMA derived from certain 
foods, to its non-odorous N-oxide (TMA N-oxide). SNPs may lead to an FMO3 
enzyme that is less active or inactive and therefore not capable of N-oxygenating 
TMA. The metabolic disorder in which the odorous unmetabolized TMA is excreted in 
body fluids is called trimethylaminuria (TMAu) and is likely the reason why FMO3 is 
the best-studied FMO isoform in regards to SNPs. Over 300 SNPs have been 
reported and deposited in the SNP database 
(http://www.ncbi.nlm.nih.gov/projects/SNP/). Many mutations have been found to 
decrease or even abolish FMO3 catalytic activity and lead to TMAu (e.g., E32K, 
A52T, N61S, N61K, M66I, P153L, I199T, R238Q, E305X, E314X, R387L, G475D, 
R500X, M82T, R223Q, and R492W). Most of these variants are rare and were found 
only in certain ethnic groups. The more common genetic variants (i.e., E158K, 
V257M, and E308G) are often linked to each other and can lead to decreased 
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catalytic activity and mild symptoms of TMAu. The polymorphic variant L360P, to 
date found only in individuals of African descent, is worth noting because it was 
found to increase FMO catalytic activity [Borbas et al., 2006b]. Polymorphic variants 
that alter FMO3 activity may also effect an individual’s drug metabolism as was 
shown for a number of drugs in several studies including benzydamine [Mayatepek et 
al., 2004], ranitidine [Kang et al., 2000], cimetidine [Cashman et al., 1993a], 
tamoxifen [Krueger et al., 2006; Shibutani et al., 2003], and sulindac [Hisamuddin et 
al., 2004; Hisamuddin et al., 2005]. 
1.6 FMO Catalytic Mechanism 
The catalytic steps of pig FMO1 are known in some detail and have been reported by 
the laboratories of Ballou [Beaty et al., 1981a; Beaty et al., 1981b; Jones et al., 1986] 
and Ziegler [Poulsen et al., 1979; Ziegler, 1988]. Presumably, the other FMO forms 
also follow a similar mechanism. The major steps in the FMO1 catalytic cycle are 
shown in Figure 1.1.  
 
Figure 1.1 Schematic representation of the catalytic steps of pig FMO1. 
S and S-O are the substrate and oxygenated substrate, respectively. Adapted from 
Cashman [Cashman, 1995].  
In the first step of the enzyme reaction (step A), the fully oxidized flavoprotein (i.e., 
FMO-Flox) reacts with NADPH in a fast step to give the enzyme in the reduced form 
 + H+ 
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(i.e., FMO-FlH2). The NADP+ produced remains at the active site of the enzyme. The 
reaction of the reduced enzyme with molecular oxygen (step B) is also rapid as 
shown in model studies, and generates the oxidant used in the enzyme reaction (i.e., 
the C4a-hydroperoxyflavin of FAD, FMO-FlOOH). The FMO structure stabilizes this 
hydroperoxyflavin intermediate and considerable spectral evidence is available that 
supports this stability, especially at low temperature [Beaty et al., 1981a]. Its 
formation is remarkable because it is unusually resistant to decomposition, and it is 
remarkably long lived. These observations suggest that non-nucleophilic FMO active 
site amino acids are present to provide an appropriate lipophilic environment to 
preserve this highly reactive species. Unlike P450 that only forms oxidizing agents 
after substrate binding, the preloaded FMO active site oxidant, the 
C4a-hydroperoxyflavin, waits in a ready position to oxygenate substrate (S). The 
prediction is that FMO will oxygenate any nucleophilic heteroatom-containing 
substrate that can be readily oxidized by hydrogen peroxide or peracids. The 
exception are highly sterically hindered substrates that cannot reach the active site. 
Oxygenation of substrate again proceeds rapidly (step C) with attack on the terminal 
flavin peroxide oxygen to produce the oxygenated product (i.e., S-O) and the 
C4a-hydroxyflavin form of FAD (i.e., FMO-FlHOH). The next step is supposed to be 
rate-limiting and must involve either dehydration of the FMO-FlHOH or release of 
NADP+ (step D). Because NADP+ is a competitive inhibitor of the pig FMO1 cofactor 
NADPH, kinetic studies suggest that NADP+ leaves the flavoprotein last. Kinetic 
analysis of a good substrate such as dimethylaniline showed that the slow step in the 
overall catalytic cycle is not the release of oxygenated product which has important 
consequences for the kinetics of good substrates, because the rate-determining step 
occurs after product release. The mechanism of Figure 1.1 predicts that all good 
substrates possess similar and large Vmax values. Solvent deuterium isotope effects 
on the kinetics of dimethylaniline N-oxygenation with pig FMO1 suggest participation 
of general acid catalysis [Fujimori et al., 1986] that would tend to support dehydration 
as the rate-limiting step in the overall reaction. However, this point is controversial. 
NADP+ appears to play a "gate-keeper" role in that the FMO-FlH2 that reacts with 
molecular oxygen in the absence of NADP+ produces significant amounts of H2O2 
that is otherwise not normally formed [Beaty et al., 1981a; Beaty et al., 1981b]. FMO 
is generally tightly coupled and only minute amounts of H2O2 "leak" away from the 
monooxygenase under normal conditions. If this were not the case, FMO would 
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serve as an NADPH oxidase that would produce copious amounts of H2O2 in the 
absence of substrate, and expose the cell to the untoward effects of oxidative stress. 
The kinetics and proposed mechanism of FMO action is in accord with this 
suggestion, and such a paradigm does not violate principles of enzyme saturation 
(i.e., Michaelis-Menten) kinetics. However, a number of studies have shown that not 
all substrates precisely obey the above model. This is especially true when 
considering the stereoselectivity of FMO, where it appears that the nature of the 
substrate in some cases can have a significant effect on the velocity of the reaction. 
1.7 Differences between P450 and FMO Enzymes 
When discussing enzymes involved in xenobiotic metabolism and especially when 
discussing the group of monooxygenase enzymes, P450 enzymes come to mind 
immediately, being the most prominent enzyme family in this field. P450s represent 
typical characteristics of xenobiotic-metabolizing enzymes such as a mostly low 
substrate and product specificity and a susceptibility to being induced or inhibited by 
many xenobiotics, particularly by some of their own substrates. In general, this 
behavior is useful when it comes to the elimination of physiologically useless 
compounds, however it also leads to several problems including drug-drug 
interactions. Although both FMOs and P450s are able to catalyze similar and in some 
cases even the same biotransformation reactions, there are quite a few differences 
between the two monooxygenase families. 
For example, the first step of the catalytic mechanism of P450 is substrate binding 
and only thereafter is P450 able to form oxidizing agents. In contrast, FMO pre-forms 
an oxygenating agent and is generally then ready to accept a substrate. The 4a-
hydroperoxyflavin formed after addition of NADPH and molecular oxygen is very 
stable and only insignificant amounts of H2O2 are formed. P450 however, forms an 
unstable ferrous-O2 complex that can decompose and lead to the generation of O2- or 
H2O2. Another significant difference in the catalytic cycle is the apparent one- vs. two-
electron nature of P450 and FMO, respectively, and a number of examples exists 
that show that FMO metabolites in many cases do not inactivate FMO but can leave 
the active site and migrate to other proteins nearby, and inhibit or covalently modify 
those proteins. This observation points out that the active site of FMO that generated 
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the highly reactive material is relatively immune to the electrophilic nature of the 
metabolite.  
In contrast to the P450 catalyzed biotransformation reactions, FMO mediated 
metabolism may be utilized to the possibility of making future drugs safer through 
fewer adverse drug-drug interactions by utilization of alternative drug metabolism 
routes, i.e., FMO catalyzed drug metabolism. 
Usually, the structure of the metabolite can be predicted with a great deal of certainty 
based on the products from treating a substrate of FMO with peracids or hydrogen 
peroxide. Although exceptions to this rule are known (i.e., N-oxide or S-oxide 
metabolites may undergo rearrangements or elimination reactions to give products 
that are not readily identifiable with FMO products), in general this chemical model 
provides an important way to predict ahead of time whether a reaction is catalyzed by 
FMO. Another advantage of FMO compared to P450 is that FMO enzymes are not 
readily inhibited or induced. Only few inhibitors of FMO enzymes (e.g., aminostilbene 
carboxylates) have been reported in the literature [Clement et al., 1996]. Variation is 
mainly due to genetic differences and FMO inhibition is usually due to alternate 
substrate competitive inhibition. In contrast CYP is induced or inhibited by a wider 
variety of xenobiotics which in many cases leads to adverse drug-drug interactions. 
Therefore it is advantageous to develop drugs that are metabolized by FMO.  
In summary FMO mediated metabolism is advantageous compared to P450 
mediated reactions because firstly, FMO enzymes are not readily induced or inhibited 
and therefore metabolism of the compound is predictable. Secondly, the likelihood of 
adverse drug-drug interactions is decreased because CYP is less dominant and most 
drugs are metabolized by CYP and not FMO. Thus, even in combination with other 
drugs, medication will not lead to drug-drug interactions [Cashman, 2005]. 
1.8 Toxicity  
In general, oxygenation of lipophilic xenobiotics by FMO enzymes leads to more 
polar, less toxic, and readily excreted metabolites. N-Oxygenation of tertiary amines, 
for example, leads to pharmacological inactivation. N-Oxygenation of (S)-nicotine to 
its trans N’-oxide by liver FMO3 constitutes a detoxication route in animals and 
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humans, shunting alkaloid substrate from the metabolic pathway mediated by P450 
that generate the electrophilic (S)-nicotine ∆1’,5’-iminium ion [Cashman et al., 1992b; 
Damani et al., 1988; Park et al., 1993]. The neurotoxicant MPTP 
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is a good substrate for FMO1 
[Cashman, 1988; Cashman et al., 1986] and tertiary amine N-oxygenation of MPTP 
affords a polar metabolite that represents a major route for detoxication [Chiba et al., 
1990; Chiba et al., 1988]. In mice, MPTP N-oxide is the major metabolite observed in 
the urine of animals treated with MPTP. Presumably, monoamine oxidase-catalyzed 
oxidation of MPTP to the Parkinson-inducing neurotoxins MPDP+ (1-methyl-4-phenyl-
2,3-dihydropyridinium cation) and MPP+ (1-methyl-4-phenylpyridinium cation) 
represent minor metabolic pathways. A study comparing metabolism of MPTP in rat 
brain with that in the brain of Suncus murinus (S. murinus) showed significant 
differences in MPTP metabolism. In contrast to rat brain, FMO activity was extremely 
low in S. murinus brain and therefore MPTP was able to penetrate into the brain to a 
higher extent. Presumably this leads to an accumulation of neurotoxic MPP+ in the 
brain of S. murinus  [Mushiroda et al., 2001]. Thus, MPTP metabolism is species 
dependent and the relative contribution of oxidative and reductive pathways may help 
determine the relative neurotoxicity of the compound [Chiba et al., 1990; Chiba et al., 
1988; Di Monte et al., 1991]. Other examples of metabolic detoxication mediated by 
an FMO enzyme include N-oxygenation of 1,1-dialkylhydrazines (some of the most 
toxic synthetic chemicals known to humans) or S-oxygenation of thiones [Prough et 
al., 1981]. 
 FMO enzymes also catalyze the N-oxygenation of a wide array of secondary and to 
some extent primary amines. In some cases, this leads to bioactivation of these 
compounds to more reactive metabolites [Cashman, 1989; Cashman et al., 1992a; 
Cashman et al., 1988; Cashman et al., 1990b; Mani et al., 1991; Vyas et al., 1990]. 
For example, amphetamine and methamphetamine are oxidized by FMO3 to their 
N-hydroxylamines, but are not very efficiently N-oxygenated further to their oxime or 
nitrone, respectively. Because these hydroxylamines are more cytotoxic than the 
parent compounds this metabolic route is considered a metabolic activation event 
[Cashman et al., 1999b]. The N-desacetyl metabolite of the anti-fungal drug 
ketoconazole, a secondary amine, has been described to be a more potent 
cytotoxicant than the parent compound and is metabolized further by FMO to three 
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metabolites. Two of them were identified to be a secondary N-hydroxylamine and a 
nitrone and may be capable of reacting with proteins or glutathione (GSH) [Rodriguez 
et al., 1997a; Rodriguez et al., 1997b; Rodriguez et al., 2003; Rodriguez et al., 2000; 
Rodriguez et al., 1999]. Also, N-arylamines can be N-oxygenated by FMO to 
N-hydroxyarylamines and subsequent metabolic activation of these metabolites to 
reactive esters are implicated in the carcinogenic properties of arylamines in animals 
[Ziegler et al., 1988]. An example for the bioactivation of arylamines is the 
N-oxygenation of dapsone and sulfamethoxazole by FMO3 to their 
arylhydroxylamines in human epidermal keratinocytes. These metabolites are further 
metabolized to the corresponding arylnitroso metabolites that can bind to cellular 
proteins [Vyas et al., 2006].  
The sulfur atom of sulfur-containing xenobiotics and drugs is the preferred site for 
FMO oxygenation, presumably because of the enhanced nucleophilicity of the 
heteroatom [Ziegler, 1980; Ziegler, 1988; Ziegler, 1990; Ziegler, 1993]. Thus, this 
class of compounds provides more examples of reactive metabolites produced by 
FMO. For example, thiols, thioamides, 2-mercaptoimidazoles, thiocarbamates, and 
thiocarbamides can be efficiently S-oxygenated by FMO to electrophilic reactive 
intermediates. These reactive metabolites do not inactivate FMO, but may covalently 
bind to other proteins. Thioamides are among the best substrates for FMO and 
sequentially form mono- and di-S-oxides [Hanzlik et al., 1983]. Remarkably, even 
thiobenzamide S,S-dioxides do not inactivate FMO, but efficiently covalently modify 
other microsomal proteins, [Hanzlik, 1986] presumably by acylation of the amide 
carbon atom [Cashman et al., 1983; Dyroff et al., 1981; Hanzlik et al., 1983]. 
Thioacetamide [Lee et al., 2003], and thiobenzamide [Hanzlik et al., 1983] are 
S-oxygenated to their hepatotoxic sulfines and sulfenes. The structurally related 
ethionamide, an agent used to treat tuberculosis, is a prodrug that is bioactivated by 
S-oxygenation in Mycobacterium tuberculosis [Vannelli et al., 2002]. Thus, in this 
case the cytotoxicity is utilized to destroy the bacterium.  
2-Mercaptoimidazoles are efficiently S-oxygenated to sulfenic acids by FMO as well 
as chemical oxidants that are subsequently S-oxygenated again to sulfinic acids 
[Decker et al., 1992b; Miller et al., 1988; Ziegler, 1980]. The intermediate sulfenic 
acid readily forms thiol adducts resulting in disulfides that serve as subsequent sites 
for disulfide exchange and net thiol oxidation and substrate regeneration [Krieter et 
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al., 1984]. Ziegler has shown that thiols that establish such a futile cycle catalyzing 
the oxidation of cellular thiols (i.e., GSH) and NADPH may render the cell susceptible 
to the toxic properties of other chemicals [Ziegler, 1993]. Thioureas are another class 
of nucleophilic compounds that are extremely efficiently S-oxygenated by FMO 
[Decker et al., 1992b; Guo et al., 1991; Kedderis et al., 1985; Krieter et al., 1984; 
Miller et al., 1988]. Depending on the substituents on the nitrogen atom or whether 
the thiourea moiety is part of an aromatic ring system, sequential S-oxygenation by 
FMO may result in electrophilic sulfine metabolites. Sulfines are either rapidly 
hydrolyzed (and detoxicated) or sufficiently stable to react with biological 
macromolecules, and thus toxic [Decker et al., 1992a; Hines et al., 1994; Hui et al., 
1988]. In summary, the relative rate of sulfenic acid oxidation (i.e., to reactive 
electrophilic sulfines) compared with the propensity for attack by a thiol (or hydrolysis 
of the corresponding sulfines) probably determines the toxic potential of thioureido-
containing chemicals and drugs. FMO2 is mainly responsible for the S-oxygenation 
of thioureas. Therefore, individuals carrying the catalytically active full length FMO2*1 
enzyme are possibly at enhanced risk for toxicity stemming from thiourea-containing 
compounds [Henderson et al., 2004b]. The thiourea-containing antitubercular 
prodrug thiacetazone acts in the same manner as the thioamide ethionamide, 
utilizing its toxicity against the bacterium. It was shown that human FMO1 and 3 
catalyze the reaction to the reactive sulfenic acid species and subsequently to its 
sulfinic acid and carbodiimide that may lead to the reported hepatotoxicity [Qian et 
al., 2006]. Nevertheless, there are also many examples of detoxication by FMO 
enzymes (e.g., the thioether-containing organophosphonate insecticides disulfoton 
and phorate) through S-oxygenation by the full-length FMO2. Again, the full length 
FMO2 enzyme is only expressed in certain mammals and a small portion of the 
human population and therefore only certain individuals may be at reduced risk of 
toxicity when exposed to these compounds [Henderson et al., 2004a].  
There are a few examples where FMO may promote the formation of electrophilic 
metabolites due to nonenzymatic rearrangement of enzymatically-generated tertiary 
amine N-oxides [Cashman et al., 1988; Mani et al., 1991]. For example, verapamil N-
oxide is efficiently formed by FMO from the tertiary amine verapamil but the N-oxide 
is not indefinitely stable and undergoes decomposition to a hydroxylamine and 
3,4-dimethoxystyrene [Cashman, 1989]. It is possible that formation of these 
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unanticipated metabolites of verapamil may contribute to the cardiotoxicity observed 
with the parent drug.  
1.9 Clinical Significance  
In adult humans, FMO serves a role in the metabolism of many tertiary amine-
containing xenobiotics (e.g., trimethylamine [Ayesh et al., 1993], (S)-nicotine [Park et 
al., 1993], tamoxifen [Krueger et al., 2006], ranitidine [Chung et al., 2000], 
benzydamine [Mayatepek et al., 2004], itopride [Mushiroda et al., 2000], and 
olopatadine [Kajita et al., 2002]) to polar, readily excreted tertiary amine N-oxides. 
Tamoxifen, a breast cancer therapeutic, is hydroxylated by P450 3A4 and 
subsequently sulfated producing a metabolite capable of binding to DNA whereas the 
N-oxygenation by FMO1 and to a lesser extend FMO3 represents a detoxification 
pathway [Krueger et al., 2006; Mani et al., 1991].  
Heterocyclic amines metabolized by FMO enzymes include clozapine [Tugnait et al., 
1997], olanzapine [Ring et al., 1996], and xanomeline [Ring et al., 1999]. 
Xanomeline, a tetrahydropyridine and selective M1-muscarinic agonist, is 
metabolized to xanomeline N-oxide in kidney and liver by FMO1 and 3 although 
FMO3 has a much higher Km than FMO1. The antipsychotic drug clozapine is 
N-oxygenated by FMO3 but also metabolized by P450 enzymes including P450 1A2 
and 3A4 [Tugnait et al., 1997]. In the brain of rats administered clozapine, clozapine 
N-oxide was found to be the major metabolite [Fang, 2000]. The structurally related 
antipsychotic olanzapine is metabolized by FMO to its N-oxide, but also by P450 
enzymes 2D6 and 1A2 to its 2-hydroxymethyl and 4’-N-desmethyl metabolite, 
respectively [Ring et al., 1996].  
Sulphur-containing drugs metabolized by FMO enzymes include sulfides or 
thioethers that are S-oxygenated to their corresponding sulfoxides (e.g., albendazole 
[Molina et al., 2007], cimetidine [Cashman et al., 1993a], methionine [Duescher et al., 
1994; Ripp et al., 1999a], sulindac sulfide [Hamman et al., 2000; Hisamuddin et al., 
2004; Hisamuddin et al., 2005], and tazarotenic acid [Attar et al., 2003]), sulfoxides 
that are oxygenated to sulfones (e.g., ethionamide [Krueger et al., 2005], flosequinan 
[Kashiyama et al., 1994], S-methyl esonarimod [Ohmi et al., 2003; Zhang et al., 
2007a], and other S-containing drugs such as methimazole and 
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S-methyl N,N-diethyldithiocarbamate [Pike et al., 2001]. S-Methyl esonarimod, an 
active metabolite of the antirheumatic drug esonarimod, is mainly deactivated 
through FMO catalyzed S-oxygenation and P450 2C9-catalyzed 4-hydroxylation and 
excreted as sulfoxide and 4-hydroxy sulfoxide, respectively [Ohmi et al., 2003]. 
FMO1 and FMO5 seem to be the major FMO forms involved in this oxygenation 
reaction. Studies with recombinant mouse FMO1, 3 and 5 showed that mFMO1 and 
mFMO5, but not mFMO3 catalyze S-oxygenation with a similar Km value for both 
FMO1 and 5, but with a 3-fold higher Vmax value for mFMO1 [Zhang et al., 2007a]. 
Because recombinant FMO5 and human liver microsomes have the same Km value 
and because FMO5 is the major FMO isoform in human liver, FMO5 is believed to be 
the major enzyme catalyzing this reaction in human liver [Ohmi et al., 2003]. S-Methyl 
N,N-diethyldithiocarbamate (MeDDC), a metabolite of the alcohol deterrent 
disulfiram, is S-oxygenated in human kidney by FMO1 to MeDDC sulfine, a proposed 
necessary intermediate metabolite for the in vivo inhibition of aldehyde 
dehydrogenase by disulfiram, whereas in liver P450 is the major catalyst. Although 
the contribution of human kidney microsomal FMO1-mediated S-oxygenation of the 
S-methyl metabolite is 2- to 3-fold greater than P450, the clinical significance is not 
clear because the human kidney has at least 14-fold less metabolic capacity than the 
human liver [Pike et al., 2001].  
Many of these FMO substrates are stereoselectively metabolized and the 
stereoselectivity of the S-oxygenation by FMO is often distinct from that of P450 
enzymes [Cashman et al., 1993a; Cashman et al., 1990a]. Also, for some substrates, 
a particular FMO could be highly stereoselective, and for other FMO orthologues the 
same substrate could be oxygenated with only modest stereoselectivity. Sulindac 
sulfide, the active metabolite of sulindac, is stereoselectively oxygenated by FMO1, 
2, and 3 mainly to R-sulindac sulfoxide. This is consistent with the finding, that this 
enantiomer is enriched in human serum and urine [Hamman et al., 2000]. (S)-
Nicotine and cimetidine are probably the best studied in vivo stereoselective probes 
of FMO function. In the presence of (S)-nicotine, FMO2 and FMO3 exclusively form 
trans-(S)-nicotine N-1'-oxide [Cashman et al., 1992b; Park et al., 1993], whereas 
FMO1 as well as P450 enzymes form a mixture of cis- and trans-(S)-nicotine 
N-1′-oxide [Damani et al., 1988; Park et al., 1993]. Constraints on the binding 
channels of especially FMO2 and 3 as well as additional interactions could be at 
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work to produce the stereoselectivity observed. In vitro studies with adult human liver 
microsomes showed that N-oxygenation was solely dependent on FMO3 [Cashman 
et al., 1992b] and exclusively resulted in trans-(S)-nicotine N-1'-oxide formation  
[Cashman et al., 1992b; Cashman et al., 1993b]. Thus, in adult male humans, 
(S)-nicotine is N-1'-oxygenated with absolute stereoselectivity to produce only 
trans-(S)-nicotine N-1'-oxide and formation of this metabolite is a selective functional 
marker of adult human liver FMO3. The fact that no cis-(S)-nicotine N-1'-oxide was 
observed suggests that neither extra-hepatic (i.e., kidney, intestine, or elsewhere) 
(S)-nicotine N-1'-oxygenation metabolism in humans (e.g., catalyzed by FMO1) nor 
autooxidation is occurring [Park et al., 1993]. Cimetidine S-oxygenation represents 
another example in which FMO enzyme structural differences are manifested in 
functional differences in enzyme stereoselectivity [Cashman et al., 1993a; Stevens et 
al., 1993]. In vitro studies with adult human liver microsomes showed a clear 
stereopreference of FMO3 toward (-)-cimetidine S-oxide (i.e., (-):(+) 84:16) formation 
[Cashman et al., 1995; Cashman et al., 1993a] whereas FMO1 S-oxygenation 
resulted in almost equal amounts of (+)- and (-)-cimetidine S-oxide (i.e., (+):(-) 57:43) 
[Cashman et al., 1993a]. In human urine samples cimetidine S-oxygenation 
stereopreference was (+):(-), 75:25. This is in relatively good agreement with the 
enantiomeric composition of cimetidine S-oxide found with human liver microsomes. 
The general conclusion is that stereoselective formation of cimetidine S-oxide (or 
formation of trans-(S)-nicotine N-1'-oxide) may be a useful bioindicator of the 
functional contribution of FMO3 in the human, or FMO1 and FMO3 in a particular 
species. In summary, knowledge of the stereoselective oxygenation of cimetidine 
and/or (S)-nicotine has been used as a diagnostic indicator of functional FMO activity 
in humans and animals.  
1.10  Aim  
The overall aim of this study was the characterization of structural and functional 
relations of FMO 3 and 5. The family of FMO enzymes consists of five isoforms 
(FMO1 – FMO5); the best studied of these are FMO1 and 3. In case of FMO1, the 
most prevalent FMO enzyme in adult kidney, this is due to its early purification from 
pig liver [Cashman et al., 2006; Zhang et al., 2006; Ziegler, 1980]. FMO3 is also well 
studied because of its association with the disorder TMAu and because of its high 
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expression in adult human liver. Nevertheless, there are still large gaps of knowledge 
in certain areas concerning FMO3. Although this isozyme has been studied to some 
extend and although TMAu is a disorder with a long history, many aspects need 
further investigation.  
Self-reporting TMAu patients need to be examined because new polymorphic 
variants of the FMO3 gene with unknown effect on metabolism may be found in 
these cases that need further investigation. Findings from these studies may provide 
important new information to our understanding of factors contributing to TMAu. In 
addition, it may help identify functionally important residues of human FMO3, and 
thus further our knowledge of the relationship between FMO enzyme structure and its 
function. Herein, a novel mutation observed from phenotyping and genotyping 
studies of self-reporting TMAu patients should be characterized. 
For a long time FMO3 had been considered the major form in adult human liver. 
However, it has now been verified by more recent studies that FMO5 mRNA is the 
most abundantly expressed FMO mRNA in adult human liver [Cashman et al., 2006; 
Janmohamed et al., 2004]. Thus, besides FMO3, the largely understudied FMO5 is 
of special interest and investigations concerning its structure and function should be 
done within this thesis. Three main areas were of special interest: The first goal was 
to get an insight of the structure of FMO5. Since the underlying principle of function is 
structure, this will advance the knowledge of FMO5s catalytic mechanism as well as 
its substrate specificity and its general function. Solving the three-dimensional 
structure of FMO5 will in addition help advance our knowledge of FMO enzymes in 
general. Secondly, species differences of FMO5 and associated differences in pKa 
values were of interest. This is also an important part when investigating the 
connection between structure and function of FMO enzymes. Although mouse and 
human FMO5 share a sequence identity of 84 % [Cherrington et al., 1998], there are 
distinct differences in their pH dependent activity profile which should be compared in 
this study in order to identify and analyze the amino acids responsible for the 
difference. The third main area of interest was the development of a rapid and easy 
method to screen for possible FMO5 substrates. Although FMO5 is highly expressed, 
to date only very few substrates have been identified. Thus, the identification of new 
substrates will help further the knowledge of FMO5 and possibly help determine a 
physiological function of FMO5. In order to facilitate these studies, it was crucial to 
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have sufficient quantities of purified and well characterized enzyme. Thus, 
recombinant maltose-binding protein (MBP)-tagged FMO5 should be produced by 
expression in bacteria and subsequent purification and characterization.  
The work will advance the knowledge of how SNPs and resulting amino acid 
changes may alter catalytic enzyme activity. It will provide additional knowledge 
regarding function of FMO enzymes through structure analysis and aid defining the 
substrate structure activity relationship for FMO enzymes further. Also, it will provide 
an understanding as to how the human family of FMOs work together to detoxicate 
drugs and chemicals. 
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2 Novel Variant of the Human FMO3 Gene Associated with 
Trimethylaminuria 
2.1 Introduction 
2.1.1 FMO3 Polymorphisms  
More than 300 SNPs of FMO3 are deposited in the SNP database and/or reported 
elsewhere spanning the 26.92 kb human FMO3 gene region. Only a small portion of 
those SNPs have been reported to be associated with interindividual differences in 
the expression and/or function of FMO enzymes that potentially contribute to an 
individual’s susceptibility to toxicants and drug response. Further, in vivo studies of 
drugs like benzydamine [Mayatepek et al., 2004], ranitidine [Kang et al., 2000], 
cimetidine [Cashman et al., 1993a], tamoxifen [Krueger et al., 2006], and sulindac 
[Krueger et al., 2005] showed a close connection between certain common FMO3 
polymorphic variants and drug metabolism. The most prominent example of a direct 
causative relationship between mutations of the FMO3 gene and disease is the 
disorder TMAu, which will be discussed in more detail below.  
Some FMO gene variants appear to be restricted to certain ethnic populations. In 
most cases this is due to founder effects, meaning that a small number of individuals 
carrying only a fraction of the originals population’s genetic variation establishes a 
new population, with only a few exceptions where ethnic specific association has 
been demonstrated [Cashman et al., 2003]. Overall, these interethnic differences 
contribute to the variability of FMO enzyme activity. Thus FMO-mediated drug 
metabolism and possible differences among ethnic groups are probably due to more 
common FMO3 genetic variants such as E158K, V257M, E308G and not rare 
polymorphic variants. 
2.1.2 Diseases and Disorders Associated with FMOs 
TMAu is the metabolic disorder most studied that has been associated with FMO 
enzymes. TMAu patients suffer from a strong body odor that is due to a decreased 
ability of the FMO3 enzyme to metabolize the odorous TMA to its non-odorous TMA 
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N-oxide. TMA is subsequently excreted in body fluids. The disorder will be discussed 
in more detail in section 2.1.3.  
Changes in FMO functional activity have been associated with type I and II diabetes. 
Streptozotocin-induced diabetic (i.e., insulin deficient) rats and mice and congenital 
insulin resistant Ob/Ob mice were shown to express FMO with increased specific 
activity [Krueger et al., 2005; Rouer et al., 1988]. FMO3 mRNA increased 
dramatically in genetically modified male Db/Db mice with Type II diabetes compared 
with normal (Db/+) male mice, whereas female Db/Db mice showed lower 
mRNA-levels for FMO1, 3, 4, and 5 compared to female Db/+ mice. Thus, FMO3 is 
likely to be responsible for the previously reported increase in FMO activity. In 
diabetic rats, hepatic FMO1 activity increased and was restored after insulin-
treatment [Borbas et al., 2006a]. Also, hepatic FMO1 activity correlated with average 
blood glucose concentration. Thus, insulin appears to be involved in hepatic FMO1 
regulation and blood glucose may serve as a good marker for FMO induction. In rats, 
FMO1 appears to be responsible for the observed increase in FMO activity. 
Other diseases associated with FMOs include primary and secondary 
hemochromatosis [Barber et al., 2000; Muckenthaler et al., 2003] and hypertension 
[Cashman et al., 2003; Cashman et al., 2002; Dolan et al., 2005; Larsen et al., 2001], 
but much more work is needed in these fields. 
2.1.3 Trimethylaminuria 
TMAu is a metabolic disorder characterized by the inability of the affected individual 
to metabolize the odorous TMA to its non-odorous N-oxide (TMA N-oxide). Often 
individuals with TMAu have a fish-like body odor, therefore the disorder is also known 
as ‘fish odor syndrome’. 
2.1.3.1 History 
Although there is no clinical report of TMAu until the 20th century, it is a disorder that 
can be found in numerous ancient anecdotal descriptions. The first time TMAu is 
mentioned was in 1000 BC in an epic of the Bharata Dynasty from India. In this story, 
a young woman named Satyavata is cast away from society to live a solitary life as a 
ferry woman because she stank like ‘rotting fish’. The next entry of TMAu is from 
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around 1500 AD. Thai folklore of this time says that the fish odor syndrome was the 
major cause of suicide among concubines in the Sukhothai period. In William 
Shakespeare’s ‘The Tempest’ from the 16th century the jester Trinculo speaks of the 
slave Caliban smelling strongly of old fish [Mitchell et al., 2001]. In the early 17th 
century, the physician John Arbuthnot described in his ‘Nature of Aliments’ that 
certain individuals smelled rancid when their diet was mostly fish. Together with two 
other early papers published in the Lancet this was the first scientific description of 
the disorder [Cashman et al., 2003]. In addition, several reports by physicians and 
chemists have also described patients with strong fish-like body odor, that could not 
be avoided just by paying more attention to cleanliness but instead seemed to 
decrease when omitting certain foods like fish [Mitchell et al., 2001]. The first clinical 
report of TMAu was by Humbert and colleagues in 1970 who reported a case of a girl 
that had a fish-like odor. Biochemical studies showed that after a TMA challenge, the 
excretion of TMA increased and a subsequent biopsy of a liver sample revealed that 
the TMA N-oxidizing system was defective. Later reports showed that the disorder 
could affect children as well as adults and was associated with the excretion of an 
increased amount of TMA relative to TMA N-oxide [Mitchell et al., 2001]. 
2.1.3.2 Cause and Severity 
TMAu is due to excretion of TMA in body fluids such as sweat and urine. TMA is a 
strong neuro-olfactant that can be detected by the human nose in concentrations as 
low as 1 ppm. It is formed endogenously from the breakdown of precursors such as 
choline and carnitine or by reduction of TMA N-oxide through gut bacteria. Normally, 
over 95 % of TMA is metabolized in the liver by FMO3 to its non-odorous N-oxide. 
However, a number of genetic variants of the FMO3 gene leads to enzymes not 
capable of oxygenating the odorous TMA. At least 40 genetic polymorphisms have 
been reported to cause TMAu, many of them associated with the incidence and 
severity of the disorder [Shimizu et al., 2007a]. Some gene mutations lead to FMO 
enzymes that are still partly capable of oxygenating TMA. In these cases the 
individual has a mild form of TMAu and the disease is often only discovered by a 
choline challenge. Other genetic variants produce a totally inactive FMO3 leading to 
a severe form of TMAu where no or almost no TMA is N-oxidized. In general, an 
individual is recognized as not affected when more than 90 % of TMA is metabolized. 
When 10 – 39 % of the TMA remains unmetabolized, the disease is considered to be 
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mild. Individuals having over 40 % unmetabolized TMA or more than 10 mg/ml TMA 
in their urine are considered to be severely affected [Cashman et al., 2003].  
2.1.3.3 Incidence 
The National Institute of Health (NIH) classifies this disease as rare, but the actual 
incidence is probably underreported because it is often mistaken for poor hygiene 
[Krueger et al., 2005]. The incidence seems to be higher in females [Lambert et al., 
2001] and symptoms worsen for some but not all women during menstruation. 
Apparently, owing to a founder effect, the incidence is higher in areas that have 
populations derived from British, Scottish, and Irish descent like certain regions in the 
United States and Australia [Akerman et al., 1999; Mitchell et al., 2001]. Also, it has 
been stated that there is an elevated incidence of TMAu in tropical regions that 
possibly arises from the advantage of TMA as an anti-insect secretion [Mitchell et al., 
1997]. 
2.1.3.4 Clinical Manifestation 
Clinically, TMAu is closely associated with several social and psychological problems 
no matter if adults or children are affected [Mitchell et al., 2001]. Thus, it cannot 
simply be considered a ‘social’ or benign condition. The strong offensive body odor 
can be highly disruptive for an individual’s personal life and work. Ayesh et al. [Ayesh 
et al., 1993] described various psychological reactions noticed in a group of TMAu 
patients including shame, embarrassment, low self-esteem, and frustration. 
Associated social exclusion and isolation may further cause anxiety, paranoia, and 
depression. Also, suicidal personalities were described and it was noticed that many 
individuals had problems with addiction to cigarettes, alcohol, and drugs. Whether 
the depression that is seen in some cases is due to the social isolation or due to a 
dysfunctional metabolism of other endogenous substrates is not quite clear yet. 
Besides the body odor it was reported that some male patients showed adverse 
reactions to choline loading, with fever and vomiting and that these symptoms were 
also observed on a number of occasions during periods of excessive malodor 
[Chalmers et al., 2006]. McConnell et al. presented a boy with diagnosed TMAu 
whose TMA levels were associated to the seizures and behavioral disturbances he 
suffered from. This case suggests that not all of the psychiatric disturbances seen in 
2  Novel Variant of the Human FMO3 Gene Associated with Trimethylaminuria 
   
28 
 
this disorder are necessarily related to a psychosocial reaction to the odor itself 
[McConnell et al., 1997]. Another observation of this and other reports is that some 
individuals with TMAu are aware of their strong body odor while others remain 
unaware of the smell [Ayesh et al., 1993]. 
2.1.3.5 Diagnosis 
Accurate diagnosis is essential for appropriate genetic counseling and long-term 
management so that the affected individual can be treated as soon as possible 
[Chalmers et al., 2006]. For diagnosis, the urinary ratios of TMA N-oxide to TMA 
should be measured. In healthy individuals the TMA N-oxide:TMA+TMA N-oxide ratio 
in the urine should be ≥95 %. It is not always entirely satisfactory to test for TMAu if 
the person is on normal diet because the intake of TMA precursors may not be 
known. Therefore it was suggested that the urine should be investigated after a 
challenge dose of the TMA precursor choline [Murphy et al., 2000]. In addition, 
genotyping the individuals and studying mutations in the FMO3 gene that cause 
TMAu is also important. 
2.1.3.6 Classification of TMAu 
TMAu is generally divided into primary and secondary forms. The primary form is due 
to a dysfunction of the FMO3 enzyme that may be either a result of a mutation of the 
FMO3 gene or due to hormonal or inhibitory chemical influences. The secondary 
form is the result of an overload of TMA precursor or TMA itself while the individual 
has normal or only slightly decreased FMO3 enzyme activity. Secondary TMAu may 
be observed in patients with chronic liver disease or in those individuals with bacterial 
overgrowth that results in an increased production of TMA from its dietary precursors 
[Cashman et al., 2003; Fraser-Andrews et al., 2003]. 
The primary form that accounts for the majority of TMAu reported cases is the 
genetic form. It is due to an autosomal recessively inherited gene defect that leads to 
FMO3 enzyme deficiency [Ayesh et al., 1993; Mitchell, 1999]. Some of the 
polymorphic variants of FMO3 lead to enzymes that have abolished (severe TMAu) 
or decreased catalytic activity (mild TMAu). Combinations of common genetic 
polymorphisms may also lead to a mild form of TMAu [Akerman et al., 1999; 
Cashman et al., 2003; Zschocke et al., 1999]. In case the disorder is present from 
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birth it becomes apparent as foods containing high amounts of choline or TMA 
N-oxide are introduced into the diet [Chalmers et al., 2006; Mitchell et al., 2001]. 
TMAu is further divided into various sub-forms, some of which are discussed below. 
The acquired form may emerge in adulthood without any genetic familial background 
[Cashman et al., 2003; Mitchell, 1999; Mitchell et al., 2001]. In several cases an 
incidence of hepatitis in adult life was reported that might have been responsible for 
the manifestation of the disorder. Possibly, viral DNA has been inserted into the 
genome affecting normal FMO expression [Cashman et al., 2003; Mitchell et al., 
2001]. 
The transient childhood form may appear in early childhood when the child is fed a 
choline-containing diet. This form of TMAu is only temporary though. FMO3 is 
induced after birth (0 – 8 month), but is absent in fetal liver. The FMO3 expression 
levels increase afterwards, reaching significantly high levels at age 1 – 2 years and 
mature levels at age 11 – 18 years. TMAu disappears when FMO3 is fully expressed 
[Cashman et al., 2003; Cashman et al., 2002].   
Another transient form of TMAu is associated with menstruation [Shimizu et al., 
2007a; Yamazaki et al., 2004; Zhang et al., 1996]. Further, it was proposed that even 
in otherwise healthy women, a mild form of TMAu may occur around time of 
menstruation that is due to a change in metabolic capacity. In those suffering from 
TMAu, the symptoms seem to intensify during menstruation. First observations for 
the decreased TMA metabolism were from self-reporting TMAu suffering patients. 
These were supported in studies on same individuals [Shimizu et al., 2007a; 
Yamazaki et al., 2004; Zhang et al., 1996]. 
Another cause of TMAu may be an overload of precursors such as TMA N-oxide, 
choline, or carnitine [Zhang et al., 1996]. The disorder may become apparent 
especially in individuals with certain FMO3 variants [Mitchell et al., 2001]. Enzymatic 
oxidation capacity is usually not exceeded when on a normal diet [Zhang et al., 
1996], but it was reported that patients suffering from Huntington’s disease who were 
treated with a daily oral dose of 8 – 20 g choline complained of a fishy odor in their 
urine, sweat, and breath [Growdon et al., 1979]. Further, patients that suffer from 
impaired hepatocellular function have problems with the clearance of TMA as well as 
2  Novel Variant of the Human FMO3 Gene Associated with Trimethylaminuria 
   
30 
 
those with bacterial overgrowth in the small intestine due to an increased TMA 
liberation from its precursors [Cashman et al., 2003; Mitchell, 1999]. 
Indole-containing materials that may be formed in the gastrointestinal system after 
consuming Brussels sprouts are potent inhibitors of human FMO3. They decrease 
FMO3 activity [Cashman et al., 1999a; Mitchell, 1999] and may exacerbate the TMAu 
condition. 
The fact that TMA metabolism decreases in some but not all women at the onset of 
menstruation and the observation that the fishy odor is aggravated around puberty, 
after taking oral contraceptives, and around menopause [Zhou et al., 2006] support 
the hypothesis that FMO activity may be modulated by hormones [Mitchell, 1996; 
Mitchell et al., 2001; Shimizu et al., 2007a] (see also chapter 1.4.3). 
2.1.3.7 Treatment 
Currently, there are only few ways to treat TMAu. On the one hand restriction of 
foods with a high content of TMA and its precursors such as TMA N-oxide (i.e., 
saltwater fish [Zhang et al., 1999], cephalopods and crustaceans) and choline (eggs, 
liver, kidney, peas, beans, peanuts, soy products, and other legumes) is an option 
[Chalmers et al., 2006; Mitchell, 1996]. It was reported though that dietary restriction 
primarily helped individuals that suffered from the mild form of TMAu. It was reported 
that breastfeeding infants after consumption of TMA precursors also had an effect on 
the baby [Mitchell, 1996]. Nevertheless, it is important not to over-restrict choline 
intake in young children and pregnant or nursing women because choline is crucial 
for the fetus’ and young infant’s nerve and brain development. For some individuals 
suffering from severe TMAu, adverse tyramine reactions have been described in the 
literature [Treacy et al., 1998]. Therefore, individuals with a severe form of TMAu 
should also be careful with tyramine-containing foods such as aged cheese, red 
wine, meats, and yeast products [Cashman, 2002].  
Also, temporary treatment with antibiotics like neomycin, metronidazole, or amoxicillin 
to inhibit the enterobacterial reduction of the TMA N-oxide in the intestine may help 
some patients. Antibiotics are able to decrease the production of TMA from choline to 
a limited extent and also slow the rate of TMA production, but antibiotics do not 
completely prevent formation of TMA from choline. Antibiotics should only be used in 
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exceptional cases and with caution. They should only be applied temporarily and as 
an adjunct to dietary treatment due to the risk of developing multi-antibiotic drug 
resistances. Temporary antibiotic treatment may be helpful if TMAu symptoms are 
exacerbated when the patient undergoes periods of great stress, emotional upset, 
exercise, or infection, or in women at the onset of menstruation, or whenever dietary 
restriction cannot be realized. To avoid resistance to antibiotics it is imperative to 
alternate the therapy of different antibiotics [Chalmers et al., 2006; Mitchell et al., 
2001].  
Treatment with charcoal or copper chlorophyllin may be effective to decrease free 
urinary TMA levels and increase TMA N-oxide levels to normal values. The effects of 
copper chlorophyllin appear to last longer [Yamazaki et al., 2004]. Supplementation 
with folate is necessary because dietary choline restriction increases 
folate-requirements. To enhance residual hepatic FMO3 activity, addition of riboflavin 
(that might help stabilize FMO3 and increase its half-life) may be supplemented 
[Cashman et al., 2003]. The use of soap with a pH value of 5.5 – 6.5 can remove 
traces of free TMA from the skin. At this pH odorous TMA (pKa 9.8) is protonated and 
will be retained in a less volatile salt form and the salt can be washed off with water 
[Chalmers et al., 2006; Mitchell, 1996]. 
2.1.4 Aim of the Study  
TMAu often manifests itself in a body odor for individuals affected which is due to 
decreased metabolism of dietary-derived TMA. Several SNPs of the FMO3 gene 
have been described and result in an enzyme with decreased or abolished functional 
activity for TMA N-oxygenation thus leading to TMAu. Herein, a novel mutation 
associated with TMAu that was observed from phenotyping and genotyping 
self-reporting individuals will be reported and characterized. 
In a 33 year old woman, in addition to the common polymorphisms E158K and 
E308G, a SNP at position 187 (i.e., V187A) that had not been described to date and 
a truncation mutation E305X reported previously were observed. Examination of both 
biological parents showed that the biological mother carried the 
E158K/V187A/E308G allele, and the biological father carried the E305X allele. While 
it is known that E305X will abolish FMO3 function, the V187A mutation has not been 
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reported nor previously characterized. Aim of this study was to characterize this new 
and unusual variant. Thus, the V187A and the V187A/E158K variants of FMO3 
should be cloned, expressed, and purified as maltose-binding fusion proteins. The 
triple mutant E158K/V187A/E308G reflecting the genotype of one allele of the 
affected individual examined was not studied because of difficulties in expression 
and characterization of the enzyme. The variants will be tested in vitro for the 
oxygenation of selective functional substrates for the FMO3 enzyme 
(i.e., 10-(N,N-dimethylamino pentyl)-2-trifluoromethyl)phenothiazine (5-DPT), 
10-(N,N-dimethylamino octyl)-2-trifluoromethyl)phenothiazine (8-DPT), 
mercaptoimidazole (MMI), TMA, and sulindac sulfide). The thermal stability of the 
variant FMO3s will also be examined and compared to wild-type enzyme. 
2.2 Materials and Methods 
2.2.1 Reagents  
Chemicals and reagents used in this study were purchased from Sigma-Aldrich 
Chemical Co. (St Louis, MO, USA) in appropriate purity. Buffers and other reagents 
were purchased from VWR Scientific, Inc. (San Diego, CA, USA). The synthesis of 
the phenothiazines 5-DPT and 8-DPT has been previously described [Lomri et al., 
1993b; Nagata et al., 1990; Zhang et al., 2007a] and was done by Dr. Karl 
Okolotowicz (HBRI, San Diego, USA). 
2.2.2 Genomic DNA Preparation and PCR Amplification 
Genomic DNA preparation and polymerase chain reaction (PCR) amplification had 
been done previously at the HBRI (San Diego, CA, USA) as described before [Zhang 
et al., 2003]. Briefly, blood samples from individuals with self-reported TMAu 
symptoms were collected by their primary care physicians and sent to the HBRI 
laboratory for genotype analysis. All human samples were approved by the 
Independent Review Consultant Inc. (San Anselmo, CA, USA) institutional review 
board. The ethnicity of the individuals was defined by a self-report questionnaire that 
indicated the race of both biological parents. The individuals tested in this study were 
U.S. citizens from Northern European descent. Genomic DNA was prepared from 
whole blood using the Qiagen QIAmp Blood Kit (Valencia, CA, USA) following the 
manufacturer’s protocol. Eight coding exons of FMO3 and neighboring flanking 
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intronic regions were amplified from genomic DNA and sequenced using the primers 
listed in Table 2.1 and PCR conditions reported previously [Zhang et al., 2003]. DNA 
sequences were analyzed with Sequencher Software (Gene Code Corporation, Ann 
Arbor, MI, USA) by procedures that could resolve heterozygotes under reliable 
quality-control conditions. Genebank sequence NT_004487 was used as the wild-
type FMO3 reference sequence.  
Table 2.1 Polymerase chain reaction and sequencing primers for coding exons of 
FMO3. 
Exon Length Primer Sequence (5’-3’) 
2 498 bp forward  TCAAACTCCTGGGCTCAAGT 
  reverse  TTTCCAACCTGCTCTTGACA 
3 581 bp forward  CAGATTCAACCCACCATTGA 
  reverse  TTCTTCAGCATTATGACAAGAGC 
4/5 651 bp forward  ATCTGCCAAAACCATTTGCT 
  reverse  ACGAGAGTCACCCGAGTACC 
6 408 bp forward  GGGGTGCTCACCAGAATATC 
  reverse  AAAAGCCAGCAGGCATATCA 
7 429 bp forward  TCCAATAATTGTCTCTGTTTTCCA 
  reverse  TTCATCTTCGCAATCCATGA 
8 473 bp forward  GGAAAATTACAGGCTGGTCCT 
  reverse  CATTCCAATGATGTCATTCAGG 
9 475 bp forward  GCGAGCCATTTTCTCTGTTC 
  reverse  CCCCTGTCTGGGTATTGTCA 
 
2.2.3 FMO3 Phenotyping by Urinary TMA and TMA-N-Oxide Analysis  
FMO3 phenotyping by urinary TMA and TMA-N-oxide analysis had been done 
previously at the HBRI (San Diego, CA, USA). A selective functional method was 
used to characterize the FMO3 phenotype in humans by determining the amount of 
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TMA and TMA N-oxide from urine. After collection of first void morning urine sample 
the TMA and TMA N-oxide concentrations following a normal diet were determined. 
The urine was cooled to 4 °C with ice and acidified  to pH 1 with 6 N HCl and 
immediately stored at -80 °C until thawing for assa y. TMA and TMA N-oxide 
concentration was determined by electrospray ionization mass spectrometry with a 
deuterated TMA internal standard as previously described [Cashman et al., 2001]. 
2.2.4 Cloning and cDNA Expression 
The expression vector for FMO V187A and E158K/V187A constructs were cloned 
into pMAL-2c (New England BioLabs, Ipswich, MA, USA) by site directed 
mutagenesis methods as described previously [Brunelle et al., 1997; Zhang et al., 
2003]. Cloning was done by Kiersten Riedler (HBRI, San Diego, CA, USA). Briefly, 
wild-type FMO3, FMO3 V187A, and FMO3 V187A/E158K were expressed as 
N-terminal maltose-binding fusion proteins (i.e., MBP-FMO3, MBP-FMO3 V187A, 
and MBP-FMO3 V187A/E158K). After transformation of E. coli DH1α cells with 
pMAL-MBP-FMO3 plasmid, cells were grown at 37 °C in SOC medium to  an 
absorbance of 0.4 - 0.5 at 600 nm and then 0.2 mM IPTG, 0.05 mM riboflavin, and 
100 µg/ml ampicillin were added and the cells were further shaken at room 
temperature overnight and harvested by centrifugation for 10 minutes at 6,000 g. 
2.2.5 Purification of MBP-FMO3 Fusion Proteins 
All of the following procedures including the purification process were carried out at 
4 °C. The cell pellet was resuspended in lysis buff er as described previously [Lattard 
et al., 2003b]. After stirring the cell suspension on ice for 30 minutes, the cells were 
disrupted by sonication (i.e., five 8-seconds bursts separated by periods of cooling) 
on a Sonics Vibracell ultrasonic processor (Sonics and Materials Inc., Newtown, CT, 
USA). The solution was centrifuged and the resulting supernatant was loaded onto 
an amylose column (New England BioLabs, Ipswich, MA). In order to obtain a higher 
yield of protein, the pellets were extracted a second time as described above and the 
resulting supernatant of the second extraction was also loaded onto the amylose 
column. Protein purification was carried out on a low pressure chromatography 
system, Biologic LP (Bio-Rad, Hercules, CA, USA). After loading the supernatants at 
0.75 ml/min onto an amylose column that was equilibrated with 10 column volumes 
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of buffer A (i.e., 50 mM Na2HPO4 pH 8.4 and 0.5 % Triton® X-100 containing 
15 µg/ml FAD) the column was washed with at least 10 column volumes of buffer A. 
Bound MBP-FMO3 protein was then eluted with a linear maltose gradient: 0 - 100 % 
10 mM maltose in buffer A. Eluted fractions (5 ml each) were analyzed and the 
fractions with the highest enzyme activity were pooled and concentrated with a 
Centriprep centrifugal filter unit with Ultracel-30 membrane (Millipore, Billerica, MA, 
USA).  
2.2.6 Determination of MBP-FMO3 Concentration 
MBP-FMO3 and variants were quantified by SDS-PAGE and Coomassie Blue 
staining and compared with a bovine serum albumin (BSA) standard. Briefly, 
MBP-FMO3 proteins and different quantities of standard BSA (2, 1.5, 1.0, 0.5, and 
0.1 µg per lane) were fractionated by electrophoresis on a 10 % polyacrylamide gel 
under denaturing conditions and stained with Coomassie Blue. After destaining, 
MBP-FMO quantification was done by densitometry analysis employing Kodak 
molecular imaging software (Eastman Kodak Company, Rochester, NY, USA). 
2.2.7 Enzyme Assays 
Oxygenation of mercaptoimidazole (MMI) was determined spectrophotometrically by 
measuring the rate of MMI S-oxygenation via the reaction of the oxidized product 
with nitro-5-thiobenzoate (TNB) to generate 5,5’-dithiobis(2-nitrobenzoate) (DTNB). 
The reaction is shown in Figure 2.1. The assay contained 50 mM sodium phosphate 
buffer, pH 8.5, 0.5 mM NADP+, 0.5 mM glucose-6-phosphate, 1.5 IU/ml glucose-6-
phosphate dehydrogenase, 0.06 mM DTNB, 0.04 mM dithiothreitol (DTT), and 
depending on the variant 45 - 360 µg/ml MBP-FMO3. Reactions were initiated by the 
addition of 2 mM final concentration of substrate and the disappearance of the yellow 
color was followed spectrophotometrically at 412 nm. Kinetic parameters (i.e., Vmax 
and Km) for MBP-FMO3-mediated MMI S-oxygenation were determined by initiating 
the enzyme reaction with different amounts of substrate. The final substrate 
concentrations were 800, 400, 200, 100, 40, 10, and 1 µM for wild-type MBP-FMO3, 
800, 200, 100, 40, 20, 10, 5, and 1 µM for the MBP-FMO3 V187A variant, and 200, 
100, 40, 10, and 5 µM for the MBP-FMO3 V187A/E158K variant.  
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Figure 2.1 S-Oxygenation of MMI by FMO and reaction of the oxidized product with 
TNB to DTNB.  
MMI, mercaptoimidazole; TNB, nitro-5-thiobenzoate; DTNB, 5,5’-dithiobis(2-
nitrobenzoate). Adapted from Dixit et al. [Dixit et al., 1984]. 
Kinetic parameters (i.e., Vmax and Km) for MBP-FMO3-mediated TMA N-oxygenation 
were determined by spectrophotometrically monitoring the oxidation of NADPH 
associated with TMA N-oxygenation. The assay medium contained 50 mM sodium 
phosphate buffer, pH 8.5, 0.5 mM diethylenetriaminepentaacetic acid (DETAPAC), 
0.2 mM NADPH, and 160 - 640 µg/ml MBP-FMO3. Incubations were initiated by the 
addition of different amounts of substrate and monitored at 340 nm for NADPH 
depletion. The final substrate concentration was 100, 40, 20, 10, and 5 µM for wild-
type MBP-FMO3 and the MBP-FMO3 V187A variant and 800, 400, 200, 100, and 
40 µM for MBP-FMO3 V187A/E158K. 
N-Oxygenation of 5- and 8-DPT was determined by HPLC analysis as previously 
described [Lattard et al., 2003b]. The reaction is shown in Figure 2.2. Both 
compounds are mainly N-oxygenated by FMO enzymes, but not S-oxygenated as 
described previously for phenothiazine drugs [Clement et al., 1993] because of the 
electron withdrawing effect of the trifluoromethyl group inseted at the 2 position of the 
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phenothiazine ring system. Briefly, a standard incubation mixture of 250 µl final 
volume contained 50 mM potassium phosphate buffer, pH 8.4, 0.4 mM NADP+, 
0.4 mM glucose-6-phosphate, 4 U glucose-6-phosphate dehydrogenase, 0.25 mM 
DETAPAC, and 40 µg/ml wild-type MBP-FMO3 or its variant at 4 °C. Inc ubations 
were initiated by the addition of substrate to a final concentration of 200 µM at 37 °C. 
After incubation for 20 minutes shaking under aerobic conditions, enzyme reactions 
were stopped by the addition of 4 volumes of cold dichloromethane. About 20 mg of 
Na2CO3 was added and the incubations were mixed and centrifuged to partition 
metabolites and remaining substrate into the organic fraction. The organic phase was 
collected and evaporated under a stream of argon. Metabolites and remaining 
substrate were dissolved in methanol, mixed thoroughly, centrifuged and analyzed 
with a Hitachi HPLC system (Hitachi L-7200 autosampler and L-7100 pump 
interfaced to a Hitachi L-7400 UV detector). Chromatographic separation of analytes 
was done on an Axxi-Chrom normal phase analytical column (250 x 4.6 mm 5 µm, 
silica) with a mobile phase of 80 % MeOH/20 % isopropanol/0.025 % HClO4 (v/v/v). 
The flow rate was 1.6 ml/min and the total run time was 10 minutes for 5-DPT and 
8.5 minutes for 8-DPT. The wavelength for UV detection was set to 243 nm. The 
retention times for 5-DPT and 5-DPT N-oxide, and 8-DPT and 8-DPT N-oxide were 
6.4, 4.6, 5.8, and 4.1 minutes, respectively. 
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Figure 2.2 N-Oxygenation of 5- or 8-DPT by FMO. 
n equals 5 or 8 for 5- and 8-DPT, respectively. 
The S-oxygenation of sulindac sulfide was determined by HPLC analysis as 
previously described with slight modifications [Hamman et al., 2000; Shimizu et al., 
2007b]. The reaction is shown in Figure 2.3. A standard incubation mixture of 250 µl 
final volume contained 50 mM potassium phosphate buffer, pH 8.4, 0.4 mM NADP+, 
0.4 mM glucose-6-phosphate, 4 U glucose-6-phosphate dehydrogenase, 0.25 mM 
n n 
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DETAPAC, and 40 µg/ml wild-type MBP-FMO3 or MBP-FMO3 variant. Incubations 
were initiated by the addition of sulindac sulfide to a final concentration of 200 µM. 
After incubation for 20 minutes with continuous shaking under aerobic conditions at 
37 °C, the incubation was stopped by addition of 20  µl cold 25 % phosphoric acid and 
4 volumes of ethyl acetate. The incubations were mixed and centrifuged to partition 
metabolites and remaining substrate into the organic fraction. The organic fraction 
was collected and evaporated under a stream of argon. Metabolites and remaining 
substrate were dissolved in methanol, mixed thoroughly, centrifuged, and analyzed 
with a Hitachi HPLC system (Hitachi L-7200 autosampler and L-7100 pump 
interfaced to a Hitachi L-7400 UV detector). Chromatographic separation of analytes 
was performed on an Axxi-Chrom reverse phase analytical column (250 x 4.6 mm 5 
µm, Supelco) with a mobile phase consisting of 70 % acetonitrile and 30 % 
phosphate buffer, pH 3. The flow rate was 1.0 ml/min and the total run time was 12 
minutes. The wavelength for UV detection was set to 360 nm. The retention times for 
sulindac sulfide and sulindac S-oxide were 9.6 and 5.0 minutes, respectively. 
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Figure 2.3 S-Oxygenation of sulindac sulfide by FMO.  
To determine the thermal stability of wild-type MBP-FMO3, MBP-FMO3 V187A, and 
MBP-FMO3 V187A/E158K, all three FMO enzymes were incubated at 40 °C for 0, 1, 
and 5 minutes in the presence or absence of an NADPH-regenerating system prior to 
the addition of the completed reaction mixture. N-Oxygenation of 8-DPT was 
determined using the HPLC method described above. Mean velocity calculated for 
0 minutes incubation at 40 °C was designated as 100  % for each recombinant 
enzyme, and the velocities for heat-treated enzymes were normalized accordingly. 
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2.2.8 Data Analysis 
The kinetic parameters for TMA and MMI were determined by examining the data 
from incubation of at least five different substrate concentrations with MBP-FMO3 
variants. Incubations were done in triplicate and for data analysis a nonlinear 
regression curve fit tool using a Michaelis-Menten model (Y= (Vmax · X)/(Km + X) with 
Vmax = Ymax and Km = Xmid) in Graphpad software (Graphpad Prism, Version 3.00, 
San Diego, CA, USA) was utilized. Data obtained was presented as the best fit value 
± standard error. Statistical analysis was also done using Graphpad Prism software 
and statistical significance was judged at P<0.05. 
2.3 Results  
2.3.1 Phenotyping and Genotyping Results   
Diagnosis of TMAu included measurement of the urinary ratios of TMA N-oxide to 
TMA and genotyping of the affected individuals. A urine and blood sample from a 
young woman of Northern European descent with a history of unpleasant body odor 
was examined and the phenotype as well as genotype was determined. When 
determining TMA and TMA N-oxide levels in the urine of this sample, TMA could be 
detected whereas no TMA N-oxide was detectable indicating severely abnormal TMA 
metabolism.  
Genotyping of the 33 year old female showed several mutations at a number of 
different loci. One heterozygous missense mutation identified was Val (GTT) to Ala 
(GCT) at position 187 in exon 4 of the FMO3 gene. This is the first time this mutation 
was detected after genotyping over 100 individuals with self-reported body odor at 
HBRI. The V187A mutation has not been reported in the literature by any other group 
genotyping and phenotyping individuals for FMO3. The individual was also identified 
as heterozygous for E305X, a known mutation leading to TMAu due to abolished 
FMO3 function. In addition, two common polymorphisms (i.e., E158K and E308G) 
were also identified and these SNPs have been shown to generally decrease FMO3 
activity when observed together [Cashman et al., 2003; Dolan et al., 2005; Zschocke 
et al., 1999]. Sometimes, TMAu observed from individuals harboring the 158/308 
mutations was modest and only observable under challenge situations such as 
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conditions of large dietary intake of TMA or TMA precursors. Other mutations were 
observed in the intronic regions with unknown biological significance and are not 
described here. Both biological parents of the young woman were also genotyped. 
The father was found to be heterozygous for E305X whereas the mother was 
heterozygous at three positions E158K/V187A/E308G. Thus, it was clear that 
E158K/V187A/E308G is on the same chromosome and inherited from the mother, 
and E305X is on the other chromosome inherited from the father. Unfortunately, the 
urine samples from the parents were not available for analysis. 
2.3.2 Cloning, Expression and Purification of Wild-type MBP-FMO3 and 
MBP-FMO3 Variants 
To study the effect of the novel V187A mutation on FMO3 enzyme function, and its 
effect on FMO3 enzyme activity in combination with the common E158K 
polymorphism, wild-type, V187A mutant, and V187A/E158K double-mutant FMO3s 
were expressed in E. coli as MBP-fusion proteins and assayed for their ability to 
catalyze the N- and S-oxygenation of various typical FMO substrates. When 
expressing the protein, we observed that the expression of both mutants (i.e., MBP-
FMO3 V187A and MBP-FMO3 V187A/E158K) was less efficient than that of wild-type 
MBP-FMO3, yielding only about 20 % of the wild-type protein expressed. Due to the 
significant decrease in expression and enzyme activity for both, V187A/E158K and 
E158K/E308G, the triple mutant E158K/V187A/E308G reflecting the genotype of one 
allele of the affected individual examined was not studied because of the difficulty in 
expression and characterization of the enzyme. 
2.3.3 Comparison of N- and S-Oxygenation Functional Activity of Wild-
type MBP-FMO3 with MBP-FMO3 Variants 
To compare the N- and S-oxygenation of wild-type MBP-FMO3 with MBP-FMO3 
V187A and MBP-FMO3 V187A/E158K, selective functional substrates (i.e., 5- and 
8-DPT) were used to examine N-oxygenation and sulindac sulfide was used as 
substrate to investigate differences in S-oxygenation. The results (Figure 2.1) 
showed that wild-type MBP-FMO3 had the highest N-oxygenation activity followed by 
MBP-FMO3 V187A with a specific activity of 69 % of wild-type N-oxygenation activity 
for 5- and 8-DPT. MBP-FMO3 V187A/E158K had the lowest specific activity with only 
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15 and 17 % of wild-type activity for 5- and 8-DPT, respectively. MBP-FMO3 V187A 
had an S-oxygenation activity of 102 % for sulindac sulfide compared to wild-type 
MBP-FMO3. For MBP-FMO3 V187A/E158K the S-oxygenation was decreased to 
only 31 % of wild-type values for sulindac sulfide S-oxygenation. 
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Figure 2.1 Specific activity for N-oxygenation of 5-DPT and 8-DPT and 
S-oxygenation of sulindac sulfide by wild-type MBP-FMO3 (white bars), MBP-FMO3 
V187A (grey bars), and MBP-FMO3 V187A/E158K (black bars) in nmol/min/mg of 
FMO3 enzyme.  
Statistically significant differences between wild-type MBP-FMO3 and MBP-FMO3 
V187A or wild-type MBP-FMO3 and MBP-FMO3 V187A/E158K are identified with 
*  for P<0.05, ** for P<0.01, and *** for P<0.001. 
2.3.4 Kinetic Parameters for TMA N-Oxygenation by MBP-FMO3 and 
MBP-FMO3 Variants 
To determine the kinetic parameters for TMA N-oxygenation by MBP-FMO3 V187A 
and MBP-FMO3 V187A/E158K, the enzymes were incubated with different 
concentrations of TMA. The single mutant V187A had a similar Vmax and Km value as 
the wild-type enzyme. However, the double mutant MBP-FMO3 V187A/E158K had a 
much lower Vmax value and a Km that was 25-fold greater than that of MBP-FMO3 
  ** 
**   *** 
  *** 
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V187A or wild-type MBP-FMO3, causing a 65-fold decrease in catalytic efficiency for 
TMA (Table 2.2).  
Table 2.2 N-Oxygenation of trimethylamine (TMA) by wild-type MBP-FMO3, 
MBP-FMO3 V187A, and MBP-FMO3 V187A/E158K. 
 WT FMO3 FMO3 V187A FMO3 V187A/E158K 
Km (µM) 15.3 ± 5.1 17.5 ± 5.3 430 ± 150 
Vmax (nmol min-1 mg-1) 11.9 ± 1.3 19.3 ± 2.0 6.3 ± 1.1 
Vmax/Km (10-3 min-1 mg-1) 0.8 ± 0.2 1.1 ± 0.2 0.02 ± 0.01 
Data are best fit values ± standard error. WT MBP-FMO3 data was calculated from 
one or two assays from two separate enzyme preparations. Data of MBP-FMO3 
V187A was calculated from four assays from pooled enzyme of three enzyme 
preparations. MBP-FMO3 V187A/E158K data was calculated from two assays from 
pooled enzyme of four enzyme preparations. 
 
2.3.5 Kinetic Parameters for MMI S-Oxygenation by MBP-FMO3 and 
MBP-FMO3 Variants 
To determine the kinetic parameters for MMI S-oxygenation by MBP-FMO3 V187A 
and MBP-FMO3 V187A/E158K, the enzyme was incubated with different 
concentrations of MMI. All three enzymes had similar Km values. The single mutant 
V187A also had a similar Vmax value as the wild-type enzyme, but the Vmax value of 
the double mutant MBP-FMO3 V187A/E158K was only 24 % of that of the wild-type 
enzyme (Table 2.3). 
 
 
 
 
2  Novel Variant of the Human FMO3 Gene Associated with Trimethylaminuria 
   
43 
 
Table 2.3 S-Oxygenation of mercaptoimidazole (MMI) by wild-type MBP-FMO3, 
MBP-FMO3 V187A, and FMO3 V187A/E158K. 
 WT FMO3 FMO3 V187A FMO3 V187A/E158K 
Km (µM) 12.7 ± 2.0 9.7 ± 1.9 11.7 ± 1.7 
Vmax (nmol min-1 mg-1) 27.8 ± 0.9 30.3 ± 1.4 6.8 ± 0.2 
Vmax/Km  (10-3 min-1 mg-1) 2.2 ± 0.3 3.1 ± 0.5 0.6 ± 0.1 
Data are best fit values ± standard error. WT MBP-FMO3 data was calculated from 
two enzyme preparations. Data of MBP-FMO3 V187A was calculated from two 
assays from pooled enzyme of three enzyme preparations. MBP-FMO3 
V187A/E158K data was calculated from pooled enzyme of four enzyme preparations. 
2.3.6 Stability of MBP-FMO3 and MBP-FMO3 Variants 
The N-oxygenation of 5-DPT was determined by HPLC analysis as described under 
enzyme assays after incubation of the three FMO enzymes at 40 °C for 0, 1, 2, and 5 
minutes in the presence or absence of an NADPH-regenerating system. In Figure 2.2 
only wild-type MBP-FMO3 and MBP-FMO3 V187A are shown, because the 
functional activity of MBP-FMO3 V187A/E158K was non-detectable after incubation 
at 40 °C regardless of the presence or absence of a n NADPH regeneration system. 
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Figure 2.2 N-Oxygenation of 5-DPT by wild-type MBP-FMO3 (white bars) and 
MBP-FMO3 V187A (hatched bars) after incubation at 40 °C for 1 and 5 minutes with 
or without cofactor added expressed as % remaining activity.  
The 0 minutes time point is set 100 % and equals 72 and 19 nmol/min/mg of FMO3 
for wild-type MBP-FMO3 and MBP-FMO3 V187A, respectively. Statistically 
significant differences between wild-type MBP-FMO3 and MBP-FMO3 V187A are 
identified with * for P<0.05, ** for P<0.01, and *** for P<0.001.   
While no significant difference between the relative loss of activity for the wild-type 
enzyme compared to MBP-FMO3 V187A was observed after pre-incubation at 40 °C, 
a distinct difference was notable when both enzymes were pre-incubated at elevated 
temperature in the presence of NADPH for 1 and 5 minutes (Figure 2.2, P<0.001). 
About 70 % of the wild-type MBP-FMO3 activity was retained whereas the enzyme 
activity of MBP-FMO3 V187A increased to 140 and 170 % of its original activity after 
1 and 5 minutes preincubation with NADPH, respectively. 
  *** 
  *** 
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2.4 Discussion 
Comprehensive biochemical characterization of recombinant variant FMO3 enzymes 
based on data from genotype and phenotype analysis of individuals with 
self-reported symptoms of TMAu can potentially reveal important new information 
about structure and function of human FMO3 [Akerman et al., 1999; Cashman, 2002; 
Cashman et al., 2002; Dolphin et al., 1997a; Shimizu et al., 2007b; Treacy et al., 
1998; Yeung et al., 2007]. Findings from the studies herein provide important new 
information to our understanding of factors contributing to the primary genetic form of 
TMAu, and identify a functionally important residue of human FMO3. For the samples 
examined from the 33 year old woman, the novel mutation V187A in combination 
with the two common polymorphisms, E158K and E308G, were causative for 
decreased TMA metabolism and the resultant severe TMAu was confirmed by 
phenotyping studies. 
Despite the subtlety of the V187A mutation, in combination with the E158K and 
E308G polymorphisms, a major impact on FMO3 enzyme functional activity could be 
observed that led to an enzyme with significantly decreased activity. To confirm this, 
not only the FMO3 V187A mutant enzyme, but also the double mutant, FMO3 
V187A/E158K were expressed and purified and the enzyme function of both 
enzymes was characterized and compared with wild-type FMO3 using selective 
functional substrates. As shown in Figure 2.1, FMO3 enzyme activity observed from 
wild-type MBP-FMO3 confirmed that all substrates examined were efficiently 
oxygenated by human FMO3. The V187A mutation decreased the catalytic efficiency 
of the enzyme for 5-DPT and 8-DPT, and the double mutant V187A/E158K further 
decreased enzyme activity significantly for all substrates tested. Kinetic parameters 
for TMA N-oxygenation by MBP-FMO3 V187A and MBP-FMO3 V187A/E158K (Table 
2.2) showed that although Vmax/Km for MBP-FMO3 V187A did not differ from wild-type 
MBP-FMO3, the Vmax/Km for MBP-FMO3 V187A/E158K was significantly decreased 
(65-fold). The kinetic parameters of MMI S-oxygenation by FMO3 (Table 2.3) showed 
similar Vmax/Km values for wild-type MBP-FMO3 and MBP-FMO3 V187A whereas the 
Vmax/Km for V187A/E158K for MMI S-oxygenation was about 4-fold lower than that of 
wild-type MBP-FMO3.  
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It has been reported previously that mutations that did not have a significant impact 
on specific activity of FMO3 by themselves decrease its oxygenation activity 
significantly in combination with other SNPs [Akerman et al., 1999; Cashman et al., 
2003; Zschocke et al., 1999]. Similarly, the effect of the V187A mutation on FMO3 
functional activity is not very distinct, but in combination with the common mutation 
E158K the enzymes oxygenation activity is drastically decreased for all substrates 
tested. 
As shown in 2.3 A, position V187 is a highly conserved residue within the FMO gene 
family (i.e., FMO1 to 5) and across species (i.e., chimpanzee, rhesus monkey, dog, 
cattle, rabbit, chicken, rat, and mouse). From the primary sequence, the mutation is 
immediately upstream of the essential FMO3 NADPH binding domain (GXGXXG) 
(Figure 2.3). According to the human FMO3 homology structure model we developed 
based on four related proteins [Borbas et al., 2006b], the residue V187 resides at the 
beginning part of a β-sheet leading to the NADPH binding domain. The residue is 
also conserved in FMO from Schizosaccharomyces pombe and Methylophaga sp. 
strain SK1, two FMO related enzymes with crystal structures recently solved [Alfieri 
et al., 2008; Eswaramoorthy et al., 2006], and phenylacetone monooxygenase from 
Thermobifida fusca, the first Baeyer-Villiger monooxygenase crystallized [Malito et 
al., 2004] (Figure 2.3 B). Based on the crystal structure of these related enzymes, the 
hypothesis is that the Val resides in the second Rossmann fold involved in 
NADP+/NADPH binding. From the structure of Methylophaga FMO with NADP+, the 
Val side chain does not directly interact with NADP+. We hypothesize that the mutant 
amino acid of FMO3 V187A interferes with NADPH and NADP+ binding indirectly 
through affecting the Rossmann fold conformation. Alternatively, it is possible that the 
enzyme adopts large conformational changes during catalytic processes to 
accommodate substrate binding and hydroperoxyflavin formation [Alfieri et al., 2008]. 
However, no crystal structure is available yet to illustrate those conformations. During 
such putative conformational changes, the Val could directly interact with NADPH 
and/or NADP+ binding, and therefore the V187A can possibly have direct interference 
with NADPH and/or NADP+ binding as well. As expected, the data from heat 
treatment (Figure 2.2) showed that wild-type MBP-FMO3 is not stable under elevated 
temperature when incubated in the absence of NADPH. Interestingly, a significantly 
higher activity was observed after pre-incubation of the V187A mutant 
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Figure 2.3 A Alignment of amino acids 179 to 200 for various FMOs.  
V187 is highly conserved in FMO family members (FMO1, 3, 4, and 5) and across species 
lines. Amino acids adjacent to V187 including the nearby NADPH-binding domain (GxGxxG). 
Human FMO family members (FMO1 – 5) and FMO3 from different species including 
chimpanzee, rhesus monkey, dog, cattle, rabbit, chicken, rat, and mouse, are aligned based 
on homology. The GenBank accession number for each gene is indicated. The NADPH 
binding domain (GxGxxG) located downstream of V187 is marked. The V187 residue is 
conserved in all FMO genes listed except for human FMO2. 
B Alignment of FMO3 amino acids 179 to 200 with the bacterial FMO from Methylophaga 
sp., a yeast FMO from Schizosaccharomyces pombe as well as a Baeyer-Villiger 
monooxygenase, PAMO (Phenylacetone monooxygenase).  
V187 is highly conserved in all aligned flavoprotein monooxygenases. The GenBank 
accession number for each gene is indicated. The NADPH binding domain (GxGxxG) located 
downstream of V187 is marked. 
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enzyme with NADPH at 40 °C. This also points to a d ecreased or slower interaction 
with the enzyme’s cofactor. Based on the literature, the departure of NADP+ is 
proposed to be the rate-limiting step in the catalytic cycle of FMO enzymes [Beaty et 
al., 1981a; Beaty et al., 1981b; Jones et al., 1986; Poulsen et al., 1979; Ziegler, 
1988]. It is possible that the V187A mutation interferes with NADPH binding and the 
enzyme binds the NADPH less efficiently. To verify the possibility that wild-type 
FMO3 and FMO3 V187A kinetics differ from each other the effect of NADP+ on the 
selective functional activity of both enzymes was examined. NADP+ has been 
reported in the literature to be a non-competitive inhibitor of FMO1 against the 
xenobiotic substrate and a competitive inhibitor of NADPH binding to FMO1 [Beaty et 
al., 1981b; Poulsen et al., 1979]. The effect of NADP+ on the selective functional 
activity of wild-type MBP-FMO3 and MBP-FMO3 V187A was examined. For MBP-
FMO3 V187A, increasing concentrations of NADP+ not only led to a decrease in Vmax, 
but also resulted in a significant decrease in Km (data not shown), suggesting that this 
variant follows an un-competitive model rather than a non-competitive model as 
proposed for pig-liver FMO1. Unfortunately, the photometric assay readouts in the 
presence of NADP+ reduced the range of assay detection limit and a conclusion of 
whether the inhibition mechanism is significantly different for the V187A variant 
compared to wild-type FMO3 cannot be reliably made. Alternative stopped-flow 
kinetic analysis will be necessary to clarify this issue. Thus, NADP+ could not be 
confirmed as a non-competitive inhibitor of MMI S-oxygenation in the presence of 
wild-type FMO3. Characterization of the V187A mutant in this report may prompt 
additional studies to test the hypothesis of cofactor interaction once additional FMO3 
structural information becomes available and stopped-flow kinetic studies are 
performed.   
It is also notable that enzyme expression for the recombinant protein is significantly 
lower for the V187A containing variants, suggesting that protein folding may not be 
as efficient as the wild-type enzyme. Whether this is occurring in the in vivo situation 
and results in lower overall FMO3 protein concentration in the adult human liver of 
affected individuals remains to be determined. 
It has been reported previously that patients carrying heterozygotic FMO3 mutations 
show the TMAu phenotype, [Fujieda et al., 2003; Zhang et al., 2003; Zschocke et al., 
1999]. The possibility that other mutations in intronic regions of the allele that encode 
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for the functional enzyme can affect the enzyme expression level cannot be 
excluded. However, in the presence of different detergents formation of stable and 
catalytically active oligomeric forms of purified recombinant human FMO3 was 
observed (chapter 3) and similar observations were reported earlier [Ziegler et al., 
1972]. Whether FMO3 mutants can interfere with self oligomer-formation and/or 
hetero oligomer formation with wild-type enzymes and hence lead to lower overall 
enzyme activity is not known. The characterization of these effects in the in vivo 
setting that may affect oligomerization of FMO3 expressed from different alleles 
remains to be investigated.    
In summary, a novel FMO3 gene mutation associated with TMAu was recombinantly 
expressed and proved to influence substrate oxygenation characteristics. This novel 
mutation of human FMO3, V187A, in combination with the common polymorphism 
E158K leads to an enzyme that has less than 3 % TMA N-oxygenating activity 
compared with wild-type FMO3. Generally, the common polymorphisms E158K and 
E308G alter FMO3 enzyme activity only slightly [Cashman et al., 2000], but often, if 
the two polymorphisms occur together, they can lead to an FMO3 enzyme with 
decreased activity [Cashman et al., 2000; Cashman et al., 2003; Dolan et al., 2005; 
Zschocke et al., 1999] and this has been reflected in in vivo functional activity leading 
to elevated unmetabolized TMA [Lambert et al., 2001; Zschocke et al., 1999]. 
Similarly, the novel V187A mutation in conjunction with the common polymorphisms 
E158K and E308G significantly impairs FMO3 resulting in an enzyme with drastically 
decreased function that manifests itself in severe TMAu. 
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3 Expression, Purification, and Characterization of Human 
FMO5 
3.1 Introduction and Aim of the Study 
FMOs are, after cytochromes P450, the most important monooxygenase system in 
humans and are involved in metabolism of many xenobiotics. Nevertheless, there is 
still a need to further the knowledge of this enzyme family, especially of to date 
neglected but possibly important isoforms such as FMO5. 
In order to study structure and function of FMO5, the protein needs to be expressed 
and purified successfully. It is further important to characterize the purified FMO5. 
Detailed characterization becomes indispensable when attempting crystallography 
studies (chapter 4). The protein has to fulfill several requirements including sufficient 
purity and monodispersity. Also, it has to be functionally active and stable over a 
reasonable time period. 
For future characterization studies of FMO5 the enzyme should be expressed as 
N-terminal maltose-binding fusion protein in E. coli (i.e., MBP-FMO5), solubilized 
from the bacterial membrane, and purified. The MBP-fusion construct has proven to 
be successful in expression of FMO enzymes yielding stable and highly active 
enzyme at greater purity than was readily possible before [Brunelle et al., 1997]. 
Solubilization studies should be done to determine a suitable detergent for extraction 
of FMO5 from cells and subsequent purification utilizing different methods (i.e., 
affinity chromatography, ion exchange chromatography) to obtain highly pure FMO5. 
Further, the purified enzyme should be analyzed in various ways. Firstly, the 
expressed and purified recombinant produced MBP-tagged hFMO5 should be 
compared to commercially available hFMO5 (BD Gentest Supersomes, BD 
Biosciences, San Jose, CA, USA) in order to show that MBP-FMO5 may be used 
instead of commercially available FMO5 for kinetic and structural studies. Secondly, 
stability, oligomerization state as well as monodispersity of the purified FMO5 should 
be examined. 
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3.2 Materials and Methods 
3.2.1 Reagents 
Chemicals and reagents used in this study were purchased from Sigma-Aldrich 
Chemical Co. (St Louis, MO, USA) in appropriate purity. Buffers and other reagents 
were purchased from VWR Scientific, Inc. (San Diego, CA, USA). The synthesis of 
the phenothiazine 8-DPT has been previously described [Lomri et al., 1993b; Nagata 
et al., 1990; Zhang et al., 2007a] and was done by Dr. Karl Okolotowicz (HBRI, San 
Diego, USA). Detergents were purchased from Anatrace (Maumee, OH, USA). MBP 
column material was purchased from New England BioLabs (Ipswich, MA, USA). 
Fast performance liquid chromatography (FPLC) columns were purchased from GE 
Healthcare (Uppsala, Sweden). Baculovirus-insect cell expressed FMO5 was 
purchased from BD Biosciences (BD Gentest Supersomes, BD Biosciences, San 
Jose, CA, USA). 
3.2.2 Expression of MBP-hFMO5 and Optimization of the Affinity 
Chromatography Purification Method  
3.2.2.1 Cloning and Expression 
Human FMO5 was expressed as N-terminal maltose-binding fusion protein (MBP-
FMO5).  As described previously for mouse FMOs [Zhang et al., 2007a], the hFMO5 
gene was amplified at HBRI (San Diego, CA, USA) via reverse transcription (RT-) 
PCR from RNA using the following primers: 5’-hFMO5 
GATCTCTAGAATGACTAAGAAAAGAATTGCTGTGA (XbaI site underlined) and 
3’-FMO5 GATCCTGCAGCCAATGAAAAACAGGGCAGT (PstI site underlined). The 
hFMO5 gene was then subcloned into the expression vector pMAL-c2 (New England 
BioLabs, Ipswich, MA, USA) through the corresponding cloning sites XbaI and PstI. 
The construct is shown in Figure 3.1.  
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Figure 3.1 pMAL Vector with human FMO5.  
The ampicillin-resistant site not shown in the Figure. 
E. coli DH1α cells transfected with pMAL-MBP-FMO5 plasmid were grown at 37 °C 
and 300 rpm in SOC medium containing 100 µg/ml ampicillin to an absorbance of 
0.4 – 0.5 at 600 nm. Induction solution (containing 0.2 mM isopropyl 
β-thiogalactopyranoside and 0.05 mM riboflavin) was added, flasks were covered 
with aluminum foil to keep riboflavin from light induced degradation, and the cells 
were further incubated shaking for 20 hours at room temperature. Cells were 
harvested by centrifugation at 6,000 g for 10 minutes.  All of the following procedures 
were carried out at 4 °C. The cell pellet was resus pended in lysis buffer (consisting of 
50 mM Na2HPO4, pH 8.4, containing 0.5 % Triton® X-100, 0.2 % 
pMal-hFMO5
8273 bp
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m alE
Ptac
lacI
Pst I (4353)
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L-α-phosphatidylcholine, 0.5 mM phenylmethylsulfonylfluoride, and 100 mM FAD) as 
described previously [Lattard et al., 2003b]. The resuspended cells were disrupted by 
sonication (i.e., five 8-seconds bursts separated by periods of cooling on a Sonics 
vibracell ultrasonic processor (Sonics and Materials Inc., Newtown, CT, USA)). The 
solution was centrifuged for 25 minutes at 18,000 g and 4 °C. 
3.2.2.2 Extraction and Solubilization Studies 
Effect of Different Detergents on N-Oxygenation Activity of MBP-hFMO5  
The effects of a variety of detergents on N-oxygenation activity of FMO5 protein were 
tested by measuring enzyme activity of FMO5 after precipitation and re-solubilization 
with 8-DPT as substrate. 
For precipitation polyethylene glycol (PEG) was used as previously described [Lomri 
et al., 1993a]. An equal amount of 40 % PEG 8000 was added to the enzyme 
solution, mixed thoroughly, and centrifuged at 15,000 g in a bench top centrifuge for 
20 minutes at 4 °C. Supernatant was discarded and t he remaining pellet was 
resuspended in 50 mM potassium phosphate buffer, pH 8.4, containing 1 or 2 x 
critical micelle concentration (CMC) of one of the following detergents: the zwitter-
ionic detergents CHAPS (3-[(3-Cholamidopropyl)dimethylammonio]-1-
propanesulfonate) or FOS-CHOLINE®-12 (n-Dodecylphosphocholine, FC12), or the 
non-ionic detergents, n-decyl-β-D-maltoside (DM), n-dodecyl-β-D-maltoside (DDM), 
n-Octyl-β-D-glucoside (ODG), Cymal®-5, 6, and 7 (5-Cyclohexyl-1-pentyl-β-D-
maltoside, C5), and Triton® X-100 (α-[4-(1,1,3,3-Tetramethylbutyl)phenyl]-hydroxy-
poly(oxy-1,2-ethanediyl, TX100) (Table 3.1). The different batches were analyzed 
afterwards for 8-DPT N-oxygenation activity. 
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Table 3.1 Detergents tested in solubilization studies. 
Detergent CMC (H2O)1 Structure 
CHAPS 
8 mM  
(0.49 %) 
 
 
 
 
 
 
 
FC12 
1.5 mM 
(0.047 %) 
 
 
 
DM 
1.8 mM 
(0.087 %) 
 
 
 
 
DDM 
0.17 mM 
(0.0087 %) 
 
 
 
ODG 
18-20 mM 
(0.53 %) 
 
 
 
C5-7 
C5 = 2.4-5 mM 
(0.12 %) 
C6 = 0.56 mM 
(0.028 %) 
C7 = 0.19 mM 
(0.0099 %) 
 
TX 100 
0.23 mM 
0.010 - 0.016 %  
 
 
 
 
1CMC values taken from supplier (Anatrace, Maumee, OH, USA); % given as (w/v). 
FOS-CHOLINE®-12, FC12; n-decyl-β-D-maltoside, DM; n-dodecyl-β-D-maltoside, 
DDM; n-Octyl-β-D-glucoside, ODG; Cymal®-5, 6 and 7, C5-7, and Triton® X-100, 
TX100. 
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Comparison of Extraction Efficiency of DDM and DM 
E. coli with human pMAL-MBP-FMO5 was grown, induced, and pelleted. The pellets 
were than resuspended in lysis buffer containing either 0.1 – 0.2 % DM or 0.01 –  
0.02 % DDM and disrupted by sonication. After addition of NADPH-regenerating 
system (see chapter 3.2.4.2) the solution was mixed thoroughly and centrifuged. To 
determine extraction efficiency, the supernatant was afterwards incubated with 
8-DPT for 20 minutes for determination of enzyme activity (see chapter 3.2.4.2). 
Extraction Efficiency of Triton® X-100 vs. DDM 
E. coli with human pMAL MBP-FMO5 was grown, induced, and pelleted. The pellets 
were than resuspended in lysis buffer containing either 0.01 % DDM or 0.5 % 
Triton® X-100 and disrupted by sonication. As control, the pellet resulting from lysis 
with DDM was extracted a second time after centrifugation, this time with 
Triton® X-100. For batch-wise purification, 300 µl amylose column material 
equilibrated with 50 mM sodium phosphate buffer, pH 8.5, was added to all three 
supernatants (each 5 ml). After 3 hours incubation at 4 °C, the column material was 
washed with equilibration buffer and finally MBP-hFMO5 was eluted with 50 mM 
sodium phosphate buffer, pH 8.5, containing 10 mM maltose by incubation at 4 °C for 
20 minutes and subsequent centrifugation. Afterwards, the supernatant was analyzed 
for enzyme activity as described in chapter 3.2.4.2. 
3.2.2.3 Affinity Chromatography  
The first purification step after cell lysis exploited the MBP-affinity tag connected to 
the FMO5 enzyme. Thus, after centrifugation of the lyzed cells, the supernatant was 
loaded onto an amylose column (New England BioLabs, Ipswich, MA, USA). In order 
to improve the yield of protein, the pellets were extracted one more time as described 
above (chapter 3.2.2.1) and the resulting supernatant was also loaded onto the same 
amylose column. Protein purification was carried out on a low pressure 
chromatography system, Biologic LP (Bio-Rad, Hercules, CA, USA). For a 6 l 
bacterial culture, a 10 ml amylose column was used. After loading the supernatants 
at 1 ml/min onto a column equilibrated with ten column volumes of buffer A (i.e., 
50 mM Na2HPO4, pH 8.4, and 0.5 % Triton® X-100 containing 15 µg/ml FAD) the 
column was washed with at least ten column volumes of buffer A. Bound 
MBP-hFMO5 protein was then eluted with 3 mM maltose in buffer A at 1 ml/min. 
3  Expression, Purification, and Characterization of MBP-hFMO5 
   
56 
 
Eluted fractions were analyzed via absorption at 280 nm (Figure 3.5), SDS-PAGE 
(chapter 3.2.4.1), or HPLC-based enzyme activity assay (chapter 3.2.4.2). Fractions 
containing the fusion protein were concentrated with an Amicon Ultra-15 centrifugal 
filter unit with an Ultracel-50 filter (Millipore, Billerica, MA, USA). 
3.2.3 Development of an Ion Exchange Chromatography Method  
3.2.3.1 Buffer and Column Selection 
A protocol for further protein purification utilizing ion exchange chromatography was 
developed. 700 mg of MBP-hFMO5 from 4 separate 6 l bacterial cultures was pooled 
after affinity chromatography and used to develop such a protocol. 2.5 mg of this 
protein was loaded at 1 ml/min onto a 1 ml DEAE, Q, or ANX column (HiTrap FF 
columns, GE Healthcare, Uppsala, Sweden) at four different pHs (i.e., pH 6, 7, 8, and 
9). Elution profiles showing absorption at 280 nm and SDS gels of eluted fractions 
were evaluated regarding capture of MBP-hFMO5 protein. 
3.2.3.2  Determination of a Salt Gradient 
After choosing a column, an adequate salt gradient was determined. Affinity column 
purified MBP-hFMO5 was loaded onto a 1 ml HiTrap Q FF column at 1 ml/min and 
washed with 50 mM Bis-Tris , pH 6 (buffer B) containing 0.01 % DDM. A linear salt 
gradient of first 0 – 50 % and later 1 – 30 % 1 M NaCl in buffer B containing 0.01 % 
DDM was applied over 20 column volumes. Salt concentrations for a suitable step 
gradient for separation of contaminating protein and MBP-hFMO5 was roughly 
estimated from the first two linear gradients. The approximated step gradient was 
refined by repetitive ion exchange purification and SDS gel analysis of resulting 
fractions varying only the salt concentration of the different steps in the gradient. 
3.2.3.3 Scale-Up Experiments 
For larger amounts of purified protein the ion exchange chromatography method 
developed was transfered to a 5 ml Q HP column (GE Healthcare, Uppsala, 
Sweden). 30 mg of affinity purified MBP-hFMO5 was loaded onto a 5 ml Q HP 
column at 5 ml/min and eluted with a step gradient of 6.5 % and 25 % 1 M NaCl. 
Likewise, ion exchange purification could be adapted to 1 ml HiTrap Q HP columns 
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(GE Healthcare, Uppsala, Sweden) using a flow rate of 1 ml/min and a step gradient 
of 65 mM and 250 mM NaCl. 
An overview of the purification process including columns, buffers, and flow rates is 
given in Table 3.2. 
Table 3.2 Overview over the parameters in the purification process. 
 Chromatography method 
 Affinity Anion exchange Size exclusion 
Column 10 ml amylose 
column 
1 ml HiTrap Q 
FF or HP 
5 ml HiTrap Q 
HP  
Superose 6 
10/300 GL 
Equilibration 
buffer 
50 mM Na2HPO4 
pH 8.4, 15 µg/ml 
FAD, ± 0.5 % 
Triton® X-100 
50 mM Bis-Tris 
pH 6 ± 0.01 % 
DDM 
50 mM Bis-Tris 
pH 6 ± 0.01 % 
DDM 
50 mM Bis-Tris 
pH 6, 0.01 % 
DDM 
Elution buffer 50 mM Na2HPO4 
pH 8.4, 15 µg/ml 
FAD, 3 mM 
maltose, ± 0.5 % 
Triton® X-100 
50 mM Bis-Tris 
pH 6 ± 0.01 % 
DDM, 
stepgradient: 
0, 65, 250 and 
1000 mM NaCl 
50 mM Bis-Tris 
pH 6 ± 0.01 % 
DDM, 
stepgradient: 
0, 65, 250 and 
1000 mM NaCl 
 
Flow rate 1 ml/min 1 ml/min 5 ml/min 0.5 ml/min 
Fraction size 5 ml 1 ml 5 ml 1 ml 
Detection  
wavelength 
280 nm 280 and 
450 nm 
280 and 
450 nm 
280 and    
450 nm 
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3.2.4 Characterization of Purified MBP-hFMO5 
3.2.4.1 Determination of MBP-hFMO5 Concentration 
Concentration of purified MBP-hFMO5 was determined by SDS-PAGE and 
Coomassie Blue staining and compared with bovine serum albumin (BSA) standard. 
MBP-hFMO5 proteins and different quantities of standard BSA (i.e., 2, 1.5, 1.0, 0.5, 
and 0.1 µg per lane) were fractionated by electrophoresis on a 10 % polyacrylamide 
gel under denaturing conditions and stained with Coomassie Blue. After destaining, 
FMO5 quantification was done by densitometry analysis employing Kodak molecular 
imaging software (Eastman Kodak Company, Rochester, NY, USA) or Adobe 
Photoshop Elements (Version 7). 
For protein concentration measurements of Q column purified fractions containing 
DDM instead of Triton® X-100 or no detergent at all, the absorbance at 280 nm was 
measured on a NanoDropTM ND-1000 UV/VIS Spectrophotometer (Thermo Fisher 
Scientific, Wilmington, DE, USA) using a calculated extinction coefficient of 
121 M-1cm-1 estimated after the method of Gill and von Hippel [Gill et al., 1989] using 
the online Protein Calculator v3.3. 
3.2.4.2 8-DPT N-Oxygenation Activity and Stability of MBP-hFMO5 
N-Oxygenation of 8-DPT HCl was determined by HPLC analysis as previously 
described [Lattard et al., 2003b]. A standard incubation mixture of 250 µl final volume 
contained 50 mM potassium phosphate buffer at pH 8.5, 0.4 mM NADP+, 0.4 mM 
glucose-6-phosphate, 4 U glucose-6-phosphate dehydrogenase, 0.25 mM 
DETAPAC, and 40 µg MBP-hFMO5. Reactions were initiated by addition of substrate 
to a final concentration of 400 µM. After incubation for 20 minutes shaking under 
aerobic conditions at 37 °C, enzyme reactions were stopped by addition of 4 volumes 
of cold dichloromethane. About 20 mg of sodium carbonate
 
was added to incubations 
and they were mixed and centrifuged in order to partition metabolites and remaining 
substrate into the organic fraction. The organic phase was collected and evaporated 
under a stream of argon. Metabolites and remaining substrate were dissolved in 
methanol, mixed thoroughly, centrifuged, and analyzed with a Hitachi HPLC system 
(Hitachi L-7200 autosampler and L-7100 pump interfaced to a Hitachi L-7400 UV 
detector). Chromatographic separation of analytes was done on an Axxi-Chrom’s 
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normal phase analytical column (250 x 4.6 mm 5 µm, silica) with a mobile phase of  
80 % methanol/ 20 % isopropanol/ 0.025 % perchloric acid (v/v/v). The flow rate was 
1.6 ml/min and the total run time was 11 minutes. The wavelength for UV detection 
was set to 243 nm. Retention times for 8-DPT and 8-DPT N-oxide were 5.8, and 
4.3 minutes, respectively, and the enzyme activity was determined by calculation of 
the ratio of 8-DPT to 8-DPT N-oxide peak. 
Comparison of recombinant expressed MBP-hFMO5 and commercially available 
FMO5 (BD Gentest) was done by evaluating kinetic parameters and enzyme stability 
over 30 minutes at 37 °C for both enzymes. The kine tic parameters (i.e., Vmax and 
Km) for N-oxygenation of 8-DPT HCl by FMO5 was determined by HPLC analysis as 
described above. Incubations were initiated by the addition of different amounts of 
substrate. The final substrate concentrations were in the range of 10 µM – 2 mM. 
Stability was determined by incubating the enzyme in presence of cofactor and 
400 µM 8-DPT HCl for 5, 10, 20, and 30 minutes. 8-DPT HCl and its N-oxide were 
then analyzed on a HPLC system as described above. 
Stability of MBP-hFMO5 was determined by incubating 5 ml HP Q column-purified 
MBP-hFMO5 at 4 °C for 5 days. The 8-DPT N-oxygenation activity of MBP-hFMO5 
was determined for three time-points (i.e., day 0, day 3, and day 5). 500 mM NADP+ 
and/or 20 % glycerol was added to determine whether these supplements improve 
the enzyme’s stability. 
3.2.4.3 Native Gel Electrophoreses 
MBP-hFMO5 and five standard proteins (i.e., thyroglobulin (669 kDa), ferritin 
(440 kDa), aldolase (158 kDa), conalbumin (75 kDa), and ovalbumin (43 kDa)) were 
fractionated by electrophoresis on a NativePAGE Novex 3 – 12 % Bis-Tris Gel with 
Native-PAGE Running Buffer Kit (Invitrogen Corporation, Carlsbad, CA, USA) 
following the vendors instructions. After destaining, molecular weight determination of 
sample protein was done by comparison of MBP-hFMO5 bands with standard protein 
bands employing Kodak molecular imaging software (Eastman Kodak Company, 
Rochester, NY, USA).  
3  Expression, Purification, and Characterization of MBP-hFMO5 
   
60 
 
3.2.4.4 Size Exclusion Chromatography 
MBP-hFMO5 purified via affinity chromatography or ion exchange chromatography 
following affinity chromatography was also analyzed utilizing size exclusion 
chromatography.  Peak fractions of the protein from either column were concentrated 
and loaded onto a Superose 6 10/300 GL size exclusion column equilibrated with 
50 mM Bis-Tris, pH 6, containing 0.01 % DDM. 
3.2.4.5 Dynamic Light Scattering 
Protein was analyzed via dynamic light scattering (DLS) in order to determine the 
size distribution profile of the protein sample and ensure monodispersity before 
setting up crystallography experiments (chapter 4). For this purpose, 60 µl protein 
solutions in different concentrations and with various additives were analyzed with a 
Zetasizer Nano-S (Malvern Instruments Ltd, Malvern, United Kingdom). DLS 
measurements were done at the Zentrum für Biochemie und Molekularbiologie 
(ZBM), University of Kiel. FMO5 fractions analyzed included affinity column purified 
MBP-hFMO5, Q-purified MBP-hFMO5 with and without 20 % glycerol. Some 
MBP-hFMO5 fractions were treated with Calbiosorb Adsorbent beads (Merck, 
Darmstadt, Germany) in order to evaluate the effect of removal of excess detergent 
on monodispersity. Also, Calbiosorb Adsorbent beads treated Q-purified FMO5 was 
examined in different concentrations (i.e., 25, 10, 5, 2.5, and 0.25 mg/ml). 
3.2.5 Data Analysis 
Kinetic parameters for 8-DPT N-oxygenation activity were determined by examining 
the data from incubations of seven different substrate concentrations with 
MBP-hFMO5 (i.e., 0, 10, 40, 100, 200, 400, 800 µM, and 2 mM). Incubations were 
done in duplicates and for data analysis a nonlinear regression curve fit tool using a 
Michaelis-Menten model (Y= (Vmax · X)/(Km + X) with Vmax = Ymax and Km = Xmid) in 
Graphpad software (Graphpad Prism, Version 3.00, San Diego, CA, USA) was 
utilized. Time dependence of MBP-hFMO5 was also done in duplicates and data was 
analyzed with linear regression using Graphpad software. Data obtained was 
presented as the best fit value ± standard error. Statistical analysis was also done 
using Graphpad Prism software.  
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3.3 Results 
3.3.1 Expression and Purification of MBP-hFMO5 via Affinity 
Chromatography 
3.3.1.1 Extraction and Solubilization  
Effect of Different Detergents on N-Oxygenation Activity of MBP-hFMO5 
In order to determine a suitable detergent for MBP-hFMO5 solubilization and 
purification, the effect of nine different detergents (i.e., Triton® X-100, CHAPS, DM, 
DDM, ODG, FC12, and Cymal®-5, 6 and 7) on N-oxygenation activity of MBP-hFMO5 
were tested.  
In control experiments with MBP-hFMO5 solubilized in Triton® X-100 and 
MBP-hFMO5 after PEG precipitation and re-solubilization in Triton® X-100 no 
significant difference in enzyme activity between the two was observed (Figure 3.2). 
Overall, results showed that DM and DDM performed best even in concentrations of 
2 x CMC. Thus, these detergents were chosen for further analyzation. 
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Figure 3.2 Effect of a variety of detergents on MBP-hFMO5 activity.  
Amylose column purified MBP-hFMO5 was precipitated with 40 % PEG and 
resuspended in 50 mM phosphate buffer (pH 8.4) containing a variety of different 
detergents in two different concentrations: 1 x (grey bars) and 2 x CMC (black bars). 
8-DPT N-oxygenation activity of the enzyme was determined. For comparison, 
regular amylose column-purified MBP-hFMO5 in buffer containing 0.5 % 
Triton® X-100 that was not precipitated with 40 % PEG is shown as a white bar. 
Triton® X-100, TX100; n-decyl-β-D-maltoside, DM; n-dodecyl-β-D-maltoside, DDM; 
n-Octyl-β-D-glucoside, ODG; FOS-CHOLINE®-12, FC12; Cymal®-5, 6 and 7, C5-7.  
Extraction Efficiency of DDM and DM in Comparison 
Comparison between DM and DDM showed a very slight advantage of DDM over DM 
(data not shown). Thus, extraction efficiency of DDM was afterwards compared to 
that of Triton® X-100 anticipating replacement of the latter. 
Extraction Efficiency of Triton® X-100 and DDM 
Comparison of MBP-hFMO5 extraction efficiencies from bacterial cell pellets with 
Triton® X-100 and DDM showed that although DDM seemed to have no negative 
influence on enzyme activity, it was not suitable for extraction (Figure 3.3). When 
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extracting the bacterial cells with lysis buffer containing Triton® X-100 a larger 
amount of MBP-hFMO5 was obtained after purification with amylose resin in 
comparison to bacterial cells extracted with lysis buffer containing DDM. 
Only after the second extraction (i.e., with Triton® X-100 instead of DDM) of the 
bacterial pellet already extracted with DDM, an appropriate MBP-hFMO5 band could 
be observed on the SDS gel. Thus, Triton® X-100 was chosen for extraction of 
MBP-hFMO5 from bacterial cells and was used in the first purification step.  
Triton® X-100 is rather heterogeneous and thus not suitable for crystallography 
studies. In order to remove it, a buffer exchange was done on the ion exchange 
column switching to DDM as detergent (see also Figure 3.15) because although 
DDM did not extract the protein very efficiently, it was superior with regards to 
enzyme activity (Figures 3.2 and 3.3). 
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Figure 3.3 Extraction efficiency of Triton® X-100 and DDM. 
Coomassie stained SDS gel of: 1, pellet extracted with Triton® X-100; 2, pellet 
extracted with DDM; 3, second extraction of already with DDM extracted pellet with 
Triton® X-100; molecular weight (MW) marker, SeeBlue® Plus2 (Invitrogen 
Corporation, Carlsbad, CA, USA). The arrow points to the MBP-hFMO5 band. 
Later, after ensuring that no interference of DDM with the amylose column would 
occur, Triton® X-100 was replaced with DDM in the chromatography buffer in this first 
purification step (Figure 3.15). Subsequent studies showed that treatment of MBP-
hFMO5 with an excess amount of polystyrene beads to remove residual detergents 
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from the protein sample did not result in precipitation of MBP-hFMO5 (chapters 
4.2.4.3 and 4.3.1.3). Additional experiments also showed that MBP-hFMO5 could be 
purified in the absence of detergent. Thus, in the final purification protocol, 
Triton® X-100 was used to extract MBP-hFMO5 from E. coli cells, but all purification 
steps were done in the absence of detergent. An overview of the development and 
design of purification process including usage of detergents is given in Figure 3.15 at 
the end of this chapter. 
3.3.1.2 Affinity Chromatography  
In the first purification step utilizing an amylose column, a total of about 700 mg 
MBP-hFMO5 was obtained from four separate 6 l bacterial cultures (Figure 3.4). A 
representative elution chromatogram from this affinity purification step is shown in 
Figure 3.5. Protein concentration and the 8-DPT N-oxygenation activity were 
determined by HPLC analysis (Table 3.3). The obtained protein preparations were 
pooled and stored at -80 °C until used for ion exch ange chromatography method 
development and initial crystallography screens.  
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                        marker  2µg  0.8 µg   
Figure 3.4 Representative Coomassie stained SDS gel with 2 and 0.8 µg of affinity 
chromatography purified MBP-hFMO5 protein.  
SeeBlue® Plus2 (Invitrogen Corporation, Carlsbad, CA, USA) was used as MW 
protein marker. The arrow points to the MBP-hFMO5 band. 
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Figure 3.5 Representative elution profile of affinity chromatography of MBP-hFMO5.  
0 – 93 minutes, loading of protein; 93 – 188 minutes, wash step; 188 – 236 minutes, 
elution step with 3 mM maltose. 
 
Table 3.3  MBP-hFMO5 protein preparations of four separate 6 l bacterial cultures 
after affinity purification. 
Batch 8-DPT assay  Yield  
 
Specific activity  
(nmol/(min·mg)) 
Protein 
(mg/ml) 
Total volume of 
fraction (ml) 
Total amount of 
protein (mg) 
1 12.5 54 2.7 146 
2 5.0 39 3.2 126 
3 7.2 69 3.6 249 
4 7.1 57 3.5 199 
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3.3.2 Purification of MBP-hFMO5 via Ion Exchange Chromatography 
3.3.2.1 Columns, Buffers, and pH 
After affinity chromatography, a protocol for further protein purification utilizing ion 
exchange chromatography was developed using affinity column purified 
MBP-hFMO5 (section 3.2.2.3). The most promising conditions for further purification 
with an FPLC-system (Äkta-Purifier, GE Healthcare, Uppsala, Sweden) were 
determined by testing three different columns (i.e., DEAE, Q, and ANX) at different 
pHs (6 – 9). Most protein was captured at pH 6 on the ANX column followed by the Q 
column (Figure 3.6). For further purification, 1 ml or 5 ml HiTrap Q HP columns (GE 
Healthcare, Uppsala, Sweden) with Bis-Tris buffer at pH 6 were chosen because 
high performance columns are available for the Q column. Also, choosing a strong 
ion exchanger such as Q over a weak one (i.e., DEAE or ANX) is advantageous 
because it does not show variation in ion exchange capacity with change of pH.  
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Figure 3.6 Determination of a suitable anion exchange column and pH.  
% Area under the curve (AUC) of MBP-hFMO5 peaks in relation to AUC of all peaks 
eluted from the column (= 100 %) observed is shown for Q (black bars), ANX (grey 
bars), and DEAE (white bars) columns at pH 6, 7, 8, and 9.  
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3.3.2.2 Salt Gradient 
To separate protein impurities from MBP-hFMO5, a step gradient was determined on 
1 ml HiTrap Q FF column with affinity chromatography purified protein. Most 
impurities were eluted with 65 mM NaCl in buffer B. MBP-hFMO5 was then eluted 
with 250 mM NaCl in buffer B (Figure 3.7). 
3.3.2.3 Scale-Up Experiments 
For purification of larger amounts of MBP-hFMO5, a 5 ml HiTrap Q HP column was 
utilized. This column had been successfully used with 30 mg of affinity column 
purified MBP-hFMO5 and the previously determined step-gradient (elution of most 
impurities with 65 mM NaCl in buffer B followed by elution of MBP-hFMO5 with 250 
mM NaCl in buffer B). The elution profile as well as the SDS gel of the fractions 
obtained (Figure 3.8) look similar to those obtained with the 1 ml HiTrap Q FF 
column. 
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Figure 3.7 A Elution profile of MBP-hFMO5 purified on a 1 ml HiTrap Q FF column. 
Absorbance at 280 nm is shown as solid line, absorbance at 450 nm as dashed line.  
B Coomassie stained SDS gel of fractions from 1 ml HiTrap Q FF column eluted with 
a NaCl step-gradient as shown in A.  
The column was loaded with 7 mg concentrated amylose column-purified 
MBP-hFMO5. The washing buffer consisted of 50 mM Bis-Tris buffer, pH 6, 
containing 0.01 % DDM. SeeBlue® Plus2 (Invitrogen Corporation, Carlsbad, CA) was 
used as MW protein marker. The arrow points to the MBP-hFMO5 band.  
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Figure 3.8 A Elution profile of MBP-hFMO5 purified on a 5 ml HiTrap Q HP column. 
Absorbance at 280 nm is shown as solid line, absorbance at 450 nm as dashed line.  
B Coomassie stained SDS gel of fractions from 5 ml HiTrap Q HP column eluted with 
a NaCl step-gradient as shown in A.  
The column was loaded with 30 mg concentrated amylose column-purified 
MBP-hFMO5. The washing buffer consisted of 50 mM Bis-Tris buffer, pH 6, 
containing 0.01 % DDM.  SeeBlue® Plus2 (Invitrogen Corporation, Carlsbad, CA) was 
used as MW protein marker. The arrow points to the MBP-hFMO5 band.  
     1       2                                3                               4 
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3.3.3 Characterization of Purified MBP-hFMO5 
3.3.3.1 Comparison between Recombinant Expressed MBP-hFMO5 and 
Commercially Available FMO5 
8-DPT HCl Substrate Dependence 
Kinetic parameters (i.e., Vmax and Km) for N-oxygenation of 8-DPT HCl by FMO5 were 
determined by HPLC analysis and the results are shown in Figure 3.9 and Table 3.4.  
Both enzymes had very similar Km values (i.e., 120 ± 21 µM for Gentest FMO5 and 
117 ± 21 µM for MBP-hFMO5). The Vmax values were also similar, with a slightly 
higher value for MBP-hFMO5.  
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Figure 3.9 Determination of kinetic parameters for 8-DPT HCl N-oxygenation with 
MBP-hFMO5 and commercially available FMO5.  
MBP-hFMO5 is shown as solid line (■), commercially available FMO5 as dashed line 
(▲). r2 Values are 0.96 and 0.97 for MBP-hFMO5 and commercially available FMO5, 
respectively. 
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Table 3.4 Kinetic parameters for N-oxygenation of 8-DPT HCl with FMO5. 
 Vmax 
(nmol/min/mg FMO5) 
Km 
(µM) 
Km / Vmax 
(min-1 mg-1) 
Commercially 
available FMO5 
2.1 ± 0.1 120 ± 21 17.5 ± 3.2 
MBP-hFMO5 3.2 ± 0.2 117 ± 21 27.3 ± 5.2 
Data are presented as best fit values ± standard error. 
 
Time Dependence 
FMO5 time dependence was determined by incubating the enzyme in presence of 
cofactor and 400 µM 8-DPT HCl over 30 minutes. Time points were taken at 5, 10, 
20, and 30 minutes. Results show linear increase of product formation over time for 
both enzymes. r2 Values for linear regression with interception point set 0 were 0.97 
and 0.99 for MBP-hFMO5 and FMO5 purchased from BD Gentest, respectively. 
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Figure 3.10 FMO5 time dependence was determined by measuring 8-DPT HCl 
N-oxygenation activity over 30 minutes.  
MBP-hFMO5 is shown as solid line (■), commercially available FMO5 as dashed line 
(▲). 
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3.3.3.2 Stability of MBP-hFMO5 at 4 °C  
The stability of MBP-hFMO5 at 4 °C was checked over  5 days and NADP+ and/or 
20 % glycerol was added to determine whether these supplements improve the 
enzyme’s stability. The addition of NADP+ and/or glycerol decreased loss of enzyme 
activity at 4 °C over 5 days. The specific activity  of MBP-hFMO5 was still at 65 %, 
73 %, and 80 % of that at day zero after addition of NADP+, glycerol, or both, 
respectively, whereas a 50 % loss in enzyme specific activity was observed when 
neither substance was added. Results are shown in Figure 3.11 and Table 3.5. 
Therefore, the NADP+ as well as 20 % glycerol was added to the enzyme to improve 
its stability in future crystallization studies (chapter 4). The observed increase of 
enzyme activity upon addition of glycerol at day 0 is probably due to the 
cryoprotective properties of glycerol.  
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Figure 3.11 Stability of MBP-hFMO5 at 4 °C.  
8-DPT N-oxygenation of MBP-hFMO5 at day 0 (black bars) and after incubation at 
4 °C for 3 (grey bars) and 5 days (white bars) with  and without addition of 500 mM 
NADP+ and/or 20 % glycerol.  
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Table 3.5 Stability of MBP-hFMO5 at 4 °C.  
 Ø + NADP+ + Glycerol + NADP
+
 
+ Glycerol 
Day 0 100.0 ± 7.7 100.0 ± 12.0 100.0 ± 0.4 100.0 ± 4.5 
Day 3 79.6 ± 16.0 82.1 ± 5.5 75.1 ± 3.1 91.4 ± 11.2 
Day 5 47.4 ± 2.8 65.3 ± 2.6 73.3 ± 2.8 79.2 ± 3.4 
8-DPT N-oxygenation of hFMO5 at day 0 and after incubation at 4 °C for 3 and 
5 days with and without addition of 500 mM NADP+ and/or 20 % glycerol are given in 
% with day 0 set 100 %.  
3.3.3.3 Oligomerization State of MBP-hFMO5 
The oligomerization state of MBP-hFMO5 was determined by native gel 
electrophoreses and gel filtration. After amylose column-purification, the enzyme 
existed mainly as mono-, tri-, and hexamer (Figure 3.12, lane 1) whereas it was 
primary found to be in a hexameric state after Q and SEC purification (Figure 3.12, 
lanes 2 and 3). After addition of 0.5 % Triton® X-100 (~30 x CMC) or 10 x CMC of 
DDM (0.1 %) to the Q and SEC-purified protein, the multimerization state changed 
towards coexistence of mono-, tri-, and hexamers (Figure 3.12, lanes 4-7). 
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Multimeric 
State 
 
 
octamer 
hexamer 
 
trimer 
 
monomer 
 
 
lane              1         2         3        4         5   6         7       8 
Sample:               A       Q     SEC       Q     SEC                                     Q SEC   STD 
Addition to sample:  0.5 % TX 0.1 % DDM  
Figure 3.12 Native gel of MBP-hFMO5 in different purity. 
Amylose-column purified MBP-hFMO5 (A, lane 1), HP Q column-purified MBP-
hFMO5 (Q, lanes 2, 4, and 6), and MBP-hFMO5 purified on Superose 6 column after 
Q-purification (SEC, lanes 3, 5, and 7) with addition of 0.5 % Triton® X-100 (TX, lanes 
4 and 5) or DDM (lanes 6 and 7). Standards (STD, i.e., thyroglobulin (669 kDa), 
ferritin (440 kDa), aldolase (158 kDa), conalbumin (75 kDa), and ovalbumin (43 kDa)) 
are loaded in lane 8. Molecular weight was determined employing Kodak molecular 
imaging software (Eastman Kodak Company, Rochester, NY, USA).  
Also, size exclusion chromatography supports this assumption. The short retention 
time (Figure 3.13) suggests high aggregation state and after calculating the size 
utilizing various standard proteins (i.e., ovalbumin, conalbumin, aldolase, ferritin, and 
thyroglobulin) hexameric state of the protein seemed most likely. 
Both MBP-hFMO5 from 1 ml HiTrap FF Q column or from amylase column were 
loaded onto a Sepharose 6 gel filtration column (Figure 3.13 A and B, respectively). 
In comparison to MBP-hFMO5 only purified via affinity chromatography where 
multiple protein species are still present, only one major peak could be observed 
after ion exchange purification.  
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Figure 3.13 Elution profile of fractions from SEC column (Sepharose 6) loaded with 
MBP-hFMO5. 
Absorption at 280 nm is shown as solid line, absorption at 450 nm as dashed line. 
A SEC elution profile of MBP-hFMO5 previously purified on an amylose column. 
B SEC elution profile of MBP-hFMO5 previously purified on Q column.  
3.3.3.4 Monodispersity of MBP-hFMO5 
DLS analysis data of affinity purified MBP-hFMO5 is shown and either size (Figure 
3.14 A) or volume (Figure 3.14 B) is plotted against intensity. When size is plotted 
against intensity two large peaks are observed, showing contamination or at least 
two species of proteins. However, when size is plotted against volume, it becomes 
apparent that the contamination is not as dominant as it seemed in Figure 3.14 A. 
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The polydispersity index (PdI) values for amylose pure MBP-hFMO5 were 
0.394 ± 0.006. 
A B 
 
 
C D  
 
 
Figure 3.14 Dynamic light scattering of affinity (A, B) and ion exchange (C, D) 
purified MBP-hFMO5. 
Dynamic light scattering of affinity purified and Q purified MBP-hFMO5 showed an 
increased monodispersity of the protein with only one peak visible in both graphs 
(Figure 3.14 C and D) and improved PdI values of 0.134 ± 0.002. 
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DLS analysis done with Q-purified MBP-hFMO5 where glycerol was added and 
Q-purified MBP-hFMO5 that was treated with Calbiosorb Adsorbent beads (Merck, 
Darmstadt, Germany) did not show significant differences. Further, Calbiosorb 
Adsorbent treated Q-purified MBP-hFMO5 was examined in various concentrations 
(i.e., 25, 10, 5, 2.5, and 0.25 mg/ml), but again no significant differences between the 
different concentrations could be observed (data not shown). For all Q-purified MBP-
hFMO5 samples measured average PdI values were 0.141 ± 0.037. 
3.4 Discussion 
For structural and functional characterization of MBP-hFMO5, highly-purified and well 
characterized protein was needed. Especially crystallography experiments (chapter 
4) require not only pure, but also monodispers and stable protein. Herein, a two-step 
purification method was developed and obtained protein was thoroughly 
characterized (Figure 3.15). 
 
Figure 3.15 Overview of MBP-hFMO5 purification protocol development.  
Dashed lines and white boxes stand for earlier steps in purification protocol 
development, solid lines and grey boxes represent final purification protocol as used 
for crystallography studies in chapter 4. 
Human FMO5 was successfully expressed as N-terminal MBP-fusion protein 
(MBP-hFMO5) in E. coli DH1α cells. After expression, a number of different 
detergents was tested for extraction of MBP-hFMO5, but only Triton® X-100 
solubilized FMO5 sufficiently. The degree in which detergents are able to cross 
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Solubilization with Triton X-100 
Amylose column (buffer 
containing Triton X-100) 
Amylose column (buffer 
without detergent) 
Amylose column (buffer 
containing DDM) 
Q column (buffer without 
detergent) 
 
Q column (buffer without 
detergent) 
 
Q column (buffer 
containing DDM) 
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membranes is said to be affecting the extend to which efficient solubilization occurs 
[le Maire et al., 2000]. Triton® X-100 showed best solubilization ability. This might be 
due to the hydrophobic-hydrophilic properties of its polyethylene chains [Israelachvili, 
1997] allowing Triton® X-100 to ‘flip-flop’ rapidly across membranes. In contrast, DDM 
has a strong hydrophilic head averting fast ‘flip flop’ across the membrane [Kragh-
Hansen et al., 1998; le Maire et al., 2000] and thus proved unsuitable for extraction of 
MBP-hFMO5 as seen in this study. For subsequent studies, Triton® X-100 was 
chosen for extraction of MBP-hFMO5 from E. coli. 
Affinity chromatography was used to purify the supernatant after cell lysis. This was 
done on an amylose column that binds to the MBP tagged to FMO5. Impurities could 
thus be eluted from the column during an extended washing step. Afterwards, the 
MBP and therefore the protein of interest was eluted with 3 mM maltose. 
After this first purification step, a second step was added. MBP-hFMO5 was further 
purified on an ion exchange column. At pH 6, MBP-hFMO5 was bound to the resin of 
a 1 ml HiTrap Q column. Following a washing step with 65 mM NaCl in which 
impurities were removed, the protein of interest was eluted at a concentration of 
250 mM NaCl. 
Purified MBP-hFMO5 was characterized in order to confirm its suitability for kinetic 
and crystallization studies. Firstly, MBP-hFMO5 was supposed to be compared to 
commercially available hFMO5 (BD Gentest) in order to show that MBP-hFMO5 may 
be used for kinetic and structural studies instead of expensive purchasable FMO5. 
The kinetic parameters of recombinant expressed MBP-hFMO5 and commercially 
available FMO5 were determined and time dependence studies were carried out. 
These studies showed very similar kinetic behavior for both enzymes, with a Km of 
roughly 120 µM for both enzymes and a Vmax of 2.1 and 3.2 for Gentest FMO5 and 
MBP-hFMO5, respectively. Time dependence studies also showed a linear behavior 
for both enzymes over 30 minutes validating the standard incubation time of 
20 minutes. Thus, MBP-hFMO5 is very similar to commercially available FMO5 and 
may be used to study kinetic as well as structural parameters. In addition to lower 
costs, MBP-hFMO5 has the advantage that it can be purified easily utilizing its MBP-
tag. Further, it can be produced in large quantities and higher purity may be achieved 
which is especially advantageous when attempting to crystallize the protein. 
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Enzyme stability was determined under various conditions at 4 °C. Results from this 
study showed that addition of glycerol and NADP+ to the sample improved 
MBP-hFMO5 stability 1.6-fold. Therefore, in subsequent crystallization studies these 
additives were added to the enzyme preparations. 
For characterization of the protein, native gel electrophoresis and size exclusion 
chromatography were used to determine the oligomerization state of MBP-hFMO5. 
Compared to affinity purified MBP-hFMO5, the monodispersity improved significantly 
upon further purification via ion exchange chromatography. As shown on native gels, 
high detergent content seemed to separate protein molecules and MBP-hFMO5 that 
was primary found to exist in a hexameric state after ion exchange chromatography 
and size exclusion chromatography changed its oligomerization state towards 
coexistence of mono-, tri-, and hexamers. Results from size exclusion 
chromatography of ion exchange purified MBP-hFMO5 also suggested hexameric 
state of the protein. The observation that FMO proteins possibly exist in higher 
ordered complexes has been made previously [Brunelle et al., 1997] and a 
hexameric state of a native FMO enzyme was first presumed in 1972 by Ziegler and 
Mitchell [Ziegler et al., 1972]. Although an MBP fusion could be affecting the 
oligomerization state of FMO, this was not the case for other MBP-tagged proteins 
like MBP-phenylalanin hydroxylase [Martinez et al., 1995]. This was an important 
observation because multimerization could have a significant effect on crystallization.  
Another important factor in crystallization studies is monodispersity of the protein. 
Thus, MBP-hFMO5 was characterized via DLS analysis. DLS is a method to 
determine particle size in solution and thus gives an estimate of the monodispersity 
of a given protein sample. It is a technique based on Brownian motion of particles. A 
laser beam is scattered by particles in solution and the time dependent change of the 
signal intensity compared to itself is used to determine the size of the particles. In 
case of small particles this change is fast whereas larger particles give ‘speckle 
patterns’ that fluctuate at a slower rate. Thus, the time gives an indication of the 
mean particle size. In addition, large particles will scatter more light than small ones 
and therefore, in case more than one peak is observed, the importance of the second 
peak will be represented more realistically if intensity is correlated to volume. This 
can also be observed with affinity column purified MBP-hFMO5 where two large 
peaks are visible when size is plotted against intensity whereas the second peak 
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(particles of larger size) decreases when size is plotted against volume. In 
comparison to only affinity-purified MBP-hFMO5 where impurities are obvious, DLS 
with Q-purified samples showed only a single peak. No significant difference could be 
observed between ion exchange purified MBP-hFMO5 and samples of the same 
purity that were treated with Calbiosorb Adsorbent beads added to remove residual 
detergent in the sample. Also, addition of 20 % glycerol and different concentrations 
of MBP-hFMO5 did not alter DLS results.  
Studies showed that E6 oncoprotein from human Papillomavirus strain 16 fused to 
MBP formed soluble high molecular weight aggregates [Zanier et al., 2007]. The size 
and amount of aggregated particles varied depending on expression conditions and 
E. coli strain, suggesting that aggregation took place in vivo. However, the 
aggregates were supposedly relatively monodispers and the E6 protein possessed a 
native-like fold. These features are advantageous in view of FMO5 crystallization 
attempts and seemed to be transferable to MBP-hFMO5. As shown for E6, 
MBP-hFMO5 seemed to be correctly folded, retaining its enzymatic activity. Also, 
DLS data suggested relatively monodispers protein, which is also in accordance with 
MBP-tagged E6 protein. 
Overall, a cost-efficient way to obtain large quantities of highly purified MBP-hFMO5 
for future structural and functional enzyme characterization studies was successfully 
developed and optimized. 
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4 Crystallography Studies of Human FMO5 
4.1 Introduction 
X-ray crystallography studies of proteins and enzymes are important tools to 
determine the 3D structure of a protein of interest. The three-dimensional structure is 
key to understanding the function of any protein. A crystal structure can give 
information about the location of the active site, substrate- and cofactor-binding 
domains, and about conformational changes a protein may undergo. This leads to a 
better understanding of the enzyme in respect of substrate binding, mechanism of 
action, as well as possible influence of different mutations. In case of FMO enzymes 
little is known about these properties because to date, the tertiary structure of the 
mammalian FMO enzymes is not known. Solving the three-dimensional structure of a 
mammalian FMO isozyme would help tremendously in the understanding of 
mammalian FMOs in general because they contain a large percentage of identical 
residues (50 – 58 % amino acid sequence identity in human FMO isozymes). 
Especially amino acids involved in FAD and NADPH binding are conserved 
throughout human FMOs and across species lines [Cashman, 1995]. 
4.1.1 FMO Model Structure 
Although the tertiary structure of mammalian FMO enzymes has not been solved to 
date, model predictions by Cashman [Cashman, 2002] as well as Ziegler and 
Poulsen [Ziegler et al., 1998] have been made for human FMO3. These were based 
on comparison with solved structures of other flavoproteins (Figure 4.1). 
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Figure 4.1 Proposed human FMO3 model. 
The model is based on homology modeling with the protein structures 1get (green), 
1vqw (yellow), 1w4x (red), and 1npx (blue). FAD (magenta) and NADPH are also 
shown. There are two domains in the structure, one being relevant for FAD, the other 
for NADPH binding. These two domains are relatively similar in all models whereas 
the rest of the structure is very divergent (cyan). Taken from [Cashman et al., 
manuscript in preparation]. 
In addition, the crystal structure of FMO from Schizosaccharomyces pombe 
(S. pombe) has been solved [Eswaramoorthy et al., 2006]. However, this information 
cannot be transferred to mammalian FMO enzymes without caution because 
S. pombe FMO consists of only 447 amino acids whereas human FMO1 – 5 are 532 
to 558 amino acids in length and it shares only 21 to 23 % sequence identity with 
human FMOs. 
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4.1.2 FMO Protein Structure, Binding Sites, and Interaction with the 
Membrane 
An overview of the different well conserved motives and their postulated functions 
was given by Krueger and Williams [Krueger et al., 2005]. These functions were 
proposed based on the PRINTS database that catalogues protein fingerprints, 
conserved motives characterizing the protein family [Attwood et al., 2003], and rabbit 
FMO2 as reference sequence for fingerprint analysis [Lawton et al., 1990]. The main 
regions of interest for FMO3 are listed below and compared to the crystal structure of 
S. pombe. 
4.1.2.1 FAD Binding 
The FAD binding motif, GXGXXG, is supposed to be within the region of amino acids 
3 – 26 and amino acids 27 – 51 are supposed to stabilize FAD binding through a 
EXXXXXGG motif [Krueger et al., 2005]. Both regions seem essential and mutations 
in either one have been reported to result in loss of activity for FMO3 [Lawton et al., 
1993b]. Likewise, the nucleotide binding motif GXGXXG makes hydrogen-bonding 
contacts with the adenine nucleotide of FAD and the N3 of adenine binds to Arg 39 
that is part of the EXXXXXGG motif in S. pombe.  
4.1.2.2 NADPH Binding 
The NADPH binding site is located in the region of residues 186 and 213. This 
proposal also seems consistent with the S. pombe structure, where NADPH is bound 
to the second nucleotide binding motif (GXGXX(G/A)). Here the nicotinamide is 
stacked with the isoalloxazine ring of the FAD so interaction between the bases of 
nicotinamide and flavin is possible [Eswaramoorthy et al., 2006].  
4.1.2.3 Substrate Binding 
The substrate in the S. pombe structure (i.e., methimazole) is supposed to stack with 
the isoalloxazine ring of bound FAD and replace the NADPH in the structure. In case 
of mammalian FMO enzymes, this seems unlikely, because kinetic studies with 
FMO1 suggested that NADP+ does not leave the flavoprotein until after substrate 
oxygenation. Maybe a different binding mechanism applies here.  
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4.1.2.4 The FATGY-Motif and Membrane Interaction Sites 
One other very prominent motif is the FATGY motif. It is a motif that is conserved in 
nearly all mammalian FMO enzymes and is located between amino acids 315 and 
342 which represent the linkage between NADPH and the active site. Only FMO4 
has a FTTGY and S. pombe FMO contains an YCTGY-motif. 
The sites of membrane interaction are still unknown although considerable 
information about protein structure is already available [Krueger et al., 2005; Lawton 
et al., 1993a]. Maybe a crystal structure of a mammalian FMO enzyme will explain 
where FMO is bound to membranes. 
4.1.3 Aim of the Study 
The objective was to purify FMO5 in order to crystallize it and finally obtain a 
three-dimensional structure of a mammalian FMO enzyme. This would give answers 
to the location of binding sites for FAD, NADPH, and substrate and would lead to a 
better understanding of the mechanistic pathway of FMO mediated metabolism.  
4.2 Materials and Methods 
4.2.1 Reagents 
Chemicals and reagents used in this study were purchased from Sigma-Aldrich 
Chemical Co. (St Louis, MO, USA) in appropriate purity. Buffers and other reagents 
were purchased from VWR Scientific, Inc. (San Diego, CA, USA). Polyethylene 
glycols (PEGs), crystallography screens, and crystallography plates (24 or 96 well 
sitting drop plates) were purchased from Hampton Research Corp. (Aliso Viejo, CA, 
USA). 
4.2.2 Cloning and Expression 
Human FMO5 was expressed as N-terminal maltose-binding fusion protein 
(MBP-hFMO5). Cloning and expression was done as described in section 3.2.2.1 
with few changes. MBP-hFMO5 was expressed in E. coli DH1α or E. coli BL21 cells. 
After induction, cells were incubated shaking either at room temperature for 20 hours 
or at 20 °C for 24 hours.   
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4.2.3 MBP-hFMO5 Purification  
The purification procedure has already been described in chapter 3, but was 
optimized for crystallization trials.  
After expression, E. coli cells were harvested by centrifugation at 6,000 g for 
10 minutes and the cell pellet was frozen in order to increase yield. After 
resuspending the cell pellet in lysis buffer as described in section 3.2.2.1, cells were 
either disrupted via sonication as described above or by passage through a French 
press (Thermo Electron Corp., Needham Heights, MA, USA) operating at 20,000 psi 
depending on what method was available. For crystallization studies the cell pellet 
was only extracted once and after centrifugation the supernatant was loaded at 
1 ml/min onto an amylose column (New England BioLabs, Ipswich, MA, USA) 
equilibrated with ten column volumes of buffer A’ (i.e., 50 mM Na2HPO4, pH 8.4, 
containing 15 µg/ml FAD). The column was washed with at least ten column volumes 
of buffer A’ and bound MBP-hFMO5 protein was eluted with 3 mM maltose in buffer 
A’ at 1 ml/min.  Eluted protein was concentrated with an Amicon Ultra-15 centrifugal 
filter unit with an Ultracel-50 filter (Millipore, Billerica, MA, USA). 
Further protein purification was carried out on an FPLC system (Äkta-Purifier, GE 
Healthcare, Uppsala, Sweden) using a 1 ml Q HP column (GE Healthcare, Uppsala, 
Sweden) with a flow rate of 1 ml/min and a step gradient of 65 mM and 250 mM NaCl 
as described in chapter 3.3.2. 
Refinement of the Lysis Protocol 
The lysis buffer was changed to 50 mM phosphate buffer, pH 8.4, containing 0.5 % 
Triton® X-100, 0.1 % L-α-phosphatidylcholine, 0.5 mM phenylmethylsulfonylfluoride, 
100 mM FAD, and 1 tablet /15 ml lysis buffer of Roche Mini Complete (EDTA-free) 
protease inhibitor mix (Roche, Indianapolis, IN, USA). This did not seem to improve 
crystallization and the original method was used for further MBP-hFMO5 purification. 
4.2.4 Crystallization of MBP-hFMO5 
4.2.4.1 Screening Kits 
For Crystallization trials, laboratory space and equipment was generously provided 
by Prof. Dr. C. D. Stout at the Scripps Research Institute, La Jolla, CA, USA and 
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Prof. Dr. A. Scheidig at the ZBM, University of Kiel. Initial crystallization conditions for 
MBP-hFMO5 were screened using different commercially available 96-well screening 
kits with conditions ranging from pH 4.6 – 8.5, various precipitants including PEGs 
ranging from 200 to 20,000, and a wide variety of salts. Four 96-well crystal 
screening kits were set up in sitting drops using the vapor diffusion method: EasyXtal 
PEGs Suite (Qiagen Inc., Valencia, CA, USA), Crystal Strategy Screen I and II, and 
PACT premier (Molecular Dimensions, Apopka, FL, USA). The protein used was 
Q-purified MBP-hFMO5, in a concentration of 15 mg/ml containing 200 µM NADP+ 
and 20 % glycerol. Protein solution was mixed with equal volumes of the reservoir 
solution.  
4.2.4.2 Refinement Screens  
The most promising results from initial 96-well screens were refined in terms of 
protein concentration as well as type and concentration of PEG and salt. 24-well 
plates were set up in sitting drops using the vapor diffusion technique.  
Protein 
In order to determine optimal protein concentration, plates were set up examining 
dependence of protein concentration vs. PEG concentration. Plates contained 0.3 M 
Na-acetate, 0.1 M Na-cacodylate, pH 6.5, PEG 2K monomethyl ether (PEG 2K 
MME). PEG concentrations screened were in the range of 20 – 30 %. Q-purified 
MBP-hFMO5 was mixed with an equal volume of reservoir solution in concentrations 
between 5 and 40 mg/ml.  
PEG 
Initial 96-well screens showed PEG to be the most successful precipitant. Thus, type 
and concentration was refined in further studies. Different concentrations of PEGs in 
the range of 400 – 20K were tested. Concentrations tested were 10 – 32 % for PEG 
2K MME, 2 – 28 % for PEG 6K and 10K, and 2 – 22 % for PEG 20K. The plates were 
set up with 0.1 or 0.2 M sodium acetate as salt and 0.1 M Bis-Tris propane at pH 6.5. 
Protein solution in concentrations of 20 – 25 mg/ml was mixed with equal volumes of 
reservoir solution. 
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Salts 
The best performing salts from the initial screens (i.e., Na-acetate, Na-formate, 
Na-tartrate, Na-phosphate, K-citrate, KSCN, MgCl2, NH4Cl, LiCl, and NaBr) were 
analyzed further. Conditions for salt screens were 0.1 M Na-cacodylate or 0.1 M 
Bis-Tris propane, pH 6.5, 22 – 26 % PEG 2K MME, and 0.1 or 0.2 M salt. Also, plates 
were set up containing 0.1 M Bis-Tris propane, pH 6.5, 24 – 28 % PEG 2K MME, and 
Na-acetate in the range of 0 - 1.5 M in order to determine the most advantageous 
salt concentration. Q-purified MBP-hFMO5 solution at 25 – 30 mg/ml was mixed with 
equal volumes of reservoir solution.  
4.2.4.3 Influence of Detergents 
Bio-Beads®-Treatment 
In some cases, Q column-purified MBP-hFMO5 was treated with Bio-Beads® 
(Bio-Beads® SM Media, Bio-Rad, Hercules, CA, USA) in order to remove excess 
detergent (Triton® X-100 and/or DDM). Bio-Beads® were activated with methanol and 
washed thoroughly with 50 mM Bis-Tris buffer, pH 6.5. Afterwards, Bio-Beads® were 
slowly added to Q-purified protein. 
For comparison between Bio-Beads®-treated and untreated MBP-hFMO5, plates 
were set up with 22 – 26 % PEG 2 K MME, 0.1 M Na-cacodylate or 0.1 M Bis-Tris 
propane at pH 6.5, and Na-formate, Na-acetate, MgCl2, or NH4Cl. Protein solution at 
a concentration of 30 mg/ml was left untreated or was treated with activated Bio-
Beads® and crystallization drops were set up with either protein solution mixed with 
equal volumes of reservoir solution. 
Detergent Refinement in the Purification Protocol 
In order to remove Triton® X-100 quantitatively, the purification protocol was refined: 
The protein was still extracted in Triton® X-100, but after binding to amylose resin the 
protein was washed and further purified with buffer devoid of detergent.  
Influence of Detergents  
The influence of addition of a wide variety of detergents to crystallization drops was 
studied. Detergents tested are listed in Table 4.1. The reservoir solution consisted of 
26 % PEG 2K MME, 0.2 M Na-acetate, and 0.1 M Bis-Tris propane, pH 6.5.  
Crystallization drops consisted of equal volumes of reservoir solution and Bio-
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Table 4.1 Detergents used in crystal screens to determine influence of detergents on 
crystallization of MBP-hFMO5. 
Detergent Concentration Detergent Concentration 
217 FA 1 and 2 x CMC Cymal®-1 1 x CMC 
231 FA 1 and 2 x CMC Cymal®-2 1 x CMC 
234 FA 1 and 2 x CMC Cymal®-5 1 x CMC 
235 FA 1 and 2 x CMC Cymal®-6 1 x CMC 
238 FA 1 and 2 x CMC Cymal®-7 1 x CMC 
C-HEGA®-10 1 and 2 x CMC n-Nonyl-β-D-glucopyranoside 1 and 2 x CMC 
Sucrose-monolaurate 1 x CMC C8E4  1 x CMC 
CTAB 1 x CMC C12E8 1 x CMC 
DDAO 1 x CMC FOS-CHOLINE® -10 1 x CMC 
n-Octanyl-sucrose 1 x CMC FOS-CHOLINE® -12 2 x CMC 
HECAMEG 1 and 2 x CMC β-Octylglucoside 1 x CMC 
n-Decanoyl-sucrose 1 x CMC n-Octyl-β-D-glucopyranoside 1 and 2 x CMC 
MEGA-8 1 x CMC CHAPS 1 x CMC 
ZWITTERGENT® 3-10 1 x CMC n-Decyl-maltoside 1 x CMC 
1-s-Nonyl-β-D-thio-glucoside 1 x CMC n-Octyl-maltoside 1 x CMC 
n-Nonyl-β-D-thio-maltoside 1 x CMC   
FA, facial amphiphile; C-HEGA®-10, Cyclohexylbutanoyl-N-hydroxyethylglucamide; CTAB, 
Cetyltrimethylammoniumbromid; DDAO, N,N-Dimethyl-1-dodecanamine-N-oxide; 
HECAMEG, Methyl-6-O-(N-heptylcarbamoyl)-α-D-glucopyranoside; MEGA-8, Octanoyl-N-
methylglucamide; ZWITTERGENT® 3-10, n-Decyl-N,N-dimethyl-3-ammonio-1-
propanesulfonate; Cymal®-1-7, Cyclohexyl-alkyl-β-D-maltoside; C8E4, tetra(ethylene glycol) 
monooctylether; C12E8, octa(ethylene glycol) dodecyl monoether; FOS-CHOLINE®-10, n-
Decylphosphocholine; FOS-CHOLINE®-12, n-Dodecylphosphocholine; CHAPS, 3-[(3-
Cholamidopropyl)-dimethylammonio]-1-propane sulfonate 
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Beads®-treated Q-pure MBP-hFMO5 (30 mg/ml) spiked with detergent to yield a final 
concentration of 1 or 2 times their CMC. 
4.2.4.4 X-Ray Diffraction Measurement 
X-ray diffraction measurement was done by Dr. Andrew Annalora (Scripps Research 
Institute, La Jolla, CA, USA). Several crystals were screend at the Stanford 
Synchotron Radiation Laboratory (SSRL, Palo Alto, CA, USA) on Beamline 7-1 and 
11-1. Prior to flash freezing and storage, several preparation conditions were tested: 
A quick (10 – 30 seconds) or long (30 seconds – 2 minutes) soak of the crystals in 
buffer identical to the reservoir condition but with addition of 20 % glycerol, and/or 
17 % ethylene glycol was done for cryoprotection. Also, crystals were frozen directly 
from the drop with and without a quick soak in 100% parrafin oil. 
 
4.2.5 Crystallography Studies of hFMO5 without MBP-tag 
4.2.5.1 Cleavage of MBP-hFMO5 with Factor Xa 
250 µg MBP-hFMO5 were incubated in a total volume of 100 µl 100 mM phosphate 
buffer, pH 7.6, containing 0.2 mM NADPH and 5 µg factor Xa (New England BioLabs, 
Ipswich, MA, USA) for 1.5 or 3 hours at 37 °C. In o rder to prevent potential 
precipitation of cleaved FMO5, incubations were also done in the presence of 
detergent (i.e., CHAPS). To compare rate of degradation or loss of activity during the 
1.5 or 3 hour incubation period, 3-hour control incubations were done without factor 
Xa at 37 °C and at 4 °C. Again, control incubations  were also done in the presence of 
CHAPS. The incubation scheme is shown in Table 4.2. 
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Table 4.2 Incubation scheme of factor Xa cleavage reaction. 
Sample Incubation conditions  
A incubation for 1.5 hrs at 37 °C + factor Xa 
B incubation for 3 hrs at 37 °C + factor Xa 
C incubation for 1.5 hrs at 37 °C + factor Xa + CHA PS 
D incubation for 3 hrs at 37 °C + factor Xa + CHAPS  
E incubation for 3 hrs at 37 °C  
F incubation for 3 hrs at 4 °C  
G incubation for 3 hrs at 37 °C + CHAPS 
H incubation for 3 hrs at 4 °C + CHAPS 
After 1.5 or 3 hour incubation, samples were put on ice and immediately assayed for 
8-DPT N-oxygenation activity as described in section 3.2.4.2 with minor changes. 
Briefly, a standard incubation mixture contained 100 mM potassium phosphate 
buffer, pH 8.4, 0.2 mM NADPH, 0.25 mM DETAPAC, and 75 µg/ml MBP-hFMO5. 
After extraction of metabolites and remaining substrate in dichloromethane, HPLC 
analysis was done on a Waters HPLC system (Waters 600E controller and Waters 
Autosampler 700 Satellite WISP interfaced to a Waters 486 Absorbance Detector). 
Chromatographic separation of analytes was done on a LiChrospher-Si 60 (250 x 
4.6 mm, 5 µm; Merck, Darmstadt, Germany) with a mobile phase of 80 % 
methanol/20 % isopropanol/0.025 % HClO4 (v/v/v). The flow rate was 1.5 ml/min and 
the total run time was 15 minutes. The wavelength for UV detection was set to 
243 nm. The retention times for 8-DPT and 8-DPT N-oxide were 5.5 and 4.0 minutes, 
respectively. 
In addition, immediately after incubation with factor Xa, samples were analyzed by 
SDS-PAGE and Coomassie Blue staining. 2 µl of protein samples were fractionated 
by electrophoresis on a 10 % polyacrylamide gel under denaturing conditions and 
stained with Coomassie Blue. Protein bands were analyzed by densitometry using 
Adobe Photoshop Elements (Version 7). 
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4.2.5.2 Purification of hFMO5 from MBP 
After cleavage of MBP-hFMO5, hFMO5 had to be separated from remaining factor 
Xa, MBP-tag and non-cleaved MBP-hFMO5. This was attempted by various methods 
including ion exchange chromatography, affinity chromatography, and size exclusion 
chromatography. 
Affinity Chromatography 
MBP-hFMO5 was cleaved with factor Xa after affinity purification and subsequent ion 
exchange purification. The ion exchange purification step also served as buffer 
exchange to eliminate remaining maltose from the first affinity purification step. 
A second affinity chromatography step was performed after cleaving the protein. 
500 µl amylose resin (New England BioLabs, Ipswich, MA, USA) equilibrated with 
50 mM phosphate buffer, pH 8.5, was incubated with 5 mg cleaved MBP-hFMO5 
over night rotating at 4 °C. The next day, amylose resin was removed by filtration and 
bound protein was eluted with 3 mM maltose. Flow through (supposedly containing 
cleaved FMO5) and eluted protein (which should contain the MBP-tag) was then 
analyzed via SDS-PAGE and 8-DPT HCl N-oxygenation activity assay as described 
in section 3.2.4.2. 
Ion Exchange Chromatography 
Purification was carried out on an FPLC system (Äkta-Purifier, GE Healthcare, 
Uppsala, Sweden) at the ZBM, University of Kiel. Cleaved MBP-hFMO5 protein was 
loaded onto a HiTrap Q HP column equilibrated with 50 mM Bis-Tris buffer, pH 6, at 
0.5 ml/min. The column was washed with at least ten column volumes of equilibration 
buffer. A linear salt gradient of 0 – 65 % 50 mM Bis-Tris buffer, pH 6 containing 1 M 
NaCl was applied to elute bound protein.  
Size Exclusion Chromatography 
Another attempt to purify hFMO5 from uncleaved MBP-hFMO5, MBP, and factor Xa 
was purification via size exclusion chromatography. Purification was carried out on a 
FPLC system (Äkta-Purifier, GE Healthcare, Uppsala, Sweden) at the ZBM, 
University of Kiel, Germany. Cleaved protein was loaded at 0.5 ml/min onto a 
Superdex 200 10/300GL size exclusion column (GE Healthcare, Uppsala, Sweden) 
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equilibrated with 50 mM Bis-Tris buffer, pH 6. Eluted fractions were concentrated with 
Microcon centrifugal filter units (Ultracel YM-30, Millipore, Billerica, MA, USA) and 
analyzed via SDS-PAGE.  
4.3 Results  
4.3.1 Crystallization of MBP-hFMO5 
4.3.1.1 Screening Kits 
Crystallization involves phase transition where an initially solubilized protein comes 
out of solution to form crystals as solution is slowly brought to supersaturation. Once 
nuclei have formed, protein concentration in the solution drops and no new crystals 
will form whereas already existing crystals one may grow [Chayen, 1998]. Vapor 
diffusion is the most widely used technique and involves a drop composed of a 
mixture of protein samle and crystallization reagent. The concentration within the 
drop is usually lower than that needed for crystallization. The drop is equilibrated 
against a liquid reservoir with higher concentrations. To achive equilibrium, water 
vapor leaves the drop and the concentration within the drop will slowly increase 
[Chayen, 1998]. At best, crystals will form, but also amorphous precipitate or 
coadunate crystals may be observed. 
The two most common set-ups for crystallization studies are hanging and sitting drop 
techniques. In the hanging drop technique, the drop of protein and reagent hangs 
from a coverslip above the reservoir solution. In case of the sitting drop technique, 
the protein-reservoir drop sits on a surface closer to the reservoir [Chayen, 1998]. 
The results of all screens showed that overall a lower pH, i.e., 6 - 6.5, seemed 
favorable. Also, PEGs were the preferred precipitant. A variety of salts was tested 
and those that performed best were: Na-acetate, Na-formate, Na-tartrate, 
Na-phosphate, K-citrate, KSCN, MgCl2, NH4Cl, LiCl, and NaBr. Especially chloride- 
and acetate-salts gave promising results. 
4.3.1.2 Refinement Screens  
The crystallization conditions were refined starting with the most promising conditions 
found in the 96-well screens. Optimal protein concentration as well as PEG type and 
concentration were determined and influence of salt concentration was evaluated.  
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Protein 
Results from screens where protein concentration was screened against PEG 2K 
MME concentration showed that higher protein concentrations of 20 – 30 mg/ml gave 
better results than lower concentrations (Figure 4.2). 
 
Figure 4.2 Protein concentration vs. PEG 2K MME concentration. 
Crystallization conditions: 20 – 30 % PEG 2K MME, 0.3 M Na-acetate, and 0.1 M 
Na-cacodylate, pH 6.5. Drops consisted of equal volumes of reservoir solution and 
5 – 40 mg/ml MBP-hFMO5. 
 
PEG 
The best results when evaluating various PEGs at different concentrations were 
obtained with PEG 2K MME, PEG 6K and PEG 10K. Lower molecular weight-PEGs 
as well as PEG 20K mostly led to heavy precipitation or no precipitation at all. For 
PEG 2K MME the preferred concentration range was 24 – 28 %, for PEG 6K it was 
20 – 28 % and PEG 10K performed best at concentrations between 23 and 27 %. 
With these PEGs dense yellow oil-like phases as shown in Figure 4.3 were obtained. 
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Figure 4.3 Picture of the yellow oil-like phase.  
Crystallization condition: 0.1 M Bis-Tris propane, pH 6.5, 0.2 M Na-acetate, and 26 % 
PEG 2K MME. Drops consisted of equal volumes of reservoir solution and 30 mg/ml 
MBP-hFMO5. 
 
Salts 
The best performing salts from initial screens (Na-acetate, Na-formate, Na-tartrate, 
Na-phosphate, K-citrate, KSCN, MgCl2, NH4Cl, LiCl, and NaBr) were analyzed further 
and the most promising were Na-formate, MgCl2, NH4Cl, and Na-acetate. The latter 
was then used to set up further crystallography experiments. Evaluation of 
Na-acetate concentrations did not show an obvious trend of whether low or high salt 
concentrations are preferable.  
Maltose 
As previously reported, MBP may adopt distinct conformational states depending on 
presence or absence of maltose [Boos et al., 1998; Spurlino et al., 1991]. Thus, it is 
important to avoid partial occupancy of maltose that might result in mixed 
conformational states and interfere with crystallization by inhibiting formation of well-
ordered crystals [Smyth et al., 2003]. In general, addition of maltose to the protein 
solution gave more “dense yellow oil” (Figure 4.2). Thus, in addition to 200 µM 
NADP+ and 20 % glycerol, maltose was routinely added to protein preparations in a 
concentration of 100 µM.  
4.3.1.3 Influence of Detergents 
Bio-Beads®-Treatment 
Crystallization trials showed that preparation of MBP-hFMO5 without detergent on 
Q column did not lead to crystals but rather resulted again in dense yellow oil phases 
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as shown in Figure 4.3. These were probably due to residual Triton® X-100 from the 
first purification step. Also, addition of different amounts (0.05 – 1 x CMC) of DDM to 
crystallization drops did not result in crystal growth.  
It was found that Triton® X-100 is strongly adsorbed onto Bio-Beads® SM-2, a neutral 
porous polystyrene-divinylbenzene adsorbent [Holloway, 1973]. Thus, in order to 
remove excess Triton® X-100 from the sample, Bio-Beads® were added. It is 
remarkable, that even after addition of excess amounts of Bio-Beads®, MBP-hFMO5 
stayed in solution. From this experiment and the solubilization study it can be 
concluded that detergent (i.e., Triton® X-100) is necessary for protein extraction from 
E. coli, but that for subsequent purification procedures, no further addition of 
detergent is required. 
A comparison was made between crystallization plates containing protein treated 
with Bio-Beads® and untreated protein. Overall, Bio-Beads®-treatment of MBP-
hFMO5 resulted in more dense yellow oil phases and brown spheres (Figure 4.4).  
 
Figure 4.4 Example of dense yellow oil and brown spheres as seen after Bio-
Beads®-treatment of purified MBP-hFMO5.  
Crystallization condition: 0.1 M Bis-Tris propane, pH 6.5, 0.1 M Na-acetate, and 30 % 
PEG 2K MME. Drops consisted of equal volumes of reservoir solution and 25 mg/ml 
MBP-hFMO5 treated with Bio-Beads®. 
The brown spheres seem to be a pre-stage of crystals because they cracked when 
shattered producing sharp edges (Figure 4.5). Thus, MBP-hFMO5 is not only stable 
without detergent, it also seems that detergent removal is important for crystal 
growth. 
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Figure 4.5 Picture showing a scattered sphere.  
Crystallization condition: 0.1 M Bis-Tris propane, pH 6.5, 0.1 M Na-acetate, and 20 % 
PEG 20K. Drops consisted of equal volumes of reservoir solution and 25 mg/ml 
MBP-hFMO5 treated with Bio-Beads®. 
 
Detergent Refinement in the Purification Protocol 
Earlier crystallization screens showed better results after addition of Bio-Beads® to 
MBP-hFMO5. Hence, it seems that complete removal of Triton® X-100 is necessary 
for crystal growth. In order to remove Triton® X-100 quantitatively, the purification 
protocol was refined.  
Although, crystallization plates did not yield crystals, this study verified the earlier 
assumption that MBP-hFMO5 does not need detergent after extraction from the cells. 
Most likely, MBP-hFMO5 is not membrane bound but rather only associated with the 
membrane. In subsequent purification procedures Triton® X-100 was used solely for 
extraction purposes, but no detergent was used on either of the columns. 
Influence of Detergents 
The influence of a great variety of detergents on crystallization of MBP-hFMO5 was 
examined. Almost all wells gave good results yielding in previously observed dense 
yellow oil phases, spheres, or crystals. The phase transition of yellow oil to brown 
spheres and yellow crystals is shown in Figure 4.6.  
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Figure 4.6 Picture showing the transition of yellow oil-like phase (in the center) to 
round spheres (on the left) and yellow crystals (on the right).  
Crystallization condition: 0.1 M Bis-Tris propane, pH 6.5, 0.2 M Na-acetate, and 26 % 
PEG 2K MME. Q-purified MBP-hFMO5 solution at 30 mg/ml was mixed with an equal 
volume of reservoir solution and the crystallization drop was spiked with 1 x CMC 
Cymal®-6. 
 
Addition of the following detergents led to best results: HECAMEG, Cymal®-5, and 
facial amphiphiles 217 and 231. Some examples are listed in Table 4.3. 
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Table 4.3 Examples of wells from screens with drops containing MBP-hFMO5 that 
were spiked with different detergents.  
Detergent added  Picture of well 
HECAMEG 
O N
H
O
OOH
OH
OH
OH
 
 
Cymal®-5 
OO
OH
OH
OH
O
OOH
OH
OH
OH
 
 
217 FA 
 
231 FA  
 
 
 
 
 
 
Crystallization conditions were 26 % PEG 2K MME, 0.2 M Na-acetate, and 0.1 M Bis-
Tris propane buffer at pH 6.5. Drops consisted of equal volumes of reservoir solution 
and 30 mg/ml Bio-Beads®-treated Q-pure MBP-hFMO5 spiked with detergent at 1 x 
(Cymal®-5, 217 FA and 231 FA) or 2 x (HECAMEG) their CMC. 231 FA (facial 
amphiphile), 3α-hydroxy-7α,12α-bis[(β-D-maltopyranosyl)ethyloxy]cholane; 217 FA, 
7α,12α-bis[(β-D-maltopyranosyl)]cholane. 
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As shown in the SDS gel (Figure 4.7) the crystals proved to be MBP-tagged FMO5. 
Crystals dissolved in buffer were run on SDS gel and a band could be obsered 
around 100 kDa. These results show that MBP-tagged human FMO5 is crystallizable.  
 
MW (kDa) 
 
204 
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48 
              MBP-hFMO5    marker 
Figure 4.7 SDS gel of redissolved MBP-FMO5 crystal.  
High Molecular Weight Prestained marker (Bio-Rad, Hercules, CA, USA) was used 
as MW protein marker. Arrow points to MBP-hFMO5. 
However, these coadunate crystals did not yield satisfactory diffraction patterns and 
none of the preparation conditions prior to flash-freezing that were tested improved 
diffraction. The crystals obtained lacked in optical clarity, smooth faces and had only 
few sharp edges. Also, arrays were probably not ordered well enough to obtain 
evaluable diffraction patterns. 
4.3.2 Crystallography Studies of hFMO5 without MBP-tag 
Crystallization studies with purified MBP-hFMO5 led to a number of crystals in 
various conditions. Unfortunately, no satisfactory diffraction pattern could be obtained 
from these crystals. Thus, crystallization or purification conditions needed to be 
altered in order to improve crystal growth. Further refinement of purification 
conditions such as including additional protease inhibitors (Roche Mini Complete 
(EDTA-free) protease inhibitor mix) in the lysis buffer, usage of an extended linear 
NaCl gradient in the ion exchange purification step, addition of NADP+ after 
purification but before concentrating the protein, or air-fuging the protein before 
crystallization plates are set up, were tested but did not lead to improved 
crystalization. 
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Although expression and purification as MBP-fusion protein has numerous 
advantages, for crystallography experiments an MBP-tag might be problematic. It has 
been suggested that MBP hinders crystal growth by introducing conformational 
heterogeneity [Smyth et al., 2003]. Since FMO5 had been cloned into a pMAL-c2 
vector that contains a protease sensitive site right after the MBP sequence (i.e., 
IEGR), the MBP-tag may be removed from FMO5 by proteolytic splicing of the fused 
protein from MBP with factor Xa. Consequently, FMO5 could be separated from its 
tag and crystallization studies with purified FMO5 could be attempted that might lead 
to good diffracting crystals. 
4.3.2.1 Cleavage of MBP-hFMO5 with Factor Xa 
After 1.5 or 3 hour incubation of MBP-hFMO5 with factor Xa, the samples were 
analyzed in regards to 8-DPT N-oxygenation activity and extent of cleavage. SDS-
PAGE showed 67 % cleavage after 1.5 and 73 % after 3 hours incubation (Figure 
4.8).  
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Figure 4.8 Coomassie stained SDS gel of fractions A-H (see also Table 4.2). 
peqGOLD Protein-Marker I (Peqlab, Erlangen, Germany) was used as MW protein 
marker. Arrows point to MBP-hFMO5 and the cleaved products, hFMO5 and MBP. 
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In the presence of NADPH, hFMO5 retains almost 100 % of its 8-DPT N-oxygenation 
activity after 1.5 or 3 hour incubation at 37 °C co mpared to enzyme stored at 4 °C 
(Figure 4.9). Also, cleavage did not precipitate or inactivate the enzyme. Thus, 
including CHAPS in the incubation mixture was not necessary. It even seems 
disadvantageous to add CHAPS because 8-DPT N-oxygenation activity decreased 
about 65 % compared to MBP-hFMO5 stored at 4 °C (Fi gure 4.9). 
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Figure 4.9 8-DPT N-oxygenation of fractions A – H (see also Table 4.2). 
 
4.3.2.2 Purification of hFMO5 from MBP 
Affinity Chromatography 
Separation of hFMO5 from MBP was attempted via affinity chromatography on 
amylose resin. SDS-PAGE as well as HPLC based enzyme activity analysis showed 
no separation of hFMO5 and MBP (Figure 4.10). HPLC analysis showed the main 
activity in the eluate rather than the flow through which is in agreement with the SDS 
gel. It is possible that cleaved hFMO5 stays somewhat associated with the cleaved 
MBP-tag. 
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Figure 4.10 Results of 8-DPT N-oxygenation activity assays and Coomassie stained 
SDS gel of amylose purified, cleaved MBP-hFMO5.  
peqGOLD Protein-Marker I (Peqlab, Erlangen, Germany) was used as MW protein 
marker. Arrows point to Q-pure MBP-hFMO5 and the cleaved products, hFMO5 and 
MBP. 
Ion Exchange Chromatography 
Another attempt to separate hFMO5 from MBP, MBP-hFMO5, and factor Xa was 
purification on a HiTrap Q HP anion exchange column. The resulting chromatogram 
is shown in Figure 4.11. The fractions were analyzed with SDS-PAGE (Figure 4.12). 
Both, chromatogram and SDS gel show good separation of MBP (peak 1) and FMO5 
(peak 2), however, hFMO5 co-elutes with uncleaved MBP-hFMO5. 
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Figure 4.12 Coomassie stained SDS gel of fractions of Q column-purified cleaved 
MBP-hFMO5.  
peqGOLD Protein-Marker I (Peqlab, Erlangen, Germany) was used as MW protein 
marker. Arrows point to Q-pure MBP-hFMO5 and the cleaved products, hFMO5 and 
MBP. 
Figure 4.11 Chromatogram of Q-column purified cleaved MBP-hFMO5. 
 
Absorbance at 280 nm is shown as solid line, absorbance at 450 nm as dotted line, 
and conductivity is shown as dashed line. 
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Size Exclusion Chromatography 
As third method for FMO5 purification, size exclusion chromatography was tested. 
The chromatogram obtained from SEC is shown in Figure 4.13 and the SDS gel of 
the corresponding fractions is shown in Figure 4.14. In a first peak, hFMO5 elutes 
clearly visible with a band at ~ 60 kDa. In a second peak, MBP elutes giving a band 
at ~ 40 kDa in the SDS gel. However, as with anion exchange chromatography, 
hFMO5 co-elutes with MBP-hFMO5.  
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Figure 4.13 Elution profile of factor Xa cleaved MBP-hFMO5 on Sephadex 200 
10/300GL size exclusion column. 
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Figure 4.14 Coomassie stained SDS gel of fractions of cleaved MBP-hFMO5 purified 
on SEC column.  
SeeBlue® Plus2 (Invitrogen Corporation, Carlsbad, CA, USA) was used as MW 
protein marker. Arrows point to Q-pure MBP-hFMO5 and the cleaved products, 
hFMO5 and MBP. 
4.4 Discussion 
It had been reported that fusion of a protein of interest to a large soluble affinity-tag 
such as MBP may improve several features of the protein like solubility [Donnelly et 
al., 2006; Kapust et al., 1999], yield [Butt et al., 1989], and folding [Kapust et al., 
1999]. In addition, it could give protection from proteolysis and resulting fusion 
proteins may be easily purified via affinity chromatography [Smyth et al., 2003]. 
Although less efficiently, even without the context of a fusion protein, MBP has been 
shown to interact preferentially with unfolded proteins and to promote their folding in 
vitro [Richarme et al., 1997]. Further, it was proposed that MBP has chaperone-like 
qualities when fused to the N-terminus of a protein of interest assisting in correct 
protein folding and enhancing solubility [Kapust et al., 1999; Sachdev et al., 1998]. 
This might be partly due to its maltose binding site, a deep hydrophobic cleft that, 
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hFMO5 
 
MBP 
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together with other hydrophobic sites located on the surface of the protein, could 
serve as binding sites to incompletely folded protein [Kapust et al., 1999]. 
In accordance with these reported theories, a fusion of hFMO5 to MBP led to soluble, 
active, and stable protein as described in chapter 3. This protein was also obtained at 
a high yield and could easily be purified via affinity chromatography. Crystallization 
experiments were done screening various commercially available crystal screen kits 
for suitable crystallization conditions. These were refined further and the conditions 
that finally led to MBP-hFMO5 crystals were 26 % PEG 2K MME and 0.2 M sodium 
acetate in 0.1 M Bis-Tris propane buffer, pH 6.5. Interestingly, these crystallization 
conditions are analog to those reported for other MBP-tagged proteins that were 
successfully crystallized. Comparison of different crystals obtained as MBP-fusion 
proteins showed that, as for MBP-hFMO5, PEG and related molecules were most 
successful as precipitants and that the pH was generally low [Center et al., 1998; 
Kukimoto et al., 2000; Liu et al., 2001; Smyth et al., 2003].  
When working with membrane associated proteins such as FMO enzymes use of 
detergents is unavoidable. As expected, surfactants play a dominant role in 
purification and crystallization of FMO5. Detergents are indispensable for 
solubilization of MBP-hFMO5 from E. coli (see chapter 3). Also in crystallography 
screens, surfactants play a major role, but the use of detergents introduces many 
problems. Detergent micelles have rough heterogeneous surfaces, their hydrophobic 
tails have considerable contact with the surrounding solution [Bogusz et al., 2000], 
and they are fluid systems exchanging micellar components with the solvent 
[Garavito et al., 2001; Wennerstrom et al., 1979]. They have a major impact on 
protein crystallization, because detergent-detergent and detergent-protein 
interactions influence the behavior of membrane proteins. In addition, interactions 
with any remaining lipids have an effect on how a protein behaves [Garavito et al., 
2001]. In mixed systems (considering only detergents and lipids) phase behavior as 
well as changes in micelle shape, size, and CMC will be hard to predict because 
these systems never behave like solutions of the pure components [Wennerstrom et 
al., 1979]. The behavior will be altered again when effects of solvent components like 
salts, PEG, or pH are considered [Arnold et al., 2008; Garavito et al., 2001]. 
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Since usage of detergents introduces a completely new layer of unpredictability, a 
detergent used in crystallization studies preferably has a defined head group size 
and type. Especially mixtures like Triton® do not seem to work well [Arnold et al., 
2008]. In case of FMO5 where usage of Triton® X-100 was inevitable for extraction of 
the protein from E. coli (see chapter 3), complete removal of detergent and possibly 
substitution with other detergents before crystallization seemed necessary. Removal 
of detergent from protein samples previous to crystallography screens has been 
done by hydroxyl apatite column chromatography [Chen et al., 1999] or by 
precipitation [Askolin et al., 2004], dialysis, or dilution of the sample [Rigaud et al., 
1997]. Another method that proved to be successful in production of two-dimensional 
[Rigaud et al., 1997] or three-dimensional crystals [Bron et al., 1999] was surfactant 
removal utilizing Bio-Beads®. In 1973, Holloway et al. already described the 
successful removal of Triton® X-100 by adsorbance onto the polystyrene based 
Bio-Beads® [Holloway, 1973]. Interestingly, upon addition of excess amounts of 
Bio-Beads® to the protein solution, MBP-hFMO5 did not precipitate suggesting that 
FMO5 is not an integral membrane protein, but rather only associated with the 
membrane. As shown in the study, removal of Triton® X-100 with Bio-Beads® 
improved results from crystallization trials of MBP-hFMO5 leading to thick yellow oil 
phases and premature crystals with spherical shape (Figure 4.4).  
Experiments in which a variety of different detergents was added after removal of 
Triton® X-100 led to further improvement of this first pre-stage of crystals (Table 4.3). 
The transition of the routinely obtained thick yellow oil to spherical shapes obtained 
after Triton® X-100 removal and to yellow crystals is shown in Figure 4.6.  
In several wells that yielded crystals, detergents were added that belong to a new 
group of amphiphilic agents that is supposed to stabilize membrane proteins and 
lower the risk of denaturing or aggregation. The structure of these new types of 
amphiphilic molecules is based on cholic acid, but they exhibit facial amphiphilicity, 
meaning that their polar and nonpolar groups are located on opposite faces instead 
of at opposite ends as usual in other detergents [Zhang et al., 2007b; Zhong et al., 
2005]. The terminal carboxylate of cholate was removed and uncharged polar groups 
were introduced at the parallel hydroxyl groups in the center of the cholic acid 
skeleton [Zhang et al., 2007b]. The advantage of this structure is that these 
surfactants are supposed to self-assemble face-to-face. Thus the hydrophobic parts 
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of two molecules have similar dimensions as that of the lipid bilayer. In initial stability 
tests, the facial amphiphiles performed much better than previously used detergents, 
keeping the protein in solution and active for a longer time [Zhang et al., 2007b]. Also 
in case of MBP-hFMO5, these detergents seemed to improve crystallization although 
others like HECAMEG and Cymals® also yielded crystals. Latter detergents have 
previously aided in crystallization studies, e.g., in case of hydrophobin HFBI from 
Trichoderma reesei that yielded crystals in the presence of Cymal®-5 [Askolin et al., 
2004]. In general, controlled addition of detergent and thus employing the concept of 
mixed micelles seems beneficial for MBP-hFMO5 crystal growth. 
Unfortunately, no satisfactory diffraction pattern could be obtained from MBP-hFMO5 
crystals. Several features of the MBP-hFMO5 construct could be argued to have 
been a cause for the poor condition of the crystals obtained. The MBP affinity tag 
itself might be problematic in crystallization experiments. Although expression and 
purification as MBP-fusion protein has numerous advantages, it has been suggested 
to hinder crystal growth by conformational heterogeneity introduced by the fusion tag 
[Smyth et al., 2003]. Circumventing cleavage of MBP-hFMO5 and leaving the 
MBP-tag in place for crystallization studies has the advantage of avoiding potential 
problems often associated with proteolytic splicing including low yield, precipitation of 
target protein, cumbersome optimization of cleavage and subsequent purification 
conditions, high cost of proteases such as factor Xa, or potential loss of activity of the 
target protein during cleavage. However, leaving the tag attached to the protein of 
interest results in a multi-domain protein that might be less likely to form well-ordered, 
diffracting crystals, which is probably due to conformational heterogeneity allowed by 
the flexible linker region between MBP and the target protein [Smyth et al., 2003]. In 
fact, most crystal structures of MBP-tagged proteins previously reported contained a 
shorter, more rigid linker between the affinity tag and the target protein [Center et al., 
1998; Ke et al., 2003; Kukimoto et al., 2000; Liu et al., 2001]. These short, two to five 
amino acid long, mostly alanine containing linkers used instead of the typical longer 
linker in the MBP-hFMO5 fusion protein might be one reason for improved 
crystallization [Kapust et al., 1999; Smyth et al., 2003].  
Also, in contrast to hFMO5, most proteins that led to crystals upon fusion with MBP 
were small in comparison with the rather large MBP-tag they were fused to. This 
could also play a role in successful crystallization as the ratio of MBP/protein might 
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be significant. Smaller proteins could be able to allow the larger MBP-tag to direct the 
construction of a crystal lattice whereas larger ones might be less susceptible to let 
MBP conduct crystal formation [Smyth et al., 2003].  
These potential problems implicated by leaving the large affinity tag fused to hFMO5 
during crystallization trials have also been encountered in this study and although 
crystals could be grown from MBP-hFMO5, no satisfactory diffraction pattern could 
be obtained. Therefore, the next step was to cleave off the MBP-tag and perform 
crystallization experiments with only hFMO5. Successive experiments attempted 
proteolytic splicing of MBP from hFMO5 and subsequent purification of the latter. The 
separation of MBP and hFMO5 was done utilizing a previously inserted protease 
sensitive site right after the MBP sequence that may be cleaved by factor Xa. After 
incubation of three hours at 37 °C, cleavage was la rgely completed and addition of 
NADPH to the incubation mixture prevented the enzyme from being heat-inactivated. 
It is notable that similar experiments had been done with MBP-hFMO3 [Brunelle et 
al., 1997]. However, after cleaving MBP from hFMO3, the latter showed intractable 
solubility and enhanced instabilities [Brunelle et al., 1997] as previously described for 
a number of purified FMO enzymes [Cashman, 1995; Guan et al., 1991]. In contrast 
to expectations, after proteolytical separation from MBP, human FMO5 stays in 
solution and is active. 
After successful cleavage, the enzyme had to be separated from remaining factor Xa, 
MBP, and residual uncleaved MBP-hFMO5. A variety of methods to purify MBP from 
the target protein have been described including affinity purification [Riggs, 2000], ion 
exchange chromatography [de Pieri et al., 2004; Guan et al., 2002; Hao et al., 2007; 
Riggs, 2000; Yan et al., 2006], and size exclusion chromatography [Branco et al., 
2008]. Herein, these methods were carried out and evaluated.  
Firstly, purification via amylose resin was attempted. In general, a disadvantage of 
this procedure is that although MBP can be removed from the cleavage mixture, the 
protease and other contaminants cannot be removed. Nevertheless, it has been 
described to be effective for MBP removal [Riggs, 2000]. After an ion exchange 
chromatography step to remove residual maltose from the elution of the first affinity 
column, the fusion protein (i.e., MBP-hFMO5) was cleaved and applied to the 
amylose resin. The target protein should be located in the flow through fractions and 
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freed of MBP. In this study however, MBP could not be separated from hFMO5. Both 
proteins were found mainly in the eluate after washing with 3 mM maltose but the 
flow through also contained both proteins to some degree. Potential difficulties might 
have arisen if MBP was denatured or otherwise damaged in the purification process, 
because than it presumably looses its affinity to the amylose resin [Riggs, 2000]. 
Maltose might also be more difficult to separate from the MBP than expected 
because it is buried in a deep groove almost inaccessible to solvent. Also, extensive 
hydrogen-bonding and van-der-Waals interactions keep the maltose in place 
[Spurlino et al., 1991]. Thus, incomplete removal of maltose might have led to 
ineffective purification on amylose resin. 
Secondly, separation of hFMO5 and the affinity tag was attempted by size exclusion 
chromatography. Successful purification of target protein from MBP after proteolytic 
splicing has been described for recombinant Lassa virus (LASV) proteins via SEC 
[Branco et al., 2008]. hFMO5 could be successfully separated from MBP, however, it 
co-elutes with MBP-hFMO5.  
Therefore, a third purification method to separate hFMO5 and MBP has been 
attempted, i.e., ion exchange chromatography. Especially anion exchange 
chromatography utilizing DEAE chromatography [de Pieri et al., 2004; Guan et al., 
2002; Hao et al., 2007; Riggs, 2000; Yan et al., 2006] or Q columns [de Pieri et al., 
2004; Riggs, 2000] has been used several times. Purification of MBP from hFMO5 
was successful using a 1ml HiTrap Q  HP column, but as in case of SEC purification, 
hFMO5 co-eluted with uncleaved MBP-hFMO5.  
Further studies are needed to succeed in purification of hFMO5 and subsequent 
crystallization experiments. Potential methods include cation exchange 
chromatography or antibody affinity chromatography. Theoretical calculation of the 
isoelectric point (pI) of MBP-hFMO5, MBP, and hFMO5 suggested that cation 
exchange purification on a HiTrap SP column (GE Healthcare, Uppsala, Sweden) at 
pH 7 could be successful (pIMBP 5, pIFMO5 8, and pIMBP-FMO5 6). To verify these 
calculated pI values, isoelectric focusing (IEF) could be performed. Afterwards, cation 
exchange should be used to purify hFMO5. Another approach to separate the MBP-
tag from hFMO5 is the usage of MBP specific monoclonal antibodies that could be 
conjugated to Sepharose beads [Park et al., 1998]. Also, a poly His site could be 
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introduced into the protein vector and protein could be purified via Ni2+-column affinity 
chromatography after proteolytic splicing of MBP from the target protein. This has 
been described previously for several other proteins [Feher et al., 2004; 
Ramachandran et al., 2007]. Using antibodies as well as using an additional His-tag 
have the disadvantage that they only remove MBP, but not the protease and other 
remaining contaminants. However, usage of biotin-labeled factor Xa has been 
reported to be advantageous because the protease can be removed after cleavage 
from the separated proteins by binding to streptavidin gel [Salek-Ardakani et al., 
2002]. 
Another approach to remove MBP from hFMO5 could exploit in-situ proteolysis. This 
is usually done by incubating trace amounts of protease with the protein of interest in 
crystallization trials [Dong et al., 2007; Wernimont et al., 2009]. The method was 
suggested to improve crystallization conditions because stable domains crystallize 
more readily and result in better diffracting crystals [Wernimont et al., 2009] and 
might not be effective in case of MBP-hFMO5. However, for hFMO5, this in-situ 
proteolysis method might be applied to the cleavage of the large MBP-tag from 
hFMO5 to improve crystals by incubation with various amounts of factor Xa and 
screening at different conditions.  
There are several of other suggestions to improve crystallization of either proteins 
that fail to crystallize or in case poorly ordered crystals are obtained. These 
improvements mainly aim at lowering molecular flexibility that may arise from motion 
of large domains, surface loops, or chain termini. Mostly, in these cases redesign of 
the protein construct is required. For instance, removal of a disoriented terminal 
extension has been successful. In case of FMOs though this may lead to a loss of 
function as has been shown for hFMO3 where even a truncation of only 22 amino 
acids led to a significant decrease in functional enzyme activity and further truncation 
(65 amino acids or more) resulted in abolished activity [Yamazaki et al., 2007]. Thus, 
truncation of the hydrophobic C-terminus is not an option for crystallization studies of 
FMO enzymes.  
Another approach is changing the surface properties of a protein. For example, 
methylation of lysine or site-directed mutagenesis of large charged residues that lie 
on the surface of the protein to smaller hydrophobic residues may be useful because 
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even small motions of these flexible, solvent-exposed amino acid side chains can be 
disruptive to a well-ordered crystal lattice [Walter et al., 2006]. Controlled dehydration 
of poorly ordered crystals has been described to be successful [Heras et al., 2003]. 
This method might afford an opportunity to improve the poor quality crystals already 
obtained.  
In summary, this study showed that MBP-hFMO5 is crystallizable. However, further 
studies are needed to seperate hFMO5 from MBP after factor Xa cleavage in order to 
start crystallization experiments with the tag-free protein and obtain better diffracting 
crystals.
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5 pH Dependence of Human and Mouse FMO5 
5.1 Introduction  
5.1.1 pH Dependence of FMO Isoforms 
FMO5 shows several unique features compared to other FMO enzymes. When 
comparing the pH dependence of three functional mouse FMOs (i.e., mFMO1, 
mFMO3, and mFMO5) and human FMO5 (hFMO5), it was found that the pH profile 
of FMO5 differed significantly from that of all other FMO isoforms examined in the 
study [Zhang et al., 2007a] (Figure 5.1). The pH optima of FMO1 and 3 lie around 
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Figure 5.1  pH Dependence of mFMO1, mFMO3, mFMO5, and hFMO5. 
Plots of mouse FMOs are shown as white bars, human plots as dotted bars. n.d., not 
detectable. Bar-graphs adapted from Zhang et al. [Zhang et al., 2007a]. 
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pH 8 through 10, whereas for FMO5 8-DPT N-oxygenation activity continues to 
increase from pH 7 to pH 11. Further, comparison of pH profiles from human and 
mouse FMO5 show significant differences in the lower pH range (Figure 5.1). 
5.1.2 Aim of the Study 
A comparison of FMOs showed that the pH dependent activity profile of FMO5 
differed significantly from that of other FMO isoforms. The objective of this study was 
to examine the pH dependence of FMO5 to gain insight into the mechanism of action 
of FMO5 enzymes. Determination of pH dependent activity profiles and subsequent 
calculation of pKa values for certain ionizable groups within the enzyme have been 
performed previously in order to reveal the roles of these amino acid residues in 
substrate binding and catalysis [Adachi et al., 2010; Cook et al., 1981; Grimshaw et 
al., 1981; Viggiani et al., 2004]. For the catalytic mechanism of FMO enzymes the 
theory is that the dehydration of the C4a-hydroxyflavin or the release of NADP+, but 
not the release of oxygenated substrate represents the rate-limiting step (see also 
section 1.6). Thus, pKa values calculated from pH dependent enzyme activity profiles 
of FMOs would have to attributed to titrable groups on amino acid residues involved 
in the rate-limiting step (e.g., NADP+ release) or in conformational changes allowing 
NADP+ release. Therefore these residues could be identified via pH studies.  
Functional recombinant human and mouse FMO5 were expressed as maltose-
binding fusion proteins (i.e., MBP-hFMO5 and MBP-mFMO5) from E. coli, purified 
with affinity chromatography, and examined with 8-DPT as substrate for their N-
oxygenation functional activity at different pH values. Results showed differences in 
enzyme activity at low pH between the two enzymes. In subsequent studies 
chimeras, i.e., enzymes composed of one part human and one part mouse 
sequence, should be expressed as MBP-fusion proteins and purified. To identify the 
region in that amino acid residues involved in an altered pH profile of hFMO5 and 
mFMO5 functional enzyme activity lie, pH dependent activity studies should be 
performed with these human-mouse chimeras. Once a manageable region of interest 
is located, human and mouse sequences will be aligned to locate amino acid 
differences between the two species within this region of interest. Amino acid/s 
involved in the pH shift between human and mouse FMO5 should be identified by 
swapping these amino acids utilizing site-directed mutagenesis. First, the amino 
acids will only be mutated in human FMO5 to those found in the mouse enzyme. To 
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verify initial results from this study, amino acid positions that seem to impact the pH 
profile in human FMO5 will also be mutated in the mouse enzyme. The results of 
these studies may help explain the mechanism of FMO function. 
5.2 Materials and Methods 
5.2.1 Reagents 
All chemicals and reagents were purchased from Sigma-Aldrich Chemical Co. (St 
Louis, Missouri, USA) in appropriate purity. Buffers and other reagents were 
purchased from VWR Scientific, Inc. (San Diego, California, USA). The phenothiazine 
8-DPT was synthesized by Dr. Karl Okolotowicz (HBRI, San Diego, USA) as 
previously described [Lomri et al., 1993b; Nagata et al., 1990; Zhang et al., 2007a].  
Plasmids pMAL-hFMO5 and pMAL-mFMO5 [Zhang et al., 2007a] were prepared as 
previously described at HBRI. 
5.2.2 Chimera-Design of hm159, mh159, hm435, and mh435  
Chimeric FMO5 hm159, mh159, hm435, and mh435 expression plasmids were 
created by swapping homologous restriction fragments of pMAL-hFMO5 and pMAL-
mFMO5 plasmid DNAs. This had been previously done by Kiersten Riedler (HBRI, 
San Diego, CA, USA). Restriction enzymes used to cut both hFMO5 and mFMO5, 
with the cut sites at the same positions within the hFMO5 and mFMO5 open reading 
frames, were HindIII and NcoI. HindIII cuts at position 3190 of both, the pMAL-
hFMO5 and pMAL-mFMO5 plasmids, between codon 159 and codon 160 of FMO5, 
as well as a cut site downstream from the FMO5 sequence. NcoI cuts at position 
4017 of both plasmids, between codons 435 and 436 of FMO5, and at position 2490, 
upstream from the FMO5 sequence (Figure 5.2). 
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Figure 5.2 Scheme of human and mouse FMO5 and the four human/mouse 
chimeras. 
The human part is shown as solid line; the mouse part is represented by a dashed 
line. Nomenclature of chimeras is due to the order of human and mouse sequence 
followed by the amino acid position where the switch was made. 
pMAL-hFMO5 and pMAL-mFMO5 plasmids were digested at 37 °C for two hours 
with HindIII and NcoI in four separate digestion reactions. Restriction digestion 
products were purified by agarose gel electrophoresis and extracted from gel using 
the QIAquick Gel Extraction Kit (Qiagen Inc., Valencia, CA, USA). All vectors (i.e., 
pMAL-hFMO5 HindIII, pMAL-mFMO5 HindIII, pMAL-hFMO5 NcoI, and pMAL-
mFMO5 NcoI) were then treated for one hour at 37 °C with  Calf Intestine 
Phosphatase (CIP) in order to minimize recircularization of the vector DNA. 
Afterwards, DNA was purified and concentrated by phenol:chloroform extraction to 
denature and remove protein followed by ethanol precipitation of the DNA. After 
redissolving DNA pellets in sterile water, pMAL-hFMO5 and pMAL-mFMO5 DNA 
inserts were ligated into either the HindIII or NcoI sites of the vectors, in order to 
produce plasmids containing chimeric FMO5 DNA. Finally, ligation products were 
transformed into MAX Efficiency® DH5α competent E. coli cells (Invitrogen 
Corporation, Carlsbad, CA, USA). In order to unambiguously identify the sequence of 
each DNA insert, plasmids purified from single colonies of each construct 
transformed into E. coli were sequenced by Eton Bioscience Inc. (San Diego, CA, 
5  pH Dependence of Human and Mouse FMO5 
   
117 
 
USA) and chromatograms obtained from each sequencing reaction were analyzed 
using Sequencher software (Gene Codes Corporation, Ann Arbor, MI, USA).  
5.2.3 Chimera-Design of hm229, mh229, hm370, and mh370 
Due to the lack of convenient homologous restriction sites, the second set of 
chimeras was constructed by swapping homologous regions of pMAL-hFMO5 and 
pMAL-mFMO5 plasmid DNA through PCR amplification. The first swapping point was 
located at position 3399/3400 of the pMAL-hFMO5 and pMAL-mFMO5 plasmids, 
between codon 229 and codon 230 of FMO5. The other was located at position 
3822/3823 of both plasmids, between codons 370 and 371 of FMO5. Chimeras were 
constructed in two steps of PCR reactions utilizing the FastStart High Fidelity PCR 
System, dNTPack (Roche Diagnostics GmbH, Mannheim, Germany): In a first PCR 
step, four human and four mouse FMO5 parts were amplified separately, each with 
25 extended bases of human and mouse FMO, respectively, at one end (Figure 5.3, 
PCR reaction 1).  Primers used are listed in Table 5.1.  PCR reactions were run using 
a Gene Amp PCR 9700 system (Perkin Elmer, Waltham, MA, USA). Each PCR 
reaction was prepared in a volume of 50 µl and contained the following components:  
5 µl 10 x FastStart High Fidelity reaction buffer (Roche Diagnostics GmbH, 
Mannheim, Germany), 1 µl template DNA (i.e., mFMO5 or hFMO5), 2 µl gene 
specific primer pair, 1 µl dNTP mix (Roche Diagnostics GmbH, Mannheim, 
Germany), 0.5 µl FastStart High Fidelity enzyme mix (Roche Diagnostics GmbH, 
Mannheim, Germany), and sterile water. The PCR was run at 95 °C for 2 minutes 
followed by 30 cycles at 95 °C for 30 seconds, 55 ° C for 30 seconds, and 72 °C for 
2 minutes. Afterwards a 10 minute-cycle was added at 72 °C.  
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Figure 5.3 Scheme of PCR reactions for constructing human/mouse chimeras: 
hm229, mh229, hm370, and mh370.  
Human parts are shown as solid lines, mouse parts as dashed lines. DNA is 
represented as lines, primers as solid black and dashed arrows. 
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Table 5.1  Polymerase chain reaction primers for human/mouse FMO5 chimeras.  
FMO5 
chimera  
FMO5 
part 
Primer  
hm229  human, 
bp 1-687  
 
hF5fXbaI 
forward 
5'- GAT CTC TAG AAT GAC TAA GAA AAG AAT TGC TGT GA -3' 
 reverse 5'- AGA GAG TAG CAG GTC AAT AGG ATA TCC GTA GTC CCC 
TAC ACG ATT CAG -3' 
 mouse, 
bp 688-
1602 
forward 5'- CTG AAT CGT GTA GGG GAC TAC GGA TAT CCT ATT GAC 
CTG CTA CTC TCT -3' 
 mF5rPstIn 
reverse 
5'- GAT CCT GCA GCT AAA AAT AAG CCA GGA TGA CAG C -3' 
mh229 mouse, 
bp 1-687 
mF5fXbaIn 
forward 
5'- GAT CTC TAG AAT GGC CAA AAA AAG GAT TGC T -3' 
 reverse 5'- AGA GAA CAA CAC ATC AGC AGG ATA TCC ATG CTT GCC 
TAC ACG GTT CAA -3' 
 human, 
bp 688-
1602 
forward 5'- TTG AAC CGT GTA GGC AAG CAT GGA TAT CCT GCT GAT 
GTG TTG TTC TCT -3' 
 hF5rPstI 
reverse 
5'- GAT CCT GCA GCC AAT GAA AAA CAG GGC AGT -3' 
hm370  human, 
bp 1-
1110 
hF5fXbaI 
forward 
5'- GAT CTC TAG AAT GAC TAA GAA AAG AAT TGC TGT GA -3' 
 reverse 5'- AAT GGC TCC CAA GGG CTG AAT TAA GCC TAT GAT TGC 
AAG AGT TGG CCT -3' 
 mouse, 
bp 1111-
1602 
forward 5'- AGG CCA ACT CTT GCA ATC ATA GGC TTA ATT CAG CCC 
TTG GGA GCC ATT -3' 
 mF5rPstIn 
reverse 
5'- GAT CCT GCA GCT AAA AAT AAG CCA GGA TGA CAG C -3' 
mh370 mouse, 
bp 1-
1110 
mF5fXbaIn 
forward 
5'- GAT CTC TAG AAT GGC CAA AAA AAG GAT TGC T -3' 
 reverse 5'- AAT GGC TCC TAA GGG CTG AAT CAA GCC GAT GAT TGC 
AAG TGT TGG TTT -3' 
 human, 
bp 1111-
1602 
forward 5'- AAA CCA ACA CTT GCA ATC ATC GGC TTG ATT CAG CCC 
TTA GGA GCC ATT -3' 
 hF5rPstI 
reverse 
5'- GAT CCT GCA GCC AAT GAA AAA CAG GGC AGT -3' 
Mouse sequence parts are underlined.   
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After gel extraction and determination of DNA concentration of PCR products 
employing Kodak molecular imaging software (Eastman Kodak Company, Rochester, 
NY, USA), human and mouse parts were annealed with their counterparts and 
amplified in a second PCR reaction (Figure 5.3, PCR reaction 2). PCR reactions 
were run using a DNA Engine Peltier Thermal Cycler (Bio-Rad, Hercules, CA, USA) 
with FastStart High Fidelity PCR System, dNTPack (Roche Diagnostics GmbH, 
Mannheim, Germany). Each PCR reaction was prepared in a volume of 24 µl and 
contained the following components: 2.5 µl 10 x FastStart High Fidelity reaction 
buffer (Roche Diagnostics GmbH, Mannheim, Germany), 50 ng of each template 
DNA, 0.5 µl dNTP mix (Roche Diagnostics GmbH, Mannheim, Germany), 0.5 µl 
FastStart High Fidelity enzyme mix (Roche Diagnostics GmbH, Mannheim, 
Germany), and sterile water. The PCR was run at 95 °C for 2 minutes followed by 
8 cycles at 95 °C for 30 seconds, 55 °C for 30 seco nds, and 72 °C for 2 minutes to 
anneal human and mouse parts with their counterparts. Afterwards a 2 minute-cycle 
was inserted at 55 °C. During this cycle 1 µl of co rresponding end primers was added 
to each reaction (Table 5.2). The PCR was then run for an additional 30 cycles at 
95 °C for 30 seconds, 55 °C for 30 seconds, and 72 °C for 2 minutes followed by a 
7 minute-cycle at 72 °C to amplify chimera. 
Table 5.2 Setup of 2nd PCR reaction.  
FMO5 
chimera 
Template DNA from 1st PCR reaction used in PCR 
reaction 
Primer used in 
PCR reaction 
hm229 human, bp 1-687  
 
mouse, bp 688-1602 
  
 
 
 
hF5 f XbaI 
mF5 r Pst In 
 mh229 mouse, bp 1-687 
 
 human, bp 688-1602 
 
 
 
 
mF5 f Xba In 
hF5 r Pst I 
hm370 human, bp 1-1110  
 
mouse, bp 1111-1602 
  
 
 
 
hF5 f Xba I 
mF5 r Pst In 
mh370 mouse, bp 1-1110 
 
human, bp 1111-1602 
 
 
 
 
mF5 f Xba In 
hF5 r Pst I 
Mouse parts are shown as dashed lines, human parts as solid lines. 
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The PCR products from this second PCR reaction were gel-purified and sequences 
of human-mouse chimera constructs were verified by sequencing analysis (Eton 
Bioscience Inc., San Diego, CA, USA). The chromatograms obtained from each 
sequencing reaction were analyzed with Sequencher software.   
In order to ligate the chimera constructs into the pMAL vector, the vector was purified 
from overnight culture utilizing a QIAfilter Plasmid Midi Kit (Qiagen Inc., Valencia, CA, 
USA). 43 µl Backbone vector or 40 µl of each insert were double digested over night 
at 37 °C with each 1 µl PstI and 1 µl XbaI enzymes,  and 5 µl 10 x buffer 3 (50 mM 
Tris-HCl pH 7.9, 100 mM NaCl, 10 mM MgCl2, 1 mM DTT). 1 µl CIP enzyme was 
added to the vector DNA and incubated at 37 °C for one hour to minimize 
recircularization. After double digestion of both constructs and pMAL-backbone, both, 
vector DNA and inserts, were run on a 1 % agarose gel and purified. Ligation of 
inserts into the backbone vector was done by incubation of 2 µl ligase buffer with 2 µl 
backbone, 3 µl insert (or water as control), 1 µl ligase T4, and 2 µl of sterile water at 
16 °C for 48 hours. Ligated DNA was than purified a nd concentrated by ethanol 
precipitation. To 10 µl ligation mix 25 µl ethanol was added. The mixture was 
vortexed and incubated at -80 °C for 4 hours follow ed by centrifugation and drying.  
Finally, ligation products were transformed into DH5α competent E. coli cells (easy 
shock 10B electro-competent cells, Bio-Rad, Hercules, CA, USA). These were 
cultured over night on ampicillin-resistant LB-agar plates. In order to unambiguously 
identify the sequence of each DNA insert, plasmids purified from single colonies of 
each construct transformed into E. coli were sequenced by Retrogen, Inc. (San 
Diego, CA, USA) and chromatograms obtained from each sequencing reaction were 
analyzed using the Sequencher program.  
5.2.4 Site-directed Mutagenesis of Human and Mouse FMO5 Variants 
Site-directed mutagenesis was done using the QuikChange Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, CA, USA) following the manufacturer’s 
instructions. Primer designed for site-directed mutagenesis in mFMO5 and hFMO5 
are listed in Table 5.3. Each PCR reaction was prepared in a volume of 50 µl and 
contained the following components:  5 µl 10 x reaction buffer for Pfu (Stratagene, La 
Jolla, CA, USA), 1 µl of each template DNA, 2 µl gene specific primer pair, 1 µl dNTP 
mix (Stratagene, La Jolla, CA, USA), 1 µl Pfu Turbo DNA polymerase (Stratagene, 
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La Jolla, CA, USA), and sterile water. The PCR was run at 95 °C for 30 seconds 
followed by 17 cycles at 95 °C for 30 seconds, 55 ° C for 1 minute, and 68 °C for 
9 minutes. Afterwards 2 µl DpnI was mixed into each reaction and incubated for at 
least 3 hours at 37 °C. PCR products were purified and concentrated by ethanol 
precipitation (in case of hFMO5 Q170K, E181V, G182V, D227K, and Y228R) or with 
QIAquick PCR Purification kit (Qiagen Inc., Valencia, CA, USA) following the 
manufacturers instructions (in case of mFMO5 K227D, H228Y and hFMO5 Y228F, 
Y228R, Y228K, and Y228A).  
DNA was transformed into electro-competent cells (easy shock 10B electro-
competent cells, Bio-Rad, Hercules, CA, USA, in case of mFMO5 H206Q and 
hFMO5 Q206H or DH5α electro-competent cells, New England BioLabs, Ipswich, 
MA, USA, in case of all other FMO5 variants), and cultured over night on ampicillin-
resistant LB-agar plates. DNA, purified from selected colonies, was sent for 
sequencing (Eton Bioscience Inc., San Diego, CA, USA). The chromatograms 
obtained from each sequencing reaction were analyzed using the Sequencher 
program in order to verify the sequence of each DNA insert. If the sequence was 
correct, plasmids were transformed into DH1α cells. Afterwards the protein was 
expressed and purified as described in section 5.2.5. 
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Table 5.3 Polymerase chain reaction primers for human and mouse FMO5 variants.  
FMO5 variant Primer Sequence 
hFMO5 Q170K forward 5'- GAG AAG TTC AAA GGG AAG TAC TTC CAC AGT CGA G -3' 
 reverse 5'- CTC GAC TGT GGA AGT ACT TCC CTT TGA ACT TCT C -3' 
hFMO5 E181V forward 5'- GAC TAT AAG AAC CCA GTG GGA TTC ACT GGA AAG AG -3' 
 reverse 5'- CTC TTT CCA GTG AAT CCC ACT GGG TTC TTA TAG TC -3' 
hFMO5 G182E forward 5'- CTA TAA GAA CCC AGA GGA ATT CAC TGG AAA GAG AGT C -3' 
 reverse 5'- GAC TCT CTT TCC AGT GAA TTC CTC TGG GTT CTT ATA G -3' 
hFMO5 Q206H forward 5'- GGC TGT AGA GAT TAG CCA CAC AGC CAA GCA GGT TTT C -3' 
 reverse 5'- GAA AAC CTG CTT GGC TGT GTG GCT AAT CTC TAC AGC C -3' 
hFMO5 D227K forward 5'- CCT GAA TCG TGT AGG GAA GTA CGG ATA TCC TGC TG -3' 
 reverse 5'- CAG CAG GAT ATC CGT ACT TCC CTA CAC GAT TCA GG -3' 
hFMO5 Y228H forward 5'- GAA TCG TGT AGG GGA CCA TGG ATA TCC TGC TGA TGT G -3' 
 reverse 5'- CAC ATC AGC AGG ATA TCC ATG GTC CCC TAC ACG ATT C -3' 
hFMO5 Y228F forward 5’- CGT GTA GGG GAC TTC GGA TAT CCT GCT -3’ 
 reverse 5’- AGC AGG ATA TCC GAA GTC CCC TAC ACG -3’ 
hFMO5 Y228R forward 5’- CGT GTA GGG GAC CGC GGA TAT CCT GCT -3’ 
 reverse 5’- AGC AGG ATA TCC GCG GTC CCC TAC ACG -3’ 
hFMO5 Y228K forward 5’- CGT GTA GGG GAC AAG GGA TAT CCT GCT -3’ 
 reverse 5’- AGC AGG ATA TCC CTT GTC CCC TAC ACG -3’ 
hFMO5 Y228A forward 5’- CGT GTA GGG GAC GCC GGA TAT CCT GCT -3’ 
 reverse 5’- AGC AGG ATA TCC GGC GTC CCC TAC ACG -3’ 
mFMO5 K227D forward 5’- GAA CCG TGT AGG CGA CCA TGG ATA TCC T -3’ 
 reverse 5’- AGG ATA TCC ATG GTC GCC TAC ACG GTT C -3’ 
mFMO5 H228Y forward 5’- CCG TGT AGG CAA GTA CGG ATA TCC TAT TG -3’ 
 reverse 5’- CAA TAG GAT ATC CGT ACT TGC CTA CAC GG -3’ 
Mutant positions are underlined. 
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5.2.5 Expression and Purification of  Human - Mouse FMO5 Chimera and 
Human or Mouse FMO5 and their Variants. 
Expression vector for the eight FMO5 chimeras and hFMO5 and mFMO5 variants 
were cloned into pMAL-2c (New England BioLabs, Ipswich, MA, USA) with site-
directed mutagenesis methods as described previously [Brunelle et al., 1997; Zhang 
et al., 2003]. Expression and purification was done as described in section 3.2.2 with 
minor changes. Briefly, the FMO5 enzymes were expressed as N-terminal maltose-
binding fusion proteins (i.e., MBP-FMO5). After transformation of E. coli DH1α cells 
with pMAL-MBP-FMO5 plasmid, cells were grown, induced and disrupted as 
described in section 3.2.2.1. The protein was then applied to a 10 – 15 ml amylose 
column at 0.75 ml/min or 1 ml/min.  Bound MBP-FMO5 protein was eluted with 3 mM 
maltose or a linear maltose gradient: 0 – 100 % 10 mM maltose in buffer A over 
100 minutes at 1 ml/min. Eluted fractions containing the fusion protein were pooled 
and concentrated with a Centriprep centrifugal filter unit with Ultracel-30 membrane 
or an Amicon Ultra-15 centrifugal filter unit with Ultracel-50 membrane (Millipore, 
Billerica, MA, USA). 
5.2.6 Determination of Protein Concentrations of FMO5 Chimera 
Concentration of purified MBP-FMO5 chimeras was determined by SDS-PAGE and 
Coomassie Blue staining and compared with BSA standard (see section 3.2.4.1). 
5.2.7 Enzyme Assays 
5.2.7.1 N-Oxygenation of 8-DPT by FMO5 
N-Oxygenation of 8-DPT was determined by HPLC analysis as described in section 
3.2.4.2 with incubation mixtures containing 100 mM potassium phosphate buffer at 
different pHs (i.e., pH 6.0, 6.3, 6.7, 7.0, 7.3, 7.7, and 8.0), 0.4 mM NADP+, 0.4 mM 
glucose-6-phosphate, 4 U glucose-6-phosphate dehydrogenase, 0.25 mM 
DETAPAC, and 80 µg MBP-FMO5. 
5.2.7.2 Optimization of Enzyme Assays 
Assay conditions for 8-DPT N-oxygenation activity by FMOs have previously been 
described and successfully used for various studies [Brunelle et al., 1997] and thus 
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were adapted with only minor changes for the pH study described herein. However, 
closer evaluation in terms of sensitivity to pH change and buffer strength showed that 
the previously used conditions can be optimized. Also, results from the determination 
of kinetic parameters (i.e., Vmax and Km) for FMO5-mediated 8-DPT HCl 
N-oxygenation suggested that a higher substrate concentration is favorable for 
routine analysis (Km = 117 µM and Vmax = 3.2 nmol/min/mg FMO5). However, 
although buffer strength and pH seem to play an important role, the Km was not 
expected to be increased at different pHs and thus, a substrate concentration of 
400 µM was considered saturation condition for all pHs examined. Therefore, for 
pH profile experiments of human and mouse FMO5 variants, a final 8-DPT HCl 
concentration of 400 µM was used. The revised assay protocol is stated hereafter.  
Nevertheless, pH profiles of human and mouse FMO5 were performed with both 
methods and comparison showed no significant changes. Thus, profiles generated 
with the original method were not repeated. 
5.2.7.3 Optimized 8-DPT Assay 
N-Oxygenation of 8-DPT was determined by HPLC analysis as described in section 
3.2.4.2 with incubation mixtures containing a buffer mix consisting of 0.1 M ACES, 
52 mM Tris, and 52 mM ethanolamine at different pHs (i.e., pH 6.0, 6.3, 6.7, 7.0, 7.3, 
7.7, 8.0, and 9.0), 0.4 mM NADP+, 0.4 mM glucose-6-phosphate, 4 U glucose-6-
phosphate dehydrogenase, 0.25 mM DETAPAC, and 40 µg MBP-FMO5. The 
advantage of this buffer system over phosphate buffer which was used earlier is that 
a) its ionic strength is virtually constant over a wide range of pHs and b) its buffer 
capacity is much better than that of phosphate buffer over the pH range tested [Ellis 
et al., 1982]. Reactions were initiated by addition of substrate to a final concentration 
of 400 µM. After 20-minute incubation the samples were processed and analyzed via 
HPLC as described in section 3.2.4.2. 
5.2.8  Data Analysis 
Results were analyzed with Graphpad software (Graphpad Prism, Version 2.00 or 
3.00, San Diego, CA, USA). For pKa determination, log-enzyme activities in 
nmol/min/mg FMO5 were plotted against pH and the following equasion was applied: 
Y=log(Vmax/(1+10pKa-X)) with Ka representing the dissociation constant of an ionizable 
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group on the enzyme [Cook et al., 1981]. Data obtained was presented as best fit 
value ± standard error. Statistical analysis was also done using Graphpad Prism 
software and statistical significance was judged at P<0.05. 
5.3 Results 
5.3.1 pH Dependence of Human and Mouse FMO5 
The pH dependence of human and mouse FMO5 was studied and pKa values were 
determined in the range of pH 6 – 8. As shown previously, the pKa determined from 
pH dependent enzyme activity profiles with mouse FMO5 was significantly higher 
than that determined with human FMO5 (6.6 ± 0.1 and 7.2 ± 0.1, respectively). 
5.3.2 pH Dependence of hm159, mh159, hm435, and mh435 
The pH dependent 8-DPT N-oxygenation activity of MBP-FMO5 chimeras hm159, 
mh159, hm435, and mh435 was analyzed and pH profiles were evaluated in regard 
to activity drop at low pH values. Comparing hm159 and mh159 FMO5, it can be 
concluded that the amino acid residues 1 – 159 of hFMO5 are not involved in the 
increased activity observed at lower pH for hFMO5 because the pH dependent 
activity profile of mh159 is close to that of human FMO5 whereas the pH drop of 
hm159 is steeper at low pH resembling the pH profile of mouse FMO5. Comparing 
the other two chimeras (i.e., hm435 and mh435), the difference in activity drop 
around pH 6 is not as pronounced. Nevertheless, the pH profile of hm435 seems 
closer to that of hm159 and thus to that of wild-type mouse FMO5, whereas the pH 
profile of mh435 seems to follow more the outline of mh159 (Figure 5.5). Therefore, 
the amino acid/s most likely to be responsible for the increased activity of hFMO5 at 
lower pH in comparison to mFMO5 lies between amino acid residues 160 and 434. 
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Figure 5.5 Human/mouse chimeras and their pH dependent activity profiles derived 
from 8-DPT N-oxygenation activity assays at pH 6 through 8.  
hm159, white bars; mh159, black bars; hm435, hatched bars; mh435, grey bars. 
 
5.3.3 pH Dependence of hm229, mh229, hm370, and mh370 
With data from the first set of chimeras, the region of interest where the amino acid 
residue/s involved in the observed higher activity of hFMO5 below pH 7 are located 
could be narrowed down (i.e., aa 160 – 434). A set of four new chimeric FMO5 
enzymes representing one part human FMO5 and one part mouse FMO5 were 
designed, expressed, and purified in order to determine their pH profiles and localize 
the amino acid/s of interest. The pH profile of hm229 FMO5 could not be determined 
due to very poor expression rates. The pH dependent FMO5 activity profiles for the 
other three chimeras analyzed do not differ significantly from each other and are 
shown in Figure 5.6.  
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Figure 5.6 Human/mouse chimeras and their pH dependent activity profiles derived 
from 8-DPT N-oxygenation activity assays at pH 6 through 8.  
mh229, white bars; hm370, black bars; mh370, hatched bars. 
 
5.3.4 Summary:  pH Dependence of Human and Mouse FMO5 Chimeras 
Chimeras of human and mouse FMO5 with swapping points at amino acids 229, 370, 
and 435 did not differ significantly in their pH dependent activity profiles (Figure 5.5 
and 5.6). Thus, amino acid residue/s involved in the observed higher activity of 
hFMO5 below pH 7 is/are most likely located between amino acids 160 and 229 
because only chimeras mh159 and hm159 showed significant differences from the 
wild-type enzymes whereas no significant differences could be observed with 
chimeras with cutting sites after codon 230. 
Sequence alignment of human and mouse FMO5 showed that within this specific 
region, six amino acids of human FMO5 differ from mouse FMO5. Utilizing site-
directed mutagenesis, these amino acids were changed in human FMO5 to the ones 
found in mouse FMO5, expressed, and purified. Their pH profile between pH 6 and 9 
was determined in 8-DPT HCl N-oxygenation activity assays. 
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5.3.5 pH Dependence of Human and Mouse FMO5 Variants 
The pH profile of wild-type hFMO5 and wild-type mFMO5 as well as hFMO5 variants 
purified was determined after optimization of assay conditions (section 5.2.7.3). 
The results of wild-type human and mouse FMO5 are shown in Figure 5.7. The 
results are similar to those obtained with the original assay conditions with pKa values 
of 7.7 ± 0.1 and 6.9 ± 0.1 calculated from the pH dependent activity profiles of mouse 
and human FMO5, respectively. 
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Figure 5.7 pH Dependence of wild-type human and mouse FMO5.  
hFMO5 is shown as solid line (■), mFMO5 as dashed line (∆). 
 
Five hFMO5 variants were successfully expressed, purified, and analyzed. Results 
for these variant hFMO5s are shown in Figure 5.8. The pKa values determined with 
wild-type human and mouse FMO5 and variant hFMO5 are listed in Table 5.5. 
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Figure 5.8 pH Dependence of human FMO5 variants.  
■ hFMO5 Q170K; ▲ hFMO5 G182E; ▼ hFMO5 Q206H; ● hFMO5 D227K; ∆ hFMO5 
Y228H. hFMO5 Q170K, hFMO5 G182E, and hFMO5 D227K are shown as solid 
lines, hFMO5 Q206H and hFMO5 Y228H are shown as dashed lines. 
 
Table 5.5 pKa Values calculated from pH dependence profiles of human FMO5 
variants compared to those of wild-type human and mouse FMO5.  
Variant pKa 
wild-type hFMO5 6.9 ± 0.1  
wild-type mFMO5 7.7 ± 0.1 
hFMO5 Q170K 6.6 ± 0.1 
hFMO5 G182E 6.6 ± 0.1 
hFMO5 Q206H  6.5 ± 0.05 
hFMO5 D227K 7.3 ± 0.1 
hFMO5 Y228H 7.9 ± 0.2 
Data is presented as best fit value ± standard error. 
 
The data clearly show that replacement of the tyrosine at position 228 with histidine 
in hFMO5 increases the pKa and thus results in a pH profile similar to that observed 
5  pH Dependence of Human and Mouse FMO5 
   
131 
 
with the wild-type mouse enzyme, whereas hFMO5 Q170K, G182E, and Q206H 
mutations do not have a significant influence on pKa. D227K showed a slightly 
increased pKa in comparison to that calculated from pH dependence profiles of wild-
type hFMO5, even though this increase was lower than hFMO5 Y228H. To confirm 
this result, the mouse counterparts with the amino acid of the corresponding human 
enzyme were made (i.e., mFMO5 K227D and H228Y) and as suspected, pH 
dependence studies with mouse FMO5 K227D as well as mouse FMO5 H228Y led to 
decreased pKa values compared to that determined with wild-type mouse enzyme 
(Figure 5.9 and Table 5.6). Also, several variants of hFMO5 Y228 were made in 
order to evaluate the effect of different amino acids at position 228. The results are 
shown in Figure 5.10 and summarized in Table 5.6. 
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Figure 5.9 pH Dependence of human and mouse FMO5 variants.  
▼ hFMO5 D227K; ■ mFMO5 K227D; ● hFMO5 Y228H; ▲ mFMO5 H228Y. hFMO5 
D227K and mFMO5 K227D are shown as solid lines, hFMO5 Y228H and mFMO5 
H228Y are shown as dashed lines. 
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Figure 5.10 pH Dependence of human FMO5 Y228 variants.  
■ hFMO5 Y228H; ▲ hFMO5 Y228F; ▼ hFMO5 Y228R; ∆ hFMO5 Y228K; ● hFMO5 
Y228A. hFMO5 Y228F, hFMO5 Y228R, and hFMO5 Y228K are shown as solid lines, 
hFMO5 Y228H and hFMO5 Y228A are shown as dashed lines. 
 
Table 5.6  pKa Values calculated from pH dependence profiles of human and mouse 
FMO5 variants compared to those of the wild-type FMO5 enzymes.  
Variant pKa 
wild-type hFMO5 6.9 ± 0.1  
wild-type mFMO5 7.7 ± 0.1 
hFMO5 D227K 7.3 ± 0.1 
mFMO5 K227D 6.6 ± 0.05 
hFMO5 Y228H 7.9 ± 0.2 
mFMO5 H228Y 6.5 ± 0.05 
hFMO5 Y228K 8.0 ± 0.1 
hFMO5 Y228A 7.8 ± 0.1 
hFMO5 Y228F 6.7 ± 0.05 
hFMO5 Y228R 7.7 ± 0.1 
Data is presented as best fit value ± standard error. 
 
As expected, in mFMO5 replacement of a histidine at position 228 by tyrosine 
(mFMO5 H228Y) significantly decreased the calculated pKa value in comparison to 
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wild-type mFMO5. The same observation was made for the K227D variant of mouse 
FMO5.  
Changing the amino acid tyrosine in wild-type hFMO5 to three of the tested amino 
acids (i.e., lysine, alanine, or arginine) also increased the pKa significantly. However, 
changing tyrosine to phenylalanine did not make a significant difference in pKa value 
(pKa of 6.9 and 6.7 determined with wild-type hFMO5 and hFMO5 Y228F, 
respectively). Overall, the low pKa seemed to be due to the amino acids at position 
227 and 228 in the human enzyme and thus they are at least in part responsible for 
the increased enzyme activity at low pH. 
5.4 Discussion 
Within this study, the observed pH dependent activity change of human FMO5 was 
compared to mouse FMO5. Interestingly, with the human enzyme a significantly 
lower pKa was observed than with the mouse enzyme. Via chimera studies the region 
in which the amino acids that are responsible for this pKa shift lie was determined. 
Alignment of human and mouse FMO5 sequences showed that this region is only 
distinguished by six amino acids. In additional site-directed mutagenesis studies 
these amino acids were changed and the pH dependent activity profiles of the 
resulting variants were determined. Resulting data clearly showed that the residues 
in question lie at positions 227 and 228 of the enzyme. 
It has been reported previously that pH dependent activity of enzymes is set mainly 
by pKa values of one or a few key ionizable groups within the enzyme, primarily in the 
active-site cleft [Joshi et al., 2000]. According to the human FMO3 homology 
structure model developed based on four related proteins [Borbas et al., 2006b] (see 
also chapter 4), the amino acid that influences the pH profile (i.e., Y228) lies on the 
surface of the protein close to the entrance of the back passage connected to the 
space between the two domains where NADPH binds. Therefore, in case of FMO5, it 
is more likely that NADPH-binding or NADP+ release is altered rather than substrate 
binding. 
It might have been expected that an amino acid change of tyrosine to histidine, which 
has a lower pKa value on its own, would also lead to a decrease in the pKa value 
measured. However, this could not be observed in this study. Instead, it is possible 
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that in wild-type human FMO5 the tyrosine at position 228 can make hydrogen 
bonding with NADP+. If tyrosine is replaced by a histidine, this interaction may be 
interrupted due to protonation at lower pH. The unpolar amino acids phenylalanine 
and alanine might not be able to interact because of the missing polar hydroxylic 
group. Indeed, with hFMO5 Y228A a significantly increased pKa value was observed 
(7.8 ± 0.1). However, replacement of tyrosine by phenylalanine (hFMO5 Y228F) did 
not alter the pKa significantly from that observed with the wild-type enzyme (6.7 ± 
0.05). Also, a significantly increased pKa for pH profiles of both hFMO5 Y228R and 
hFMO5 Y228K (i.e., 7.7 ± 0.1 and 8.0 ± 0.1, respectively) in comparison to wild-type 
human FMO5 (6.9 ± 0.1) was observed showing that both lysine and arginine might 
affect NADP+ binding. 
Conformational changes may also have an influence on titration behavior. Thus, the 
similar pKa values observed for pH dependence profiles of hFMO5 Y228 and F228 
could be explained by sterical similarity between the two amino acid side chains. It is 
possible that a benzene ring is needed in this position and that changing this might 
have an effect on neighboring residues such as D227. As the tyrosine at position 
228, aspartic acid at position 227 could possibly form hydrogen bonds with NADP+ 
and changing Asp227 to lysine resulted in an increased pKa (i.e., 7.3 ± 0.1). Shifting 
this residue by changing the size of the amino acid at position 228 might also prevent 
this interaction and lead to an altered pKa.  
Amino acid residues may be sensitive to both electrostatic and structural changes of 
others that are located in immediate vicinity. Thus, an amino acid change could have 
an effect on pKa values of sterical neighboring residues as was described for the 
substitution of asparagine with aspartic acid at position 35 in Bacillus circulans 
xylanase [Joshi et al., 2000]. In this enzyme, substitution of the basically neutral 
amino acid Asn with the acidic Asp (pKa 3.7) also influenced the pKa values of Glu78 
and Glu172. Latter ones were elevated, probably due to charge repulsion. Overall, 
the pH optimum of the xylanase was shifted from 5.7 to 4.6 [Joshi et al., 2000]. In 
addition, protonation or deprotonation of amino acids may also help stabilize other 
structurally close residues and substitution might lead to destabilization and an 
altered pH. For example, for a polyketide synthase, stabilization and promotion of a 
thiolate anion at cysteine 164 by histidine 303, as an imidazolium cation, was 
reported. Thus, upon substitution of this His303, in addition to reactivity, the pKa 
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value of the Cys164 changed [Jez et al., 2000]. It is possible that amino acid changes 
in FMO5 at position 227 and 228 may also alter pKa values of surrounding residues 
or stabilize/destabilize these depending on the charge of the amino acid in these 
positions. Thus, although based on current three-dimensional models D227 and 
Y228 lie close to the surface of the protein, they could have an impact on amino 
acids that are closer to the substrate binding site or that influence NADPH binding or 
NADP+ release. A crystal structure of a mammalian FMO may give more detailed 
answers as to how these amino acids influence residues in or close to the active site. 
The pI of the enzyme could also affect its pH dependent activity profile. The 
theoretical pI of human and mouse MBP-FMO5 are 6.3 and 7.2, respectively 
(http://www.expasy.ch/cgi-bin/protparam). It is possible that the enzyme has to be 
negatively charged to function properly. Since human FMO5 has a lower pI than the 
mouse enzyme, it will keep its negative charge longer at lower pH. Thus, human 
FMO5 has a negative charge above pH 6 whereas mouse FMO5 is negatively 
charged above pH 7. Therefore, its activity decreases faster in comparison to human 
FMO5 below this pH as seen in the pH profiles in this study. Calculation of the 
variants’ pIs shows an increase for human FMO5 D227K to 6.5 and a decrease for 
mouse FMO5 K227D to 6.8 supporting this theory. FMO5 is negatively charged at its 
pH optimum. Assuming the enzyme functions best when it is negatively charged, a 
substitution of Asn with Asp and the resulting change of pI could lead to altered 
charge of the enzyme at low pH. Also, the pI could simply be a requirement for 
stability in the surrounding environment rather than affecting substrate binding or 
turnover by determining the charge of the enzyme [Joshi et al., 2000]. 
In conclusion, the pH dependent activity change of human and mouse FMO5 were 
compared and the amino acids responsible for an observed pKa shift between the 
two were identified. Changing aspartic acid at position 227 to lysine or tyrosine at 
position 228 to histidine of human FMO5 elevated the pKa observed in pH profiles 
from 6.9 to 7.3 and 7.9, respectively. Accordingly, an amino acid switch of Lys227 to 
Asp227 or His228 to Tyr228 in mouse FMO5 lowered the pKa from 7.7 to 6.6 and 6.5, 
respectively. In order to address the question of how exactly the pH dependent 
activity profile is changed by these amino acids and whether the residues at position 
227 and 228 interact with the cofactor directly or whether the affect neighboring 
residues will need further investigation. For example, crystallographic studies with 
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both wild-type and mutant enzymes at acidic pH value or determination of pKa values 
for specific residues via NMR may lead to more comprehensive explanations of the 
mechanism of FMO5 catalysis and the influence of amino acids on pH dependent 
enzyme activity. 
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6 Substrate Selectivity and Screens of Potential FMO5 
Substrates 
6.1 Introduction 
6.1.1 FMO Substrates 
Generally, any compound containing a soft nucleophile can be a substrate to FMOs if 
it is able to gain access to the 4a-hydroperoxyflavin and the catalytic site of the FMO 
enzyme [Cashman, 1995; Krueger et al., 2005]. This leads to differences in substrate 
specificity between the FMO isoforms because the substrate binding channel of 
different FMOs are clearly distinct [Lomri et al., 1993b; Lomri et al., 1993c; Nagata et 
al., 1990]. FMO1 possesses the broadest and shallowest substrate binding channel 
of all mammalian FMOs. In contrast, FMO2 and FMO3 preferably N-oxygenate long-
chain aliphatic amines (i.e., those possessing a nucleophilic tertiary amine at least six 
or seven carbon atoms away from a bulky moiety). The channel to the 
4a-hydroperoxyflavin in pig FMO1 is about 3 Å deep and 12 Å wide [Cashman, 1995; 
Nagata et al., 1990], but the binding site of human hepatic FMO1 is more restricted 
than that of animals and lies about 5 Å below the surface and is only 4.5 Å in 
diameter [Cashman et al., 2006; Kim et al., 2000; Krueger et al., 2005; Ziegler, 2002]. 
Human FMO1 is efficient in N-oxygenating tertiary amines such as chlorpromazine, 
imipramine, and 10-[(N,N-dimethylamino)alkyl] phenothiazine derivatives (DPT), but 
does not readily catalyze N-oxygenation of primary amines, although aliphatic 
primary amines can act as positive effectors [Cashman, 1995; Cashman, 2000; 
Krueger et al., 2005]. In contrast, the binding channel of rabbit and human FMO2 and 
human FMO3 rests at least 6 to 8 Å below the mouth of the substrate binding 
channel with a diameter of about 8 Å [Krueger et al., 2005; Lomri et al., 1993b; 
Nagata et al., 1990]. FMO2 is the most size-restricted FMO isoform whereas FMO3 
appears to be intermediate.  FMO2 as well as FMO3 and 5 also N-oxygenate primary 
amines such as n-octylamine and the Km decreases with an increasing length of the 
chain between C8 and C12. The resulting hydroxylamine is a better substrate for 
FMO2 and is usually N-oxygenated to the cis-isomer of the oxime [Poulsen et al., 
1986]. When examining rabbit, monkey, and human FMO2 for functional activity, it 
appears that generally sulfur-containing chemicals are better substrates for FMO2 
than nitrogen-containing substrates [Dolphin et al., 1998; Krueger et al., 2004; 
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Krueger et al., 2002; Whetstine et al., 2000]. FMO3 enzymes generally prefer 
substrates that are slightly smaller than those accepted by FMO1, but are also able 
to N-oxygenate primary, secondary, and tertiary amines. Nitrogen atoms on longer 
side chains are more efficiently oxygenated than those on shorter side chains, 
apparently because the substrate binding site is buried deep within the enzyme. 
Typical substrates for FMO3 include benzydamine, methimazole, trimethylamine, and 
the probe substrate 5-DPT [Cashman, 2000; Cashman et al., 2006].  
Although not clearly understood to date, FMO4 and 5 supposedly have very 
restricted substrate specificities. FMO4 is very unstable and its cDNA expression is 
problematic affording poorly active enzyme [Lattard et al., 2003a]. Thus, it has been 
difficult to establish extensive FMO4 substrate specificity relations [Cashman et al., 
2006]. FMO5 does not oxygenate the typical FMO substrates such as MMI and TMA 
[Overby et al., 1995; Zhang et al., 2007a]. In studies with a series of DPT-analogs an 
8-fold increase in specific activity of mouse FMO5 was observed between 5-DPT and 
8-DPT. Thus, it was suggested that the active site of mouse FMO5 lies about 6 Å 
below the surface [Zhang et al., 2007a]. Known substrates of FMO5 are short-chain 
aliphatic primary amines such as n-octylamine, thioethers with proximal carboxylic 
acids (i.e., S-methyl esonarimod), and 5- and 8-DPT [Cashman et al., 2006; Overby 
et al., 1995; Zhang et al., 2007a].  
Endogenous substrates of FMOs include biogenic amines (i.e., tyramine and 
phenethylamine) [Cashman, 2000]. Tyramine is N-oxygenated by FMO1 and 3 to its 
trans-oxime, and FMO3 is predicted to be predominantly responsible for trans-oxime 
formation. Phenethylamine is also metabolized by human hepatic FMO3 and to a 
lesser extent by porcine liver FMO1. It is N-oxygenated to the phenethyl 
hydroxylamine and subsequently to its trans-oxime and this terminates biological 
activity [Lin et al., 1997a; Lin et al., 1997b]. FMO apparently precludes biologically 
important nucleophiles including many endogenous thiols and other heteroatom-
containing compounds from the active site [Ziegler, 1990]. This is advantageous 
because if cellular nucleophiles were to be continuously oxidized, this would 
represent a tremendous drain on the ability of a cell to produce reducing equivalents 
(i.e., NADPH) for normal cell function. In addition, oxygenation of endogenous thiols 
by FMO would also produce a large amount of electrophilic metabolites that might 
overwhelm the cells ability to detoxicate them. FMO stabilizes the peroxyflavin and 
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does so with a molecular architecture that does not allow reactive metabolites 
generated to covalently modify the active site or substrate binding region. Thus, the 
substrate binding region is presumably composed of highly lipophilic and non-
nucleophilic amino acid residues. Overall, substrate specificities of FMO1 – 3 have 
been examined thoroughly in the past. However, for FMO4 and FMO5 enzymes 
there is still a large gap in knowledge of substrate specificity and the substrate 
binding site dimensions. 
6.1.2 Aim of the Study 
As stated in 6.1.1, substrate specificity of FMO isozymes is mainly due to size 
restriction of the substrate binding channel of the enzyme. A three-dimensional 
structure of the FMO enzymes, as attempted in chapter 4 would certainly be useful to 
define substrate specificity since computational modeling studies could be 
performed. However, much can be learned about the size of the catalytic site from 
comparison of accepted substrates, as was already done for FMO1 – 3. In case of 
FMO5, however, the paucity of substrates prevents this approach.  
A photometric HPLC based functional assay has been established for mouse and 
human FMO5 [Zhang et al., 2007a]. In this HPLC analysis assay that has been 
previously described [Lattard et al., 2003b] the ratio of a known FMO5 substrate 
(i.e., 8-DPT) to product (8-DPT N-oxide) after a 20 minute incubation period at 37 °C 
is determined. However, in order to screen and identify alternative substrates for 
FMO5, an easy and quick high-throughput (HT) capable kinetic activity assay should 
be developed to aid the search for new FMO5 substrates. This would help to gain a 
clearer understanding of the substrate specificity of human FMO5 and the structure 
and size of its catalytic site. Identification of structural groups oxygenated by FMO5 
could suggest likely physiological substrates and contribute an explanation of the 
physiological role of FMO5 in mammalian tissue.  
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6.2 Materials and Methods 
6.2.1 Reagents 
Buffer reagents and substrates tested were purchased from Sigma-Aldrich Chemical 
Co. (St Louis, MO, USA) in appropriate purity. 8-DPT HCl was synthesized by Dr. 
Karl Okolotowicz (HBRI, San Diego, USA). 4’-(4-bromphenyl)-ω-
dimethylaminobutyrophenon HCl (BDAB HCl) was originally developed in our 
research group as NO-inhibitor and was synthesized by Dr. Britta Gerig 
(Pharmaceutical Institute, CAU Kiel, Germany). 4’-(4”-bromophenyl)-ω-[4-
chlorophenyl)-4-hydroxypiperidinyl]-butyrophenone (BCHP) as well as 4’-(4”-
bromophenyl)-ω-(4-phenylpiperazinyl)butyrophenone (BPPB) were developed as 
antipsychotics and were synthesized by Nikola Klein (Pharmaceutical Institute, CAU 
Kiel, Germany). All compounds synthesized were of analytical grade and 
charaterized in the usual way. 
6.2.2 Cloning, Expression, and Purification of MBP-hFMO5  
Recombinant human FMO5 was expressed as an N-terminal maltose-binding fusion 
protein (MBP-hFMO5) [Lattard et al., 2003b] and purified as described in section 
3.2.2 with minor changes. MBP-FMO5 was expressed in E. coli BL21 cells. After 
induction, cells were incubated shaking at 20 °C fo r 24 hours. After expression, E. 
coli cells were harvested by centrifugation at 6,000 g for 10 minutes and the cell 
pellet was frozen in order to increase yield. After resuspending the cell pellet in lysis 
buffer as described in section 3.2.2.1, cells were disrupted by passage through a 
French press (Thermo Electron Corp., Needham Heights, MA, USA) operating at 
20,000 psi. The cell pellet was only extracted once and after centrifugation the 
supernatant was loaded at 1 ml/min onto an amylose column (New England BioLabs, 
Ipswich, MA, USA) equilibrated with ten column volumes of buffer A’ (i.e., 50 mM 
Na2HPO4, pH 8.4, containing 15 µg/ml FAD). The column was washed with at least 
ten column volumes of buffer A’ and bound MBP-hFMO5 protein was eluted with 
3 mM maltose in buffer A’ at 1 ml/min. Eluted protein was concentrated with an 
Amicon Ultra-15 centrifugal filter unit with an Ultracel-50 filter (Millipore, Billerica, MA, 
USA). 
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6.2.3 Determination of MBP-hFMO5 Concentration 
Concentration of purified MBP-hFMO5 was determined by measuring the 
absorbance at 280 nm with a NanoDropTM ND-1000 UV/VIS Spectrophotometer 
(Thermo Fisher Scientific, Wilmington, DE, USA) using a calculated extinction 
coefficient of 121 M-1cm-1 estimated after the method of Gill [Gill et al., 1989].  
6.2.4 Enzyme Assays 
N-oxygenation of 8-DPT HCl by MBP-hFMO5 was determined by HPLC analysis as 
previously described (section 3.2.4.2).  
As primary confirmatory assay for BDAB HCl as potential FMO5 substrate, 
N-oxygenation of 8-DPT HCl by MBP-hFMO5 was determined in the presence of 
BDAB HCl. A standard incubation mixture of 250 µl final volume contained 50 mM 
potassium phosphate buffer, pH 8.5, 0.2 mM NADPH, 0.25 mM DETAPAC, and 
60 µg MBP-hFMO5. Reactions were initiated by addition of 8-DPT HCl or a mixture 
of 8-DPT HCl and BDAB HCl. For 8-DPT HCl, a final concentration of 400 µM was 
chosen, BDAB was added to a final concentration of 200 µM. After incubation for 
20 minutes shaking under aerobic conditions at 37 °C, enzyme reactions were 
stopped and processed as described in section 3.2.4.2. HPLC analysis was done on 
a Waters AllianceTM HPLC-System (Waters e2695 XC Separations Modul, Waters 
2998 Photodiode Array Detector and EmpowerTM 2 Software). Chromatographic 
separation of analytes was done on a LiChrospher-Si 60 (250 x 4.6 mm, 5 µm; 
Merck, Darmstadt, Germany) with a mobile phase of 80 % methanol/20 % 
isopropanol/0.025 % HClO4 (v/v/v). The flow rate was 1.5 ml/min and the total run 
time was 18 minutes. The wavelength for UV detection was set to 243 nm. The 
retention times for 8-DPT and 8-DPT N-oxide were 4.9 and 3.7 minutes, respectively. 
Statistical analysis was also done using Graphpad Prism software and statistical 
significance was judged at P<0.05. 
As secondary confirmatory assay, N-oxygenation of BDAB HCl was determined by 
HPLC analysis. A standard incubation mixture of 250 µl final volume contained 
50 mM potassium phosphate buffer, pH 8.5, 0.2 mM NADPH, 0.25 mM DETAPAC, 
and 60 µg MBP-hFMO5. Reactions were initiated by addition of substrate to a final 
concentration of 200 µM. After incubation for 20 minutes shaking under aerobic 
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conditions at 37 °C, enzyme reactions were stopped by addition of 4 volumes of cold 
dichloromethane. About 20 mg of Na2CO3 was added and the incubations were 
mixed and centrifuged to partition metabolites and remaining substrate into the 
organic fraction. The organic phase was collected and evaporated. Metabolites and 
remaining substrate were dissolved in methanol, mixed thoroughly, centrifuged and 
analyzed with a Waters AllianceTM HPLC-System (Waters e2695 XC Separations 
Modul, Waters 2998 Photodiode Array Detector and EmpowerTM 2 Software). 
Chromatographic separation of analytes was done on a LiChrospher-Si 60 (250 x 
4.6 mm, 5 µm; Merck, Darmstadt, Germany) with a mobile phase of 80 % 
methanol/20 % isopropanol/0.025 % HClO4 (v/v/v). The flow rate was 1.5 ml/min and 
the total run time was 18 minutes. The wavelength for UV detection was set to 
293 nm. The retention times for BDAB and BDAB N-oxide were 10.7 and 
5.7 minutes, respectively. 
6.2.5 LC/MS Analysis 
In order to identify the metabolite produced by incubation of BDAB HCl with FMO5 in 
the presence of NADPH (section 6.2.4), an LC/MS-method was developed. After 
incubation, metabolites and remaining substrate were dissolved in methanol, mixed 
thoroughly, centrifuged and analyzed with an Esquire LC MS system (Bruker 
Daltonics, Bremen, Germany) after separation with an HP HPLC-System (HP Series 
1100 Binary Pump G1312A, HP 1100 VWD UV/VIS Detector and Agilent 
ChemStation HPLC Software (Version A.09.01), and Esquire Control (Version 6.14) 
and Data Analysis (Version 3.0) MS Software). Chromatographic separation of 
analytes was done on a Symmetry C18 (250 x 4.6 mm, 5 µm; Waters) with a Guard 
Pak C18 precolumn (3 x 4 mm; Waters) and a mobile phase of 70 % of 0.1 % formic 
acid in acetonitrile, 15 % of 0.1 % acetic acid, and 15 % methanol (v/v/v). The flow 
rate was 1.5 ml/min and the total run time was 12 minutes. The wavelength for UV 
detection was set to 293 nm. The retention times for BDAB and BDAB N-oxide were 
6.3 and 3.5 minutes, respectively. MS analysis was done using electrospray 
ionization (ESI) with a dry temperature of 340 °C, a dry gas flow rate of 7 l/min, and a 
spray pressure of 30 psi. The scan was done between 50 and 1000 m/z and peaks 
were detected at m/z 346 and 362 for BDAB and BDAB N-oxide, respectively. 
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6.2.6 Development of a Photometric Activity Assay Method 
6.2.6.1 Assay Protocol Outline 
The FMO5 activity assay was based on the photometric determination of NADPH 
consumption. During substrate oxygenation by FMO5, NADPH is oxidized to NADP+ 
and the disappearance of NADPH can be monitored photometrically over time at 
340 nm. A typical reaction mixture consisted of 50 mM phosphate buffer, pH 8.4, 
200 µM NADPH, 250 µM DETAPAC to inhibit autooxidation, and 200 µg/ml 
MBP-hFMO5 in a final volume of 100 µl. This mixture was prepared in advance and 
dispensed into 96-well flat-bottom UV-Star microplates (Greigner Bio-One, 
Frickenhausen, Germany). Afterwards, the reaction was initiated by addition of 
substrate. Kinetic decrease of NADPH was measured over 20 minutes and each well 
was read every 60 seconds using a Cary 50 Scan UV-Visible Spectrophotometer 
(Varian, Palo Alto, CA, USA). For initial assay optimization studies, the known 
substrate 8-DPT HCl was used to validate the high-throughput assay and the final 
8-DPT HCl concentration in these initial studies was 400 µM.  
6.2.6.2 Optimization of Assay Conditions 
Protein Concentration 
Purified MBP-hFMO5 was evaluated over a range of enzyme concentrations in 
reactions containing 8-DPT HCl. The reaction mixture consisted of MBP-hFMO5 and 
200 µM NADPH in 50 mM potassium phosphate buffer, pH 8.4, containing 0.25 mM 
DETAPAC. The reactions were initiated by addition of 8-DPT HCl to a final 
concentration of 400 µM. Slopes representing FMO activity generated by reactions 
containing 8-DPT HCl were normalized to slopes of control reactions without the 
substrate. Reactions were done in quadruplicates and enzyme was used in 
concentrations between 0.05 and 0.8 mg/ml. 
Substrate Dependence 
Kinetic parameters (Vmax, Km) of 8-DPT HCl were evaluated. The reaction mixture 
consisted of 200 µg/ml MBP-hFMO5 and 200 µM NADPH in 50 mM potassium 
phosphate buffer, pH 8.4, containing 0.25 mM DETAPAC. Reactions were initiated 
by addition of at least five varying concentrations of 8-DPT HCl between 5 and 
400 µM. Reactions were done in quadruplicates and slopes reflecting rates of 
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cofactor depletion were calculated by normalizing to slopes of reactions lacking 
protein.  
6.2.7 Development of a Fluorimetric Activity Assay Method 
6.2.7.1 Assay Protocol Outline 
The FMO5 activity assay was based on the fluorimetric determination of NADPH 
consumption and was adapted from Simeonov et al. [Simeonov et al., 2008] who 
established a fluorescence based NADPH depletion assay for inhibitor screening of 
the Schistosoma mansoni redox cascade. During substrate oxygenation by FMO5, 
NADPH is oxidized to NADP+ and the decrease of NADPH fluorescence can be 
monitored kinetically over 40 minutes, reading each well every 60 seconds at 
excitation/emission wavelengths of 365 nm/450 nm using a Perkin Elmer LS55 
Fluorescence Spectrophotometer (Perkin Elmer, Waltham, MA, USA). A typical 
reaction mixture consisted of 50 mM phosphate buffer, pH 8.4, 200 µM NADPH, 250 
µM DETAPAC, and 200 µg/ml MBP-hFMO5. This mixture was prepared in advance 
and dispensed into white 96-well flat-bottom microplates (OptiPlate-96, Perkin Elmer, 
Waltham, MA, USA). Afterwards, the reaction was initiated by addition of substrate. 
For initial assay optimization studies, the known substrate 8-DPT HCl was used to 
validate the HT-assay and the final 8-DPT HCl concentration in these initial studies 
was 400 µM.  
6.2.7.2 Optimization of Assay Conditions 
Protein Concentration 
Purified MBP-hFMO5 was evaluated over a range of enzyme concentrations in 
reactions containing a final concentration of 400 µM 8-DPT HCl. This was done 
measuring the decrease of NADPH fluorescence kinetically at excitation/emission 
wavelengths of 365 nm/450 nm over 50 minutes. Each well was read every 
60 seconds. The reaction mixture consisted of MBP-hFMO5 in concentrations 
between 0.05 and 0.8 mg/ml and 200 µM NADPH in 50 mM potassium phosphate 
buffer, pH 8.4, containing 0.25 mM DETAPAC. The reactions were initiated by 
addition of 8-DPT HCl to a final concentration of 400 µM. Reactions were done in 
quadruplicates and slopes representing FMO5 activity generated by reactions 
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containing 8-DPT HCl were normalized to slopes of control reactions without 
substrate.  
Substrate Dependence 
Kinetic parameters (Vmax, Km) of 8-DPT HCl were evaluated. Again, the decrease of 
NADPH fluorescence was measured kinetically at excitation/emission wavelengths of 
365 nm/450 nm over 60 minutes and each well was read every 60 seconds. The 
reaction mixture consisted of 300 µg/ml MBP-hFMO5 and 200 µM of its cofactor 
NADPH in 50 mM potassium phosphate buffer, pH 8.4, containing 0.25 mM 
DETAPAC. Reactions were initiated by addition of at least five varying concentrations 
of 8-DPT HCl between 20 and 1600 µM. Reactions were done in quadruplicates and 
slopes reflecting rates of cofactor NADPH depletion were calculated by normalizing 
to slopes of reactions lacking protein.  
6.2.8 Substrate Screens 
80 Compounds were tested with the developed photometric assay method for 
MBP-hFMO5 catalyzed oxygenation. These are listed in Table 6.1. Compounds were 
either dissolved in methanol or water and reactions were started by addition of these 
to yield final concentrations of 400 µM. Methanol concentrations in final incubations 
did not exceed 1 %. At this concentration, no significant change in enzyme activity 
was observed. Reactions were done in at least duplicates and slopes reflecting rates 
of NADPH depletion were calculated by normalizing to slopes of reactions lacking 
enzyme. In all plates at least one well contained 8-DPT HCl as positive control. 
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Table 6.1 Compounds tested with the developed photometric assay method. 
Acetazolamide Acetaminophen 
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N N
N
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Adenine Amitriptyline 
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N
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O
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BCHP BDAB HCl 
Br
N
O
Cl
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 HCl 
BPPB Cadaverine 2·HCl 
Br
O
N N
 
NH2 NH2
  2 HCl 
Chloramphenicol Chloroquine 
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NCl
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Chlorpromazine Chlorprothixene 
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Cimetidine Cocaine 
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Codeine L-Cysteine 
O
OH
O
N
 
SH
COOHNH2
 
Desipramine 1,4-Diaminobutane 2·HCl 
N
NH
 
 
NH2
NH2
  2 HCl 
8-DPT HCl Dimethyl sulfoxide 
N
S
(CH2)8
CF3
N
 
S
O
 
Diphenhydramine Dithiothreitol 
O N
 
SH
SH
OH
OH
 
Dopamine HCl Drofenin 
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OH
OH
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O
O
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Ephedrine Glibenclamid 
OH
NH
 
Cl
O
NH
S
O O
NH
O
NH
OMe
 
Guanethidine Histamine 2·HCl 
N
NNH2
NH2
 
N
H
N
NH2
 2 HCl 
L-Histidine HCl Imipramine 
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 HCl 
N
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Isoaminile Isoprenalin 
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OH
OH
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Isothipendyl Levodopa 
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Lidocaine L-Lysine HCl 
NH
O
N
 
NH2 COOH
NH2
 HCl 
Mafenide Meprobamate 
NH2
S
NH2
OO
 
ONH2
O
O NH2
O
 
L-Methionine Metoclopramid 
NH2
S
COOH
 
Cl
NH2
O
NH
N
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Metoprolol N,N-Dimethylbutylamine 
O
O N
H
OH
 
N
 
N,N-Dimethylethylamine N,N-Dimethylhexylamine 
N
 
N
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N,N-Dimethyloctylamine Nitrofurantoin 
N
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O
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n-Octylamine Orciprenaline 
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OH OH
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Oxedrin Oxeladin 
OH
OH
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Perphenazin Phenacetin 
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Pheniramine Pipazethate 
N
 
N N
S
O O
O
N
 
Piracetam Pirenzipin 
N O
O
NH2
 N
NH
N
O
O N
N
 
Procaine Promethazine 
NH2
O
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Propranolol Propylthiouracil 
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Ranitidine Saccharin 
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N
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Spermidine Spermine 4·HCl 
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N
H
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NH2 N
H
N
H
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Sulfaguanidine Sulfamethoxazol 
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O
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N
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Sulfanilamide Sulfathiazole 
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Sulfisomidin Tetracain 
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Thiamine cloride·HCl Thiopental 
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O
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Thioridazine Tolbutamide 
N
S
S
N
 
S N
H
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O
N
H
O
 
L-Tryptophan Verapamil 
NH2N
COOH
 
N
O
O
O O
CN
 
 
6.3 Results 
6.3.1 Comparison of Photometric and Fluorescent Activity Assay 
Methods 
For the development of a suitable HT-adaptable FMO5 oxygenation activity assay, 
two approaches were carried out and evaluated. Both methods were based on 
NADPH consumption associated with FMO5 dependent oxygenation activity. 
However, one was a photometric approach whereas the other exploits the inherent 
fluorescence of NADPH.  
6.3.1.1 Photometric Activity Assay Method 
Time Dependence 
Protein dependence as well as substrate dependence was measured over 
20 minutes and graphs were plotted and evaluated in regards to signal stability over 
time. A stable slope for NADPH depletion at 340 nm could be observed for the whole 
time period measured.  
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Protein Concentration 
Results of protein dependence studies are shown in Figure 6.1. The protein 
concentration dependent increase of activity is clearly visible. It is necessary to use 
enough enzyme to consume sufficient amounts of NADPH to generate detectable 
and reproducible slopes. However, at a concentration of 0.8 mg/ml enzyme the 
activity decreases. This might be due to nonspecific binding of MBP-hFMO5 to the 
substrate, leading to a decrease in effective concentration. For further studies, MBP-
hFMO5 concentrations between 0.2 and 0.4 mg/ml were used. 
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Figure 6.1 MBP-hFMO5 concentration dependence of the photometric plate-reader 
based NADPH depletion assay with 8-DPT HCl as substrate. 
 
Substrate Dependence 
Data obtained from incubation of MBP-hFMO5 with varying amounts of 8-DPT HCl 
was plotted as 8-DPT concentration vs. enzyme activity in nmol/min/mg FMO5 and a 
nonlinear regression curve fit tool using a Michaelis-Menten model 
(Y= (Vmax · X)/(Km + X) with Vmax = Ymax and Km = Xmid) in Graphpad software 
(Graphpad Prism, Version 2.00, San Diego, CA, USA) was utilized to calculate the 
kinetic parameters. The obtained Km was 12.3 ± 1.0 µM and Vmax was 
6  Substrate Selectivity and Screens of Potential FMO5 Substrates 
   
156 
 
6.4 ± 0.1 nmol/min/mg FMO5 (Figure 6.2). As positive control in screening assays, a 
concentration of 200 µM 8-DPT HCl was selected. 
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Figure 6.2 8-DPT HCl concentration dependence for photometric plate-reader based 
NADPH depletion assay with MBP-hFMO5. 
 
6.3.1.2 Fluorimetric Activity Assay Method 
Time Dependence 
Protein dependence as well as substrate dependence was measured over 
60 minutes and graphs were plotted and evaluated in regards to signal stability over 
time. Signal stability was dependent on protein concentration. A clear decrease of 
NADPH fluorescence could only be observed for 10 minutes at a MBP-hFMO5 
concentration of 0.8 mg/ml. At 0.4 mg/ml, the signal was stable for 40 minutes and at 
protein concentrations below 0.4 mg/ml, the decrease was linear within the range 
tested (50 minutes) (data not shown). 
 
Protein Concentration 
Results of protein dependence studies are shown in Figure 6.3. The slopes were only 
evaluated in the range of 0 to 30 minutes because linearity was not given afterwards 
at higher enzyme concentrations (see also time dependence). The protein 
concentration dependent increase of activity is clearly visible. However, although it is 
necessary to use enough enzyme to consume sufficient amounts of NADPH to 
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generate detectable and reproducible slopes, large amounts of enzyme will consume 
substrate too quickly and the slope will decrease. Also, protein may nonspecifically 
bind to a substrate, leading to a decrease in effective concentration. The optimal 
concentration for further studies lies in the range of 0.2 and 0.4 mg/ml MBP-hFMO5.  
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Figure 6.3 MBP-hFMO5 concentration dependence of the fluorimetric plate-reader 
based NADPH depletion assay with 8-DPT HCl as substrate. 
  
Substrate Dependence 
Data from substrate dependence studies fit to Michaelis-Menten kinetic in the range 
of 20 – 400 µM. However, higher concentrations of substrate led to decreased netto 
fluorescence signal. This could be due to an inhibitory effect of substrate on the 
enzyme. Thus, data obtained from incubation of MBP-hFMO5 was plotted in the 
range of 20 - 400 µM as 8-DPT HCl concentration vs. netto decrease of NADPH 
fluorescent signal and a nonlinear regression curve fit tool using a Michaelis-Menten 
model (Y= (Vmax · X)/(Km + X) with Vmax = Ymax and Km = Xmid) in Graphpad software 
(Graphpad Prism, Version 2.00, San Diego, CA, USA) was utilized to calculate kinetic 
parameters. The obtained Km was 30.3 ± 4.5 µM and Vmax was 6.4 ± 0.2 nmol/min/mg 
(Figure 6.4). As positive control in subsequent assays, a concentration of 200 µM 
8-DPT HCl should be used. 
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Figure 6.4 8-DPT HCl concentration dependence of fluorescence plate-reader based 
NADPH depletion assay with MBP-hFMO5.  
 
6.3.2 Substrate Screens 
No significant differences in terms of protein and substrate concentration needed 
could be observed between photometric and fluorescence enzyme activity assay. For 
substrate screens, the photometric assay was chosen. Besides the positive control 
substrate 8-DPT HCl, only 4’-(4-bromophenyl)-ω-dimethylaminobutyrophenone HCl 
(BDAB HCl) showed considerable decrease in absorbance at 340 nm. For all other 
compounds tested, no decrease in absorbance could be observed at the substrate 
concentrations used in the assay. A few other substrates including chlorpromazine, 
chlorprothixene, drofenin HCl, promethazine HCl, thioridazine, and phenacetin 
appeared to be potential hits after the primary screen and were re-screened to 
eliminate false-positives. None of these compounds proved to be a substrate for 
FMO5 and thus only BDAB HCl was examined further. BDAB N-oxygenation activity 
of FMO5 was supposed to be confirmed with an independent assay. Within this 
assay, 8-DPT HCl was incubated with MBP-hFMO5 in the presence and absence of 
BDAB HCl. As shown in Figure 6.5, conversion of 8-DPT was significantly inhibited 
by addition of BDAB to the incubation mixture. This inhibition was possibly due to 
BDAB HCl being a competitive substrate for MBP-hFMO5. Thus, in a secondary 
confirmatory assay, an HPLC-based method was developed to separate BDAB HCl 
from its metabolite/s after incubation with FMO5.  
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Figure 6.5 8-DPT HCl N-oxygenation by MBP-hFMO5 with and without BDAB. 
Statistically significant differences between incubation with 8-DPT HCl and incubation 
with a combination of 8-DPT HCl and BDAB HCl are identified with *** for P<0.001. 
Only one additional peak was observed in HPLC analysis after incubation of BDAB 
with MBP-hFMO5. This peak was analyzed via LC-MS and proved to be BDAB 
N-oxide with m/z 362 (Figure 6.6). 
 
Figure 6.6 HPLC Chromatogram of BDAB HCl and BDAB N-oxide. 
*** 
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6.4 Discussion 
Two different HT-compatible screening methods that are based on NADPH 
consumption during enzyme catalysis have been developed and were compared. No 
significant difference in terms of necessary protein and substrate concentrations 
could be observed. The photometric assay was chosen to screen several potential 
FMO5 substrates.  Besides the control substrate 8-DPT HCl and BDAB HCl, none of 
the compounds tested showed considerable decrease in 340 nm absorbance. 
Further evaluation of BDAB HCl proved this compound to be a substrate for FMO5.  
Several substrates have already been tested for oxygenation activity catalyzed by 
FMO5 from various species (i.e., mouse, human, and rabbit FMO5) including 
methimazole [Atta-Asafo-Adjei et al., 1993; Overby et al., 1995; Zhang et al., 2007a], 
ranitidine and cimetidine [Overby et al., 1997], phorate [Cherrington et al., 1998], 
trimethylamine [Atta-Asafo-Adjei et al., 1993; Zhang et al., 2007a], chlorpromazine, 
perchlorperazine, imipramine, N,N-dimethylaniline, cysteamine, trimethylamine and 
n-decylamine [Atta-Asafo-Adjei et al., 1993], L-arginine and Nδ-Methyl-D,L-arginine 
[Kotthaus, 2008], n-octylamine [Atta-Asafo-Adjei et al., 1993; Cherrington et al., 
1998; Overby et al., 1995], n-nonylamine [Atta-Asafo-Adjei et al., 1993], 
S-methylesonarimod [Ohmi et al., 2003; Zhang et al., 2007a] and 8-DPT [Zhang et 
al., 2007a]. However, only the last four compounds were actually oxygenated by the 
enzyme. Of these four known FMO5 substrates, besides 8-DPT, n-octylamine was 
examind within this study. It is notable that upon incubation with n-octylamine no 
decrease of NADPH dependent absorption at 340 nm could be observed in the 
photometric assay although this compound had previously been reported by one 
group [Overby et al., 1995] to be a substrate for human FMO5. This could not be 
confirmed in this study. 
Overall, the assay methods developed may be used to screen for further potential 
substrates. Screening a library of several thousands of compounds in a HT-format 
may help find additional FMO5 substrates and may lead to identification of structural 
groups oxygenated by FMO5 that will suggest likely physiological substrates and 
contribute an explanation of the role of FMO5. 
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A potential problem of both screening methods is the requirement of high substrate 
concentrations that might make it difficult to find a suitable library. An alternative 
approach could be an inhibitor screen for competition against 8-DPT as FMO5 
substrate. Lower compound concentrations would be needed for this approach and 
the method may still identify groups capable of binding to the enzyme’s active site, 
providing an indirect perspective on true substrate structure features. In general, the 
assay protocol would be similar to that of the direct FMO5 substrate screen and the 
inhibitor approach could also be combined with HPLC analysis of 8-DPT 
N-oxygenation as a basis for secondary confirmatory assays. 
A completely different approach to test the significance of FMO5 would be the 
development of a knock-out or knock-in mouse model of FMO5 or the usage of short 
interfering RNA (si-RNA) in order to suppress FMO5 expression. Such studies could 
also give more information about the physiological role and importance of FMO5. 
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7 Summary  
In this work, the structural and functional relations of flavin-containing 
monooxygenases (FMOs) 3 and 5 were investigated. The family of FMO enzymes 
represents, after the cytochromes P450, the most important monooxygenases in 
humans. It consists of five isozymes (FMO1 – 5) which catalyze mainly the 
oxygenation of nucleophilic N- and S-containing xenobiotics [Cashman et al., 2006; 
Ziegler, 1980]. In the main drug-metabolizing organ, the adult human liver, FMO3 
and FMO5 mRNA are the most abundantly expressed FMO mRNAs [Cashman et al., 
2006; Janmohamed et al., 2004]. Thus special interest was paid to these two 
isoforms. 
In the past, FMO3 gained considerable importance because of its association with 
trimethylamineuria (TMAu). TMAu is a disorder that often manifests itself in a body 
odor for individuals affected. It is due to decreased metabolism of dietary-derived 
trimethylamine (TMA). In a healthy individual, 95 % or more of TMA is converted by 
the FMO3 to non-odorous TMA N-oxide. Several SNPs of the FMO3 gene have been 
described and result in an enzyme with decreased or abolished functional activity for 
TMA N-oxygenation thus leading to TMAu.  
The disorder may be diagnosed by genotyping or by measuring urinary ratios of TMA 
N-oxide to TMA. Accurate diagnosis is essential for the affected individuals so that 
they can be treated appropriately. Treatment comprises restriction of certain foods, 
supplementation of folate, riboflavin, and, in very severe cases administration of 
antibiotics to decrease TMA formation due to gut bacteria [Akerman et al., 1999; 
Ayesh et al., 1993; Cashman et al., 2002; Mitchell, 1996; Mitchell et al., 2001].   
Biochemical characterization of recombinant expressed variant FMO3 observed from 
genotyping and phenotyping aids to reveal important information about structure and 
function of human FMO3 [Akerman et al., 1999; Cashman, 2002; Cashman et al., 
2002; Dolphin et al., 1997b; Shimizu et al., 2007b; Treacy et al., 1998; Yeung et al., 
2007]. 
Herein, a novel mutation observed from phenotyping and genotyping of self-reporting 
individuals was examined. This novel mutation was heterozygous at position 187 
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(V187A) and occurred in combination with mutations at position 158 (E158K), 308 
(E308G), and 305 (E305X). Familial genetic analysis showed that the 
E158K/V187A/E308G derived from the same allele from the mother, and the E305X 
was derived from the father. Wild-type human FMO3 and its variants V187A and 
V187A/E158K were expressed as maltose-binding fusion proteins (MBP-FMO3), 
purified, and characterized for oxygenation of several common FMO3 substrates (i.e., 
5- and 8-DPT, mercaptoimidazole (MMI), TMA, and sulindac sulfide) and for their 
thermal stability. The novel mutation in combination with the common polymorphism 
E158K led to severely decreased enzyme activity. Similarly, although by itself, the 
common polymorphisms E158K and E308G only slightly alter FMO3 activity, in 
combination they may lead to decreased activity [Cashman, 2000; Cashman et al., 
2003; Dolan et al., 2005; Zschocke et al., 1999]. This has also been reflected in vivo 
leading to TMAu [Lambert et al., 2001; Zschocke et al., 1999]. Likewise, the novel 
V187A mutation in conjunction with the common polymorphisms E158K and E308G 
significantly impairs FMO3 resulting in an enzyme with drastically decreased function 
that manifests itself in severe TMAu. 
Although FMO5 mRNA is most abundantly expressed in human adult liver, it is a 
largely understudied enzyme. Therefore, besides FMO3, FMO5 was of particular 
interest and was characterized structurally and functionally within this thesis. 
To facilitate these studies, highly-purified and well characterized FMO5 enzyme was 
produced. Human FMO5 was successfully expressed as maltose-binding fusion 
protein (MBP-hFMO5). Solubilization studies showed Triton® X-100 to be superior in 
extracting MBP-hFMO5 from E. coli. After cell lysis, protein was purified exploiting the 
MBP-tag for amylose-column chromatography. Further purification was done on an 
anion-exchange column and remaining impurities could be removed utilizing a NaCl 
salt gradient. Comparison to commercially available FMO5 showed no significant 
differences in kinetic behavior and since MBP-hFMO5 could be readily purified at low 
cost and in high quantities, it was chosen for further studies. Also MBP-hFMO5 could 
be obtained in high purity and was thus also suitable for crystallography studies. 
Further, MBP-hFMO5 was characterized in terms of enzyme activity and purity, 
stability at 4 °C, and oligomerization state and mo nodispersity. Especially for 
crystallography studies these characterization studies are substantial. They showed 
that addition of glycerol and NADP+ to the sample improved MBP-hFMO5 stability 
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1.6-fold and in subsequent crystallization studies these additives were added to 
enzyme preparations. Results from size exclusion chromatography of ion exchange 
purified MBP-hFMO5 suggested hexameric state for the protein which is in 
accordance with previous publications [Brunelle et al., 1997; Ziegler et al., 1972]. 
Dynamic light scattering (DLS) data of ion exchange purified FMO5 samples showed 
a single peak, suggesting pure, monodispers protein suitable for crystallography 
studies. 
When working with membrane associated proteins such as FMO enzymes use of 
detergents is unavoidable. As expected, surfactants play a dominant role in 
purification and crystallization of FMO5. Unfortunately, usage of detergents 
introduces a high level of unpredictability, especially if detergents are used that are 
heterogenic by themselves, such as Triton® X-100. However, the usage of this 
detergent was inevitable for the extraction of MBP-hFMO5 from E. coli and complete 
removal of Triton® X-100 and possibly substitution with other detergents seemed 
necessary prior to crystallization trials. Removal was done using polystyrene based 
beads (e.g., Bio-Beads®) and interestingly, upon addition of excess amounts of Bio-
Beads® to the protein solution, MBP-hFMO5 did not precipitate. This result suggests 
that FMO5 is not an integral membrane protein, but rather only associated with the 
membrane. Also, removal of Triton® X-100 with Bio-Beads® improved results from 
crystallization trials of MBP-hFMO5 leading to thick yellow oil phases and premature 
crystals with spherical shapes. 
Crystallography experiments were done by initially screening various commercially 
available 96-well plate crystal screen kits for suitable crystallization conditions. The 
most promising conditions were refined further in 24-well plates evaluating protein 
concentration, salts and buffers as well as precipitant type and concentration. 
Conditions that finally led to MBP-hFMO5 crystals were 26 % PEG 2K MME and 
0.2 M sodium acetate in 0.1 M Bis-Tris propane buffer, pH 6.5. 
Experiments in which a variety of different detergents was added after removal of 
Triton® X-100 led to further improvement of these first spherical shaped pre-stages of 
crystals. Detergents that yielded best results mainly belonged to a new group of 
amphiphilic agents that is supposed to stabilize membrane proteins and lower the 
risk of denaturing or aggregation. These surfactants are based on cholic acid and 
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exhibit facial amphiphilicity [Zhang et al., 2007b; Zhong et al., 2005]. In addition, 
detergents such as HECAMEG and the Cymal® series also yielded crystals. In 
general, employing the concept of mixed micelles by controlled addition of detergent 
seemed beneficial for FMO5 crystal growth. 
Unfortunately, no satisfactory diffraction pattern could be obtained from MBP-hFMO5 
crystals. This might be due to the flexible linker region between MBP-tag and FMO5 
that possibly introduces conformational heterogeneity [Smyth et al., 2003]. Therefore, 
MBP-hFMO5 was cleaved to perform crystallization experiments with only hFMO5. 
Splicing of MBP from hFMO5 was done utilizing a previously inserted protease 
sensitive site right after the MBP sequence that may be cleaved by factor Xa. After 
incubation for three hours at 37 °C, cleavage was l argely completed and addition of 
NADPH to the incubation mixture prevented the enzyme from being heat-inactivated. 
It is notable that similar experiments had been done with MBP-hFMO3 [Brunelle et 
al., 1997]. However, after cleaving MBP from hFMO3, the latter showed intractable 
solubility and enhanced instabilities [Brunelle et al., 1997] as previously described for 
a number of purified native FMO enzymes [Cashman, 1995; Guan et al., 1991]. In 
contrast to expectations, after proteolytical separation from MBP, human FMO5 
stayed in solution and retained the same level of enzyme activity as the tagged 
protein. However, subsequent purification of hFMO5 from remaining factor Xa, MBP, 
and residual uncleaved MBP-hFMO5 using a variety of previously described methods 
including affinity purification [Riggs, 2000], ion exchange chromatography [de Pieri et 
al., 2004; Guan et al., 2002; Hao et al., 2007; Riggs, 2000; Yan et al., 2006], and size 
exclusion chromatography [Branco et al., 2008] failed.  
In summary, this study showed that MBP-hFMO5 is crystallizable. However, further 
studies are needed to purify hFMO5 from MBP in order to start crystallization 
experiments with the tag-free protein and obtain well diffracting crystals. 
FMO5 displays a significantly different pH dependent activity profile than the other 
FMO isoforms [Zhang et al., 2007a]. While pH optima of mouse FMO1 and 3 
(mFMO1 and 3) display normal bell shape curves peaking around pH 8 to 10, with 
human FMO5 (hFMO5) and mFMO5, 8-DPT N-oxygenation activity continues to 
increase from pH 7 to pH 11 [Zhang et al., 2007a]. A possible reason for the different 
pH profile found in FMO5 could be a slower overall turnover rate indicating a possibly 
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different rate-limiting step in the catalytic cycle of FMO5. To date, the catalytic steps 
of pig FMO1 are known in some detail [Beaty et al., 1981a; Beaty et al., 1981b; 
Jones et al., 1986; Poulsen et al., 1979; Ziegler et al., 1988] and presumably, the 
other FMO isoforms follow a similar mechanism. However, this might not be the case 
for all FMO isoenzymes and the assumption is that FMO5 catalytical mechanism is 
distinct from that of other FMO enzymes.  
The objective of this study was to determine the pH dependence of FMO5 to gain an 
insight into the mechanism of action of FMO5 enzymes. Therefore, functional 
recombinant hFMO5 and mFMO5 were expressed as MBP-fusion proteins from 
E. coli, purified with affinity chromatography, and examined for their 8-DPT 
N-oxygenation activity at different pH values. MBP-hFMO5 showed a broader range 
and greater functional activity from pH 6 to 11 compared to mFMO5. mFMO5 lost 
nearly all functional activity at pH 6, while hFMO5 maintained almost normal enzyme 
activity.  In order to identify the amino acid residues involved in the effects of pH on 
hFMO5 and mFMO5 functional enzyme activity, pH-studies in the range of pH 6 
through 9 were done with MBP-tagged chimeras of recombinant human and mouse 
FMO5 and variants of both. Results of this study showed that the residues 
responsible for the pH profile distinction between MBP-hFMO5 and MBP-mFMO5 are 
located at positions 227 and 228 of the enzyme. Further mutants were made to 
investigate the role of these amino acids. Combined with additional structural, 
functional and kinetic information, this study may add to provide insight into the 
mechanism of FMO5 revealing important interactions between substrate or cofactors 
of FMO and specific amino acid residues of the enzyme. In addition, results may be 
relevant for other FMO enzymes as well if the catalytic mechanism of all FMOs 
proves to be identical. 
The last objective within this thesis was the development of a high-throughput (HT) 
compatible enzyme activity assay in order to screen for new FMO5 substrates. Two 
different HT-compatible screening methods that are based on a decrease of NADPH 
during enzyme catalysis have been developed and were compared. One was based 
on fluorescence whereas the other was a photometric assay. Since no significant 
difference in terms of protein and substrate concentrations needed or sensitivity 
could be observed, the photometric assay was chosen to screen 80 compounds as 
possible FMO5 substrates. Potential hits from this first screen were re-screened in 
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order to eliminate false-positives. Besides the control substrate 8-DPT HCl only 
4’-(4-bromophenyl)-ω-dimethylaminobutyrophenone (BDAB) HCl showed 
considerable decrease in 340 nm absorbance. Thus, only this compound was 
examined further. An HPLC method was developed to separate substrate from its 
metabolite/s after incubation with MBP-hFMO5. The resulting BDAB metabolite 
observed after incubation was analyzed via LC-MS and proved to be BDAB N-oxide. 
Thus, results from the primary photometric assay could be confirmed. This compound 
fits well into the proposed selectivity range of FMO5, having a tertiary amine group 
on a long carbon side-chain away from a bulky moiety. It is still surprising that 
compounds with very similar structures such as benzydamine or tetracaine did not 
prove to be substrates of FMO5. Overall, further compound screens will be needed to 
identify additional FMO5 substrates and gain more knowledge of substrate specificity 
and thus the relationship between structure and function. 
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9 Appendix 
9.1 Constructs 
Amino acid sequences of all wild-type constructs are listed below. All constructs were 
cloned into pMAL-vector. 
MBP-hFMO3 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSG
LLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMF
NLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAM
TINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPL
GAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNN
NNNNNNLGIEGRGKKVAIIGAGVSGLASIRSCLEEGLEPTCFEKSNDIGGLWKFSDHAEEGRASIYKSVFSNSSK
EMMCFPDFPFPDDFPNFMHNSKIQEYIIAFAKEKNLLKYIQFKTFVSSVNKHPDFATTGQWDVTTERDGKKESAV
FDAVMVCSGHHVYPNLPKESFPGLNHFKGKCFHSRDYKEPGVFNGKRVLVVGLGNSGCDIATELSRTAEQVMISS
RSGSWVMSRVWDNGYPWDMLLVTRFGTFLKNNLPTAISDWLYVKQMNARFKHENYGLMPLNGVLRKEPVFNDELP
ASILCGIVSVKPNVKEFTETSAIFEDGTIFEGIDCVIFATGYSFAYPFLDESIIKSRNNEIILFKGVFPPLLEKS
TIAVIGFVQSLGAAIPTVDLQSRWAAQVIKGTCTLPSMEDMMNDINEKMEKKRKWFGKSETIQTDYIVYMDELSS
FIGAKPNIPWLFLTDPKLAMEVYFGPCSPYQFRLVGPGQWPGARNAILTQWDRSLKPMQTRVVGRLQKPCFFFHW
LKLFAIPILLIAVFLVLT 
MBP-hFMO5 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSG
LLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMF
NLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAM
TINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPL
GAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNN
NNNNNNLGIEGRISEFGSSRMTKKRIAVIGGGVSGLSSIKCCVEEGLEPVCFERTDDIGGLWRFQENPEEGRASI
YKSVIINTSKEMMCFSDYPIPDHYPNFMHNAQVLEYFRMYAKEFDLLKYIRFKTTVCSVKKQPDFATSGQWEVVT
ESEGKKEMNVFDGVMVCTGHHTNAHLPLESFPGIEKFKGQYFHSRDYKNPEGFTGKRVIIIGIGNSGGDLAVEIS
QTAKQVFLSTRRGAWILNRVGDYGYPADVLFSSRLTHFIWKICGQSLANKYLEKKINQRFDHEMFGLKPKHRALS
QHPTLNDDLPNRIISGLVKVKGNVKEFTETAAIFEDGSREDDIDAVIFATGYSFDFPFLEDSVKVVKNKIPLYKK
VFPPNLERPTLAIIGLIQPLGAIMPISELQGRWATQVFKGLKTLPSQSEMMAEISKAQEEIDKRYVESQRHTIQG
DYIDTMEELADLVGVRPNLLSLAFTDPKLALHLLLGPCTPIHYRVQGPGKWDGARKAILTTDDRIRKPLMTRVVE
RSSSMTSTMTIGKFMLALAFFAIIIAYF 
MBP-mFMO5 
MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSG
LLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMF
NLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAM
TINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPL
GAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALKDAQTNSSSNNNN
NNNNNNLGIEGRISEFGSSRMTKKRIAVIGGGVSGLSSIKCCVEEGLEPVCFERTDDIGGLWRFQENPEEGRASI
YKSVIINTSKEMMCFSDYPIPDHYPNFMHNAQVLEYFRMYAKEFDLLKYIRFKTTVCSVKKQPDFATSGQWEVVT
ESEGKKEMNVFDGVMVCTGHHTNAHLPLESFPGIEKFKGQYFHSRDYKNPEGFTGKRVIIIGIGNSGGDLAVEIS
QTAKQVFLSTRRGAWILNRVGDYGYPADVLFSSRLTHFIWKICGQSLANKYLEKKINQRFDHEMFGLKPKHRALS
QHPTLNDDLPNRIISGLVKVKGNVKEFTETAAIFEDGSREDDIDAVIFATGYSFDFPFLEDSVKVVKNKIPLYKK
VFPPNLERPTLAIIGLIQPLGAIMPISELQGRWATQVFKGLKTLPSQSEMMAEISKAQEEIDKRYVESQRHTIQG
DYIDTMEELADLVGVRPNLLSLAFTDPKLALHLLLGPCTPIHYRVQGPGKWDGARKAILTTDDRIRKPLMTRVVE
RSSSMTSTMTIGKFMLALAFFAIIIAYF 
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9.2 Buffers and Reagents 
LB-Agar LB-medium (10 g tryptone, 5 g yeast, 5 g NaCl, H2O ad 
1 l) + 1.5 % (w/v) agar. Autoclave and add antibiotic after 
cooling to ~ 50 °C. 
SOC 20g peptone 
5 g yeast 
0.5 g NaCl 
2.5 ml 1 M KCl 
5 ml MgCl2 
20 ml 1 M glucose 
H2O ad 1 l  
Autoclave.  
Induction solution 0.048 g riboflavin 
1.2 ml 1 M IPTG 
sterile H2O ad 20 ml 
Lysis buffer 600 µl FAD (10 mg/ml) 
0.36 g L-α-phosphatidylcholine 
1 ml 0.1 M PMSF 
0.5 % Triton® X-100 
50 mM K2HPO4 buffer, pH 8.4,  ad 200 ml  
10 % SDS resolving gel 9.2 ml H2O 
8.3 ml 30 % acrylamide mix  
6.3 ml 1.5 M Tris pH 8.8 
250 µl 10 % (w/v) SDS 
250 µl 10 % (w/v) APS 
10 µl TEMED 
5 % SDS stacking gel 6.8 ml H2O 
1.7 ml 30 % acrylamide mix  
1.25 ml 1.0 M Tris pH 6.8 
100 µl 10 % (w/v) SDS 
100 µl 10 % (w/v) APS 
10 µl TEMED 
5 x Tris glycine 
electrophoresis buffer 
15.1 g Tris base 
94 g glycine 
50 ml 10 % (w/v) SDS 
H2O ad 1 l 
4 x SDS gel-loading 
buffer 
0.25 M Tris HCl pH 8.5 
8 % SDS 
1.6 mM EDTA 
0.04 % bromophenol blue 
40 % glycerol 
add 20 x reducing agent (2 M DTT) right before use. 
SDS gel destain 500 ml methanol 
400 ml H2O 
100 ml glacial acetic acid 
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Coomassie staining 
solution 
0.35 g Coomassie Brilliant Blue R250  
100 ml ‚SDS gel destain’ 
Amylsoe column wash 
buffer (buffer A) 
50 mM K2HPO4, pH 8.4  
0.5 % Triton® X-100  
15 µg/ml FAD 
Amylsoe column wash 
buffer (buffer A’) 
50 mM K2HPO4, pH 8.4  
15 µg/ml FAD 
Amylsoe column elution 
buffer 
50 mM K2HPO4, pH 8.4  
15 µg/ml FAD 
3 mM maltose 
in some cases 0.5 % Triton® X-100 was included 
Q column wash buffer 
(buffer B) 
50 mM Bis-Tris buffer, pH 6 
in some cases 0.01 % DDM was included 
Q column elution buffer 50 mM Bis-Tris buffer, pH 6 
1 M NaCl 
in some cases 0.01 % DDM was included 
 
 
 
9.3 Equipment List 
Instrument Manufacturer 
Minitron incubator shaker INFORS HT, Bottmingen, Switzerland 
Centrifuge J2-21M , Rotor JA-20 and JA-
10 Beckman Coulter, Inc., Brea, CA, USA 
Optima MAX-E Ultra Centrifuge MAX 
(100K) Beckman Coulter, Inc., Brea, CA, USA 
Biofuge pico  Heraeus, Newport Pagnell, United Kingdom 
Eppendorf centrifuge 5415R Eppendorf AG, Hamburg, Germany 
Megafuge 1.0R Heraeus, Newport Pagnell, United Kingdom 
Sonicator Sonics Vibracell (VC130) Sonics and Materials Inc., Newtown, CT, USA 
French press Thermo Electron Corp., Needham Heights, MA, USA 
Bio-Rad Biologic LP System & Software Bio-Rad, Hercules, CA, USA 
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Econo-Column Chromatography 
Columns, 1.5 x 5 cm Bio-Rad, Hercules, CA, USA 
Fraction collector Redi frac Amersham Biosciences Europe GmbH, Freiburg, Germany 
ISMATEC tubing pump (MCP ISM 726) ISMATEC Labortechnik GmbH, Wertheim-Mondfeld, Germany 
UVS/Vis Spectrophotometer Cary 300 
Bio Varian Inc., Palo Alto, CA, USA 
UVS/Vis Spectrophotometer Cary 50 Bio Varian GmbH, Darmstadt, Germany 
Lambda 25 UV Vis Spectromer Perkin Elmer, Waltham, MA, USA 
Perkin Elmer LS55 fluorescence 
spectrophotometer Perkin Elmer, Waltham, MA, USA 
Zetasizer Nano-S  Malvern Instruments Ltd, Malvern, United Kingdom 
Mini-PROTEAN gel electrophoresis 
system Bio-Rad, Hercules, CA, USA 
PowerPac Basic power supply Bio-Rad, Hercules, CA, USA 
NanoDropTM ND-1000 UV/VIS 
Spectrophotometer 
Thermo Fisher Scientific, Wilmington, DE, 
USA 
Kodak Gel Logic 200 Imaging System Eastman Kodak Company, 
Rochester, NY , USA  
Hitachi HPLC system: Hitachi L-7200 
autosampler and L-7100 pump with a 
Hitachi L-7400 UV detector 
Hitachi, Peoria, IL, USA 
Waters HPLC system: Waters 600E 
controller and Waters Autosampler 700 
Satellite WISP with a Waters 486 
Absorbance Detector 
Waters, Eschborn, Germany 
Waters AllianceTM HPLC-System: Waters 
e2695 XC Separations Modul with a 
Waters 2998 Photodiode Array Detector 
and EmpowerTM 2 Software 
Waters, Eschborn, Germany 
Esquire LC with Atmospheric Pressure 
Chemical Ionisation Bruker Daltonics, Bremen, Germany 
HP Series 1100 Binary Pump G1312A 
with HP 1100 VWD UV/VIS Detektor  Hewlett Packard, Waldbronn, Germany 
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Water bath GFL 1087 Gesellschaft für Labortechnik, Burgwedel, Germany 
pH Meter inoLab pH level1 Wissenschaftlich-Technische Werkstätten GmbH, Wetheim, Germany 
Corning 440 pH Meter Corning, Electrochemistry Products, Woburn, MA, USA 
Ultrasonic bath, Sonorex, Super RK 
510H Bandelin, Berlin, Germany 
Vortex VF2 Janke & Kunkel GmbH &Co KG, Staufen, Germany 
Balance MC1, Laboratori LC 620S Satorius, Göttingen, Germany 
Balance MC1, Research RC 210P Satorius, Göttingen, Germany 
MicroPulser Elektroporator  Bio-Rad, Hercules, CA, USA 
Gene Amp PCR 9700 system  Perkin Elmer, Waltham, MA, USA 
DNA Engine Peltier Thermal Cycler  Bio-Rad, Hercules, CA, USA 
Pipettes Reference Eppendorf Eppendorf AG, Hamburg, Germany 
RAININ Classic Pipettes Rainin Instrument LLC, Oakland, CA, USA 
Polystyrene (PS) Cuvettes; 1.5–3.0; 
Semi-Micro 
VWR International, West Chester, PA, 
USA 
Cryschem Plate, HR3-160 Hampton Research Corp., Aliso Viejo, CA, USA 
96-well flat-bottom UV-Star microplates Greigner Bio-One, Frickenhausen, Germany 
OptiPlate-96 (white) 96-well flat-bottom 
microplates  Perkin Elmer, Waltham, MA, USA 
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